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Abstract 
 
 
Stroke is a significant cause of death and disability in developed countries. It is a 
multifactorial disease, resulting from the interplay between genes and well-known life-
style/environmental risk factors. Numerous studies have attempted to identify the 
genetic risk factors predisposing to stroke, but few have investigated the genetic factors 
involved in stroke outcome. This work aimed at the identification of genes contributing 
to stroke and influencing patient’s outcome after three months. Four inflammatory 
genes (IL1B, IL6, MPO and TNF) and two genes involved in the nitric oxide 
metabolism (NOS1 and NOS3) were tested for association with stroke. The results 
suggest that the IL6 and MPO genes influence stroke susceptibility through independent 
effects and non-additive interactions. Furthermore, they provided novel evidence for the 
involvement of the NOS1 gene in stroke susceptibility. Several studies have shown the 
important impact of oxidative stress, inflammation, angiogenesis, neurogenesis, 
neurovascular damage and neurovascular remodeling for stroke-associated brain 
damage and/or stroke recovery. Association analyses were thus carried out to assess the 
role of candidate genes involved in inflammatory processes (IL1B, IL6, MPO and TNF) 
and oxidative stress (NOS1 and NOS3), as well as matrix metalloproteinase genes 
(MMP2 and MMP9) and growth factor genes (BDNF, FGF2 and VEGFA) in patient’s 
outcome at three months. MMP2 genetic variants were found associated with patient’s 
outcome, and the results also indicate that two epistatic interactions between the BDNF 
and FGF2 genes and between the FGF2 and VEGFA genes influence this phenotype. A 
genome-wide association study was performed in stroke outcome using DNA pooled 
samples to provide novel insights into the mechanisms involved in stroke recovery. The 
BBS9 and GLIS3 genes were found associated with patient’s outcome at three months. 
Taken together, these results suggest that stroke susceptibility and outcome are 
modulated by a combination of main gene effects and gene-gene interactions, 
independently of stroke risk factors and/or severity parameters, highlighting the 
complexity of mechanisms predisposing to stroke and influencing recovery afterwards. 
 
Keywords: stroke, association study, candidate genes, epistatic interactions, 
susceptibility, outcome. 
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Resumo 
 
 
O Acidente Vascular Cerebral (AVC) é uma das principais causas de morte e 
incapacidade permanente nos países desenvolvidos, tendo importantes consequências 
económicas e sociais. O AVC é considerado uma doença complexa, que resulta de uma 
acção combinada entre genes e factores de risco ambientais ou de estilo de vida. Muitos 
estudos foram já levados a cabo com o intuito de identificar os factores genéticos de 
risco para o AVC, mas os resultados têm sido inconsistentes. A maioria desses estudos 
analisou o papel de genes candidatos; mais recentemente, foram também realizados 
estudos de associação ao nível de todo o genoma. Ao contrário da susceptibilidade, 
poucos estudos procuraram identificar quais os factores genéticos envolvidos na 
recuperação após um AVC.  
Este trabalho de doutoramento pretendeu assim identificar genes que contribuam 
para a susceptibilidade ao AVC e que influenciem o estado de incapacidade funcional 
(outcome) do doente ao fim de três meses de recuperação. Para isso, foram utilizadas 
duas estratégias distintas. A primeira estratégia consistiu na análise do papel de genes 
candidatos nos dois fenótipos referidos anteriormente, genes esses que tinham sido 
escolhidos com base na sua função, nos resultados de estudos de associação anteriores 
e/ou nos resultados de estudos com modelos animais de AVC, factores de risco ou 
condições médicas associadas. Foi ainda realizado um estudo de associação ao nível de 
todo o genoma com o objectivo de identificar factores genéticos que influenciem o 
outcome do doente. Nesta segunda estratégia não existia uma hipótese a priori 
relativamente ao papel de um determinado gene no fenótipo, correspondendo por isso a 
uma análise não enviesada.  
Vários estudos têm sugerido que a inflamação e o stress oxidativo desempenham 
um papel relevante na susceptibilidade ao AVC. Factores de risco já conhecidos, como 
aterosclerose, diabetes, obesidade e hipertensão, estão associados a um perfil 
inflamatório elevado. Além disso, é também conhecida a importância das enzimas 
sintase do óxido nítrico (NOS) para a aterosclerose e a regulação da pressão sanguínea. 
Atendendo a isso, foi testada a associação de quatro genes inflamatórios (IL1B, IL6, 
MPO e TNF) e de dois genes envolvidos no metabolismo do óxido nítrico (NOS1 e 
NOS3) com o risco de AVC. Foram encontradas associações de variantes genéticas nos 
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genes inflamatórios IL6 e MPO com a doença, assim como de uma interacção epistática 
entre eles contribuindo para o risco. Isto sugere que os dois genes influenciam a 
susceptibilidade ao AVC através de efeitos independentes e de efeitos de interacção não 
aditivos. Os resultados mostram ainda uma associação entre o AVC e variantes 
genéticas no gene NOS1, que codifica uma das isoformas de NOS. A análise de genes 
candidatos sugere assim que efeitos independentes dos genes inflamatórios ou de stress 
oxidativo IL6, MPO e NOS1, e efeitos não aditivos resultantes de interacções entre os 
genes IL6 e MPO têm um impacto na susceptibilidade ao AVC. Estes resultados são 
compatíveis e reforçam as observações feitas em estudos in vitro e in vivo relativamente 
ao papel da inflamação e do stress oxidativo nesta doença.  
É igualmente reconhecido o importante impacto de stress oxidativo, inflamação, 
angiogénese, neurogénese, dano e remodelação neurovasculares na lesão cerebral 
associada ao AVC e/ou na recuperação funcional dos doentes. Assim, foram também 
levados a cabo estudos de associação para avaliar o papel de genes candidatos 
envolvidos em processos inflamatórios (IL1B, IL6, MPO e TNF) e de stress oxidativo 
(NOS1 e NOS3), assim como de genes das metaloproteinases da matriz (MMPs) (MMP2 
and MMP9) e de genes de factores de crescimento (BDNF, FGF2 and VEGFA), no 
outcome do doente após três meses de recuperação. Relativamente ao gene MMP2, os 
resultados mostram a associação entre variantes genéticas deste gene e o outcome do 
doente após três meses de recuperação. Vários estudos anteriores demonstraram que a 
ruptura da barreira hemato-encefálica associada ao AVC está relacionada com a 
expressão e activação de MMPs, levando a hemorragia, edema e morte celular. No 
entanto, outros estudos sugerem que a actividade destas proteínas pode ser benéfica na 
angiogénese e na remodelação neurovascular em fases tardias de recuperação, o que 
poderá contribuir para a recuperação funcional do doente. Neste trabalho de 
doutoramento foram ainda identificadas duas interacções epistáticas entre os genes 
BDNF e FGF2 e entre os genes FGF2 e VEGFA em associação com o outcome do 
paciente. Estes três genes codificam factores de crescimento que são partilhados pelo 
sistema nervoso e vascular e que afectam a homeostasia e desenvolvimento dos dois 
sistemas. Os factores de crescimento têm importantes funções ao nível da angiogénese, 
neurogénese e protecção neuronal, influenciando o estado neurológico dos doentes e a 
recuperação dos mesmos após o AVC. Tendo em conta estes resultados, a análise de 
genes candidatos sugere que o gene MMP2 e interacções epistáticas entre os genes 
BDNF e FGF2, e entre os genes FGF2 e VEGFA têm um impacto no outcome do 
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doente ao fim de três meses de recuperação. Estes resultados são também compatíveis 
com estudos in vitro e in vivo que tinham demonstrado previamente a importância das 
MMPs e dos factores de crescimento na recuperação após um AVC. 
Foi feito um rastreio genómico com o objectivo de identificar factores genéticos 
que influenciem o outcome do doente. Para isso foi testada a associação de mais de 250 
mil polimorfismos, localizados ao longo de todo o genoma, com o outcome do doente. 
Uma das vantagens desta estratégia é a de possibilitar a descoberta de novos 
mecanismos envolvidos neste fenótipo. Para realizar este estudo de uma forma 
economicamente eficiente foram analisados conjuntos (pools) de amostras de DNA de 
doentes. Após a identificação dos marcadores mais importantes com base em quatro 
estratégias distintas, esses resultados foram validados por genotipagem individual. Este 
estudo permitiu a identificação de uma associação entre os genes BBS9 e GLIS3 e o 
outcome do doente. Sabe-se que pacientes com a síndrome Bardet-Biedl têm mutações 
no gene BBS9. A obesidade é uma das manifestações clínicas mais importantes desta 
síndrome e foi demonstrado que, após um AVC, os danos neurológicos e as lesões 
cerebrais são menores em ratinhos em regime de restrição calórica do que em ratinhos 
sem esta restrição, o que sugere que o excesso de calorias consumidas/obesidade poderá 
influenciar o outcome após AVC. Relativamente ao gene GLIS3, que codifica um factor 
de transcrição, tinham sido anteriormente reportadas associações deste gene com a 
diabetes. Esta doença é um factor de risco para o AVC e está também associada com 
maior risco de morte e incapacidade funcional de doentes quando o AVC ocorre. Apesar 
de não ser imediatamente perceptível qual o papel dos genes BBS9 e GLIS3 no outcome 
dos doentes, é possível que estes genes tenham uma influência indirecta nesse fenótipo 
através de um efeito na diabetes e obesidade.  
Em conclusão, os resultados obtidos durante este trabalho de doutoramento 
sugerem que tanto a susceptibilidade ao AVC como o outcome do doente são 
modulados por uma combinação de efeitos de genes independentes e de interacções 
entre genes. Isto indica que os mecanismos envolvidos na predisposição a esta doença e 
na recuperação posterior dos doentes poderão ser bastante complexos. É de salientar 
que, com este trabalho de doutoramento, o número de genes candidatos analisados, até 
ao momento, na área da genética do outcome praticamente duplicou. Além disso, pela 
primeira vez, foi realizado um estudo de associação ao nível de todo o genoma com o 
outcome do doente. No futuro, será desejável aumentar a dimensão da amostra, em 
especial dos doentes com informação sobre recuperação. Deverão, ainda, ser realizados 
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estudos para identificar as variantes genéticas causais que estão na base das associações 
encontradas com a susceptibilidade ao AVC e com o outcome do doente. 
  
Palavras-chave: Acidente Vascular Cerebral, estudo de associação, genes 
candidatos, interacções epistáticas, susceptibilidade, recuperação. 
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1.1 Stroke 
 
1.1.1 Definition 
 
Stroke is a major health problem in developed countries, with a very high 
incidence and mortality. Furthermore, it is also a major cause of significant disability. 
With increasing life expectancy, this public health problem tends to worsen, with 
important economic and social consequences. Stroke is defined by the World Health 
Organization [1988] as “rapidly developing clinical signs of focal (or global) 
disturbance of cerebral function, with symptoms lasting 24h or longer, or leading to 
death, with no apparent cause other than of vascular origin”. Stroke represents a 
collection of different processes, with different clinical phenotypes, etiological 
mechanisms and risk factor profiles that ultimately result in cellular death in the brain. 
Different stroke subtypes have also different degrees of heritability and genetic risk 
factors profiles [Markus 2003]. 
 
1.1.2 Incidence and prevalence  
 
Over the past four decades, age-adjusted stroke incidence rates have decreased 
in high income countries, but have increased in low to middle income countries, 
exceeding the rate observed in the more developed countries [Feigin et al. 2009]. The 
annual incidence of stroke is estimated to be about 1.1 million in the European Union, 
Switzerland, Iceland and Norway, and approximately 6 million people in these countries 
are stroke survivors [Truelsen et al. 2005]. In 2004, the cost of stroke for the European 
society was approximately 22 billion euros, but it might be larger since estimations 
were based on incidence data [Andlin-Sobocki et al. 2005]. In the same year, the total 
cost of stroke in Portugal was approximately 853 million euros, and this country had 
one of the highest stroke incidence and prevalence rates in Europe (people aged 25 
years or older) [Andlin-Sobocki et al. 2005; Truelsen et al. 2005]. Annual incidence 
rates in rural and urban areas were 2.02 (95% confidence interval [CI]: 1.69-2.34) and 
1.73 (95% CI: 1.53-1.92), respectively, per 1,000 inhabitants [Correia et al. 2004].  
Chapter 1. Introduction 
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After stroke, one third of surviving patients remain disabled and one in seven 
requires institutional care [Hankey et al. 2002]. Moreover, among 30-day survivors of 
first-ever stroke, only about 50% survive 5 years [Hankey et al. 2002]. The cumulative 
risk of a recurrent stroke is about 40% during the first 10 years after a first-ever event; 
and the case fatality of a recurrent stroke is almost twice that of a first-ever stroke 
[Hardie et al. 2004]. 
  
1.1.3 Clinical aspects, diagnosis and pathophysiology  
 
Stroke can be broadly divided into ischemic and hemorrhagic, with the latter 
comprising intracerebral hemorrhage (ICH) and subarachnoid hemorrhage. It is believed 
that ischemic and hemorrhagic stroke result from both common and different 
determinants [Humphries and Morgan 2004]. Since ICH corresponds to approximately 
70% of hemorrhagic strokes [Lloyd-Jones et al. 2009], hemorrhagic stroke will be used 
in this thesis as a synonym of ICH unless otherwise specified. According to Amarenco 
et al. [2009], stroke should also include cerebral venous thrombosis and spinal cord 
stroke. Stroke has several sudden symptoms including numbness or weakness of the 
face, arm or leg, especially in one side of the body; severe headache with no apparent 
cause; confusion, trouble speaking or understanding, and trouble seeing in one or both 
eyes.  
The only reliable method to distinguish ischemic stroke from ICH is brain 
imaging, including computed tomography (CT) and magnetic resonance (MR). CT is 
widely available and can be performed quickly, which are two important advantages of 
this method [Saenger and Christenson 2010]. Although CT is often normal in 
hyperacute ischemic stroke, it is particularly valuable to exclude the existence of 
hemorrhages and tumors [Warlow et al. 2003]. Early CT can identify ICH, but cannot 
reliably distinguish between primary ICH and hemorrhagic transformation of an 
ischemic stroke [Davenport and Dennis 2000]. MR is more sensitive than CT and can 
help the diagnosis in patients who delay seeking treatment, although some infarctions 
are equally not visible [Davenport and Dennis 2000; Saenger and Christenson 2010; 
Warlow et al. 2003]. In contrast with CT, MR is not readily available in some countries 
and it can not be safely used in many acutely ill patients [Davenport and Dennis 2000; 
Warlow et al. 2003].  
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Many studies have investigated the potential use of several blood-based protein 
biomarkers for stroke risk prediction, diagnosis or prognosis [ Baird 2006; Saenger and 
Christenson 2010]; some of these biomarkers can be specially useful for stroke patients 
that have normal or ambiguous results in brain imaging. Lipoprotein-associated 
phospholipase A2 was approved by the US Food and Drug Administration (FDA) for 
long-term prognostic risk for stroke and coronary heart disease. Other promising 
biomarkers include the asymmetric dimethylarginine, matrix metalloproteinase-9 and 
glial fibrillary acidic protein [reviewed in Saenger and Christenson 2010].  
 
Ischemic stroke 
 
Ischemic stroke corresponds to 80-90% of total stroke cases [Bhatnagar et al. 
2010; Lloyd-Jones et al. 2009] and is caused by a sudden interruption of a cerebral 
artery or, less often, by a decrease in cerebral blood flow due to stenosis [Davenport and 
Dennis 2000; NINDS 2004]. Ischemia refers to the loss of oxygen and nutrients for 
brain cells due to inadequate blood flow. If neurological deficits last less than 24h, it is 
considered a transient ischemic attack (TIA). Although TIA is less dangerous than 
stroke, early administration of thrombolytic therapies is important to attenuate the short-
term risk of ischemic stroke, cardiovascular events and death that is associated with 
TIAs [Saenger and Christenson 2010].  
In white people, approximately 50% of ischemic strokes are caused by 
atherothromboembolism, 25% correspond to lacunar infarcts due to occlusion of small 
cerebral arteries, 20% are caused by emboli from the myocardium (resulting from 
concurrent myocardial infarction, atrial fibrillation, mitral stenosis, etc.) and the 
remainder are due to rarer causes [Davenport and Dennis 2000; Saenger and 
Christenson 2010; Warlow et al. 2003]. A wide variety of classification schemes have 
been used to classify subtypes of ischemic stroke, with different weaknesses and 
strengths [Amarenco et al. 2009; Kirshner 2009]. Despite differences regarding 
nomenclature, weight placed on stroke risk factors, clinical features, and brain imaging 
techniques, these classification systems differentiate between strokes of large vessel 
(atherothrombotic), cardioembolic, small vessel (lacunar), other determined causes and 
cryptogenic strokes (undetermined etiology) [Amarenco et al. 2009; Kirshner 2009]. 
The Trial of ORG 10172 in Acute Stroke Treatment (TOAST) [Adams et al. 1993] has 
been the most widely used classification system.  
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Ischemic stroke triggers a series of events called the ischemic cascade. Cellular 
bioenergetic failure, excitotoxicity, oxidative stress, stress signalling, inflammation, 
blood-brain barrier dysfunction, hemostatic activation, apoptosis, angiogenesis, survival 
and gene expression are activated by cerebral ischemia, resulting in a series of 
biochemical, hemodynamic and neurophysiological alterations [Deb et al. 2010; Mehta 
et al. 2007; Mitsios et al. 2006; Saenger and Christenson 2010]. The adequate delivery 
of nutrients and oxygen to the cells is affected during ischemic stroke. Neurons in the 
infarcted core die in a short time due to necrosis. In contrast, the majority of neurons 
remains viable in the penumbra region for a longer period and can be saved if 
reperfused in time. If the ischemic state persists for an extended period of time, 
secondary cell death develops gradually in the penumbra region mainly due to 
excitotoxicity and apoptosis. Duration, severity and location of the ischemic insult 
influence the extent of damage [Deb et al. 2010; Mitsios et al. 2006]. 
Thrombolysis with recombinant tissue plasminogen activator (tPA) is the only 
approved therapy for acute ischemic stroke. The serine protease tPA cleaves 
plasminogen into active plasmin, whose primary function in plasma is fibrin digestion 
[Adibhatla and Hatcher 2008]. After degradation of the cross-linked fibrin, the clot 
becomes soluble and can suffer further proteolysis by other enzymes, thus restoring 
blood flow [Adibhatla and Hatcher 2008]. Only 2-8% of all stroke patients are treated 
with tPA due to delay in seeking medical care and an extensive list of contraindications, 
including prior myocardial infarction, hypertension or evidence of ICH [Kleindorfer et 
al. 2004; Wu and Grotta 2010]. Nevertheless, recent studies suggest that the time 
window for thrombolysis can be safely extended without major risk of hemorrhage or 
death [reviewed in Wu and Grotta 2010]. Although there is no thrombolytic alternative 
to tPA, major advances have occurred in stroke prevention, especially in management of 
atrial fibrillation and carotid stenosis, two conditions that increase stroke risk [Wu and 
Grotta 2010]. Clinical trials have demonstrated the efficacy of warfarin and carotid 
endarterectomy (in both symptomatic and asymptomatic patients with high-grade 
stenosis) in the treatment of atrial fibrillation and carotid artery atherosclerosis, 
respectively, and secondary stroke prevention [Wu and Grotta 2010].  
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Hemorrhagic stroke 
 
Hemorrhagic stroke corresponds to approximately 10-15% of stroke cases and 
occurs due to a rupture of a cerebral blood vessel. It is more frequently fatal than 
ischemic stroke [Davenport and Dennis 2000; Lloyd-Jones et al. 2009; Sahni and 
Weinberger 2007]. Primary ICH is mainly due to small vessel disease, which is often 
associated with hypertension and amyloid angiopathy [Davenport and Dennis 2000; 
Sahni and Weinberger 2007]. Vascular abnormalities (like aneurysms and arteriovenous 
malformations), hemorrhagic conversion of an ischemic stroke, tumor, etc are 
responsible for secondary ICH [Davenport and Dennis 2000].  
The outcome after ICH is influenced by the location of the injury and by the 
hemorrhagic volume: early fatality occurs if the hemorrhagic volume exceeds a certain 
limit, but delayed fatality may also happen as a consequence of the secondary brain 
injury that results from the hematoma [Xi et al. 2006]. The harmful effects of 
hemorrhagic stroke are due to hypoxia, increased intracranial pressure resulting from 
hematoma enlargement, which may additionally restrict cerebral blood flow, and from 
the chemical toxicity in brain parenchyma and vasculature caused by the blood that is 
released from the vessel [Deb et al. 2010].  
Nowadays, there is no specific therapy to improve outcome after ICH [Sahni and 
Weinberger 2007]. Early hematoma removal through craniotomy revealed no benefit 
and, although the activated recombinant Factor VII (an antifibrinolytic agent) limits 
hematoma expansion, it was unable to reduce disability or mortality after stroke 
[Broderick 2005; Sahni and Weinberger 2007]. 
  
 
1.2 Etiology 
 
1.2.1 Stroke risk factors 
 
Age, gender and race are non-modifiable risk factors that play a role in the 
development of stroke. Stroke incidence increases with age and is higher in males than 
females but only at younger ages [Lloyd-Jones et al. 2009; Truelsen et al. 2005]. 
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Furthermore, comparing to white people, black people have approximately twice the 
risk of suffering a stroke [Lloyd-Jones et al. 2009]. There is also evidence that the 
prevalence of stroke subtypes varies according to the race and ethnicity of stroke 
patients [Kirshner 2009].  
The estimated stroke risk also increases with the number of modifiable risk 
factors that are present in an individual [Lloyd-Jones et al. 2009]. These risk factors can 
be changed or controlled through pharmacological or surgical interventions and life-
style adjustments, as primary or secondary stroke prevention measures. Modifiable 
stroke risk factors include hypertension, atrial fibrillation, carotid stenosis, increased 
blood cholesterol, cigarette smoking, alcohol consumption, diabetes, physical inactivity 
and obesity [Hankey 2006; Lloyd-Jones et al. 2009]. Randomized controlled trials have 
shown that treating hypertension, hypercholesterolemia, carotid stenosis and atrial 
fibrillation reduce the incidence of ischemic stroke [Hankey 2006].  
 
1.2.2 Evidence for genetic liability and the multifactorial model for stroke 
 
The fact that major clinical and life-style risk factors account for approximately 
60% of the population-attributable risk for stroke [Whisnant 1997] suggests the 
existence of other risk factors that may also contribute to this disease. Studies in twins, 
families and animal models provided evidence that stroke has a genetic component 
[Dichgans 2007]. Stroke is very common in old people, which makes it difficult to 
collect enough twin pairs and increases the probability of twins dying from other 
unrelated disease [Flossmann et al. 2004; Lloyd-Jones et al. 2009]. Therefore, 
conducting twin studies in stroke is challenging, and these studies have been few and 
with small sample sizes [Flossmann et al. 2004]. A meta-analysis showed that 
monozygotic twins were only 1.6 times more likely to be concordant for stroke than 
dizygotic twins, suggesting that the genetic influence on stroke risk is small [Flossmann 
et al. 2004]. The heritability for stroke death and for stroke hospitalization or stroke 
death was estimated as 0.32 and 0.17, respectively [Bak et al. 2002]. These studies, 
however, did not analyze stroke subtypes nor assessed potential confounders. In 
addition, many studies have shown that a positive family history of stroke is a risk 
factor for this disease, even when accounting for other known risk factors [reviewed in 
Flossmann et al. 2004]. This effect is likely to be moderate (odds ratio=1.76 [95% 
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confidence interval=1.70-1.90], but there was significant heterogeneity between studies 
[Flossmann et al. 2004]. There is also evidence that genetic factors are more important 
in stroke occurring early in life, with the relative influence of genetics on stroke 
susceptibility decreasing with age [Jerrard-Dunne et al. 2003; Jood et al. 2005; Schulz et 
al. 2004]. The effect of genetic factors on stroke risk may also depend on stroke 
subtypes [Jerrard-Dunne et al. 2003; Jood et al. 2005; Polychronopoulos et al. 2002; 
Schulz et al. 2004].  
There are some rare Mendelian forms of stroke arising from single-gene defects 
that are specially important in young patients with no known clinical/life-style risk 
factors [Dichgans 2007; Gulcher et al. 2005; Hassan and Markus 2000]. Stroke may be 
the prevailing manifestation or appear in conjunction with other phenotypes [Dichgans 
2007]. These disorders are frequently associated with specific stroke subtypes and the 
mode of inheritance is variable [Dichgans 2007; Hassan and Markus 2000]. Cerebral 
Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leucoencephalopathy 
(CADASIL), Fabry’s disease, Sickle-cell disease, Marfan syndrome and syndrome of 
mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes 
(MELAS) are examples of single-gene disorders with ischemic stroke. Hereditary 
cerebral hemorrhage with amyloidosis (HCHWA) – the Icelandic type (HCHWA-I) and 
the Dutch type (HCHWA-D) – are rare forms of hemorrhagic stroke arising from 
single-gene defects. 
Although Mendelian forms of stroke are important, they only account for a small 
percentage of cases and classical patterns of inheritance cannot be demonstrated for 
most stroke patients. In contrast with monogenic forms, most stroke cases represent a 
complex trait that is likely to be polygenic in etiology, with many loci modulating 
different pathophysiological mechanisms [Dichgans 2007; Hassan and Markus 2000]. 
Genetic factors may contribute to conventional risk factors, like hypertension, to 
intermediate phenotypes, such as atherosclerosis, or act directly on stroke risk 
[Dichgans 2007; Hassan and Markus 2000]. Environmental factors, gene-gene 
interactions and gene-environment interactions may also act at these different levels 
[Dichgans 2007]. Furthermore, it is likely that different genetic and environmental 
factors predispose different individuals to specific subtypes. These subtypes have 
different degrees of heritability and risk factors profiles, and the majority of recurrent 
strokes have the same mechanism as the incident stroke [Jerrard-Dunne et al. 2003; 
Jood et al. 2005; Kirshner 2009; Polychronopoulos et al. 2002; Schulz et al. 2004]. Due 
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to this complexity, genetic studies on common stroke have been less successful than 
those on monogenic forms of stroke [Dichgans 2007]. Nevertheless, and because of 
wider distribution of complex stroke, the impact of these genetic findings on a 
population may be larger and contribute to new preventative measures and/or 
therapeutic treatments [Dichgans 2007].  
 
1.2.3 Endophenotypes 
 
The pathophysiology and clinical presentation of stroke is diverse. Since this 
disease is the end result of different processes and each of these processes may be under 
the influence of different genetic factors, this complexity can make difficult to detect 
associations between stroke and specific genes. Therefore, one of the strategies to 
reduce the complexity of the phenotype is to study intermediate phenotypes or 
endophenotypes. Intermediate phenotypes are associated with stroke and represent 
particular components of the disease process, but are not compulsory stages towards 
stroke. Affected individuals may display those traits before the stroke event and the 
number of individuals with intermediate phenotypes may exceed the number of 
available stroke patients. In comparison to stroke, fewer genes are likely to be involved, 
which may increase the chance of their identification. Genes influencing any of these 
endophenotypes should be separately assessed for their effect on stroke [Dichgans 2007; 
Markus 2004].  
Carotid intima-media thickness (IMT), for example, is an indicative of 
subclinical atherosclerosis and is a strong predictor of large artery stroke [Humphries 
and Morgan 2004]. It is associated with a specific process (atherosclerosis), which 
increases homogeneity and power. Heritability of carotid IMT is estimated in 30-40% 
[Humphries and Morgan 2004]. White matter hyperintensities (WMH) on MR brain 
scans, also known as leukoaraiosis, are associated with small artery ischemic stroke. 
Leukoaraiosis is also highly heritable (55-80%) [Paternoster et al. 2009]. Other 
intermediate phenotypes associated with stroke include presence of microbleeds or 
multiple lacunae on brain imaging. 
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1.3 Strategies for genetic analyses in stroke 
 
1.3.1 Linkage studies 
 
 Usually, the first strategy to dissect the genetics of a trait is linkage analysis, 
which allows the identification of broad genomic regions containing a disease gene in 
the absence of a previous biological hypothesis [Dawn Teare and Barrett 2005]. This 
strategy has been applied to both rare Mendelian forms of stroke and common stroke. 
Two loci are linked if, under independent inheritance, they are transmitted together from 
parent to offspring more often than would be expected [Dawn Teare and Barrett 2005; 
Mayeux 2005]. For a disease following a known Mendelian pattern of inheritance, one 
or few large family pedigrees with several affected individuals can be collected to 
investigate the genetic basis of a disease [Cui et al. 2010]. Parametric linkage methods 
are then used to try to identify the set of marker alleles that are segregating with the 
disease in families, which are assumed to be located near the disease gene [Mayeux 
2005]. The linkage strategy is the most powerful to identify rare, high-risk alleles in 
Mendelian diseases [Mayeux 2005]. For multifactorial diseases, many genes and 
environmental factors, as well as complex interactions between them, can contribute to 
risk and the disease mode of inheritance is usually unknown. In this case, non-
parametric or model-free methods are used, which rely on the principle that affected 
relatives in a pedigree would share more often haplotypes that are identical by descent 
in the region of a disease-causing gene than would be expected by chance [Cui et al. 
2010; Dawn Teare and Barrett 2005]. Two commonly applied designs are the affected 
sib-pair design and the affected relative design [Cui et al. 2010]. In contrast with 
Mendelian diseases, linkage analysis of complex diseases can only identify large 
genomic regions, which often contain hundreds of genes, including many biological 
plausible candidates [Dawn Teare and Barrett 2005]. Thus, usually nonparametric 
methods have lower resolution to fine map a susceptibility locus [Belmont and Leal 
2005]. One way to narrow the intervals of interest is to study the loss of heterozigosity 
in that region or to further fine map regions with strong linkage signals using 
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approaches that are based on linkage disequilibrium (LD) [Cui et al. 2010; Dawn Teare 
and Barrett 2005]. 
 
1.3.1.1 Single gene disorders 
 
As already mentioned, single-gene defects are a rare but important cause of 
stroke, especially in younger patients. In some Mendelian conditions, stroke is the 
prevailing manifestation, while in others it is one of the associated clinical features. 
CADASIL, Fabry’s disease, sickle-cell disease and MELAS are disorders with 
autosomal dominant, X-linked, autosomal recessive and maternal modes of inheritance, 
respectively [reviewed in Dichgans 2007; Guo et al. 2010; Hassan and Markus 2000]. 
The HCHWA-I and HCHWA-D are both autosomal dominant disorders. 
CADASIL usually occurs in middle-aged individuals, which do not have 
vascular risk factors, and its clinical phenotype include recurrent strokes and TIAs and 
progressive dementia. Brain imaging shows similarities with sporadic small-vessel 
disease. This autosomal dominant disorder is caused by mutations in the NOTCH3 gene, 
although the latter could not be detected for some persons with the typical phenotype 
[Joutel et al. 1996]. This gene encodes a cell-surface receptor that is expressed on 
vascular smooth-muscle cells and has a role in arterial development. The majority of 
patients have NOTCH3 missense mutations, which cluster in exons 3-6 and affect the 
number of cysteine residues of the protein [Peters et al. 2005].  
 Fabry’s disease is an X-linked recessive disorder. Deficiency of the lysosomal 
enzyme α-galactosidase leads to progressive accumulation of glycosphingolipids in the 
myocardium, vasculature, etc… resulting in complications such as stroke and 
myocardial infarction. Cerebrovascular symptoms can occur due to large-vessel or small 
vessel disease, or due to embolism from associated cardiac disease. Fabry’s disease 
appears in childhood or adolescence and complications are observed in mid-adulthood. 
Most patients have missense or nonsense mutations in the α-galactosidase gene 
[Dichgans 2007]. 
 Stroke is an important complication of sickle-cell disease, which is the most 
common cause of stroke in children [Switzer et al. 2006]. This disease can be caused by 
homozygous mutations in the β chain of the haemoglobin, which result in haemoglobin 
S (HbS), or by compound heterozygous states of HbS with other haemoglobinopathies 
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(e.g. α-thalassaemia) [Dichgans 2007]. Stroke is attributed to large-vessel or small-
vessel disease and stroke recurrence is common. An abnormal interaction between 
sickled red blood cells and the vascular endothelium favours thrombus formation and 
vascular occlusion. The risk of stroke can be affected by modifier genes [Steinberg and 
Adewoye 2006].   
 MELAS is characterized by seizures, stroke-like episodes, lactic acidosis, 
amongst others, and is caused by mutations in mitochondrial DNA [Martínez-Fernández 
et al. 2001]. The phenotypic heterogeneity observed for mitochondrial disorders may be 
due to variable expression of mutated DNA in different tissues. 
 HCHWA-I and HCHWA-D are both autosomal dominant forms of amyloidosis 
that are characterized by recurrent strokes. Nearly 1/5 of strokes in Icelandic patients 
aged <35 years are due to HCHWA-I, which is caused by a non-synonym mutation in 
the gene encoding for cystatin C [Revesz et al. 2002]. In contrast with the Icelandic 
type, the Dutch type is characterized by dementia and is caused by a non-synonymous 
mutation in the amyloid β precursor protein (Aβ-PP) gene [Levy et al. 1990].  
 
1.3.1.2 Common stroke  
 
 Gretardstottir and colleagues [2002] performed the first genome-wide linkage 
scan in common stroke. 476 Icelandic patients with TIA, ischemic or hemorrhagic 
stroke, and 438 of their relatives (179 families in total) were analyzed using a 
framework set of 1,000 microsatellite markers, and a major locus, mapped on 
chromosome 5 (5q12), was identified. After the linkage scan, a case-control association 
analysis of 864 patients with TIA, ischemic or hemorrhagic stroke, and 908 controls 
was performed to fine map this locus, with the strongest association being found 
between the phosphodiesterase 4D gene (PDE4D) and ischemic stroke [Gretarsdottir et 
al. 2003]. In addition, they observed that the PDE4D mRNA was significantly lower in 
affected individuals than in controls. The PDE4D gene encodes different isoforms of 
the enzyme PDE4D, which regulates the levels of the second messenger cAMP (cyclic 
adenosine monophosphate) [Houslay and Adams 2003]. Evidence suggests that cAMP 
plays a role in the proliferation of smooth muscle cells and macrophages, and possible 
in atherosclerosis and plaque stability [Matarin et al. 2010]. Therefore, the authors 
proposed that the PDE4D gene might be involved in the pathogenesis of stroke through 
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atherosclerosis. However, the association of this gene with ischemic stroke was only 
confirmed in some replication studies [Bersano et al. 2008] and a meta-analysis showed 
no association after exclusion of the original study, which suggests that the association 
observed in Iceland may be restricted to specific populations [Bevan et al. 2008]. 
 Two genome-wide linkage scans searching for susceptibility genes for 
myocardial infarction and stroke were performed by the same group [Helgadottir et al. 
2004]. 296 Icelandic families, including 713 individuals with myocardial infarction, and 
164 Icelandic families that had been collected for a previous study [Gretarsdottir et al. 
2002], including 342 patients with ischemic stroke or TIA, were independently 
analyzed. The authors observed linkage to the same locus on chromosome 13 (13q12-
13). Subsequent analyses using 779 individuals with myocardial infarction, 702 stroke 
patients and 624 unrelated controls lead to the identification of a susceptibility gene for 
both diseases: arachidonate 5-lipoxygenase-activating protein (ALOX5AP). ALOX5AP 
converts unesterified arachidonic acid to leukotrienes [Dixon et al. 1990] and 
leukotrienes have been implicated in critical stages of atherosclerosis [Spanbroek et al. 
2003]. Like PDE4D, replication studies have shown conflicting results [Bersano et al. 
2008]. A meta-analysis failed to confirm the association of ALOX5AP with ischemic 
stroke [Zintzaras et al. 2009], but a different meta-analysis indicated that a SNP in this 
gene is associated with ischemic stroke [Domingues-Montanari et al. 2010]. These 
contradictory findings may be a result of different inclusion criteria used in each study. 
The former study analyzed more individuals, but also identified significant 
heterogeneity between studies, which was not observed by Domingues-Montanari and 
co-workers [2010].  
 A whole-genome linkage scan of common stroke was also performed in 56 
families from northern Sweden, which had been selected from a relatively genetically 
homogenous region, but the study did not identify any major locus for ischemic stroke 
[Nilsson-Ardnor et al. 2007]. 
 
1.3.2 Association studies 
 
Linkage analysis has successfully identified the genetic causes of many single-
gene disorders. In polygenic stroke, however, the situation is more difficult due to 
several reasons: stroke is a late-onset disease, which reduces the possibility of making 
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genetic comparisons between living relatives, it has phenotypic and genetic 
heterogeneity, variable penetrance and it coexists with confounding risk factors [Hassan 
and Markus 2000]. The majority of genetic studies in stroke have, thus, employed 
association analysis. 
Association analysis is considered one of the best methods to identify genetic 
factors contributing to complex traits [Mayeux 2005; Palmer and Cardon 2005]. Genetic 
association studies investigate if a specific marker allele is associated with a disease in a 
population. In a case-control study, for instance, this is performed by examining if a 
marker allele is more often present in affected individuals than in healthy controls 
[Cordell and Clayton 2005; Healy 2006]. In contrast to linkage, where different alleles 
may be associated with the trait in different families, association assumes that the same 
allele (or alleles) is associated with the trait in an identical manner across the whole 
population [Cordell and Clayton 2005].  
Association studies can target genetic markers that are assumed to be the 
disease-causing variants and test these markers for association with a disease (direct 
association mapping), but the probability of selecting the true causative variant is low 
[Cordell and Clayton 2005; Orr and Chanock 2008; Palmer and Cardon 2005]. Usually, 
association studies analyze subsets of single nucleotide polymorphisms (SNPs) in a 
specific region or throughout the genome. In this case, an association of a marker allele 
with a disease is likely to be due to LD between that allele and a nearby causal variant 
(indirect association mapping) [Cordell and Clayton 2005; Orr and Chanock 2008; 
Palmer and Cardon 2005]. LD is the “non-random association of alleles at different 
loci”, which is weakened every time recombination occurs between these loci in the 
population [Dawn Teare and Barrett 2005]. Thus, although association analysis has 
more power to detect low effect sizes than linkage analysis, it requires that large 
numbers of genetic markers be genotyped to cover a genomic region, since LD is 
usually observed for short chromosomal segments [Cordell and Clayton 2005; Mayeux 
2005]. Due to the fact that association operates over short distances, this strategy has 
been used to fine map regions initially detected by linkage analysis [Cordell and 
Clayton 2005].  
Evidence suggests that most of the human genome consists of regions with little 
evidence of historical recombination (with high levels of LD between markers), where 
only a few haplotypes are observed, intercalated by hotspots of recombination (with low 
levels of LD) [Gabriel et al. 2002; Healy 2006]. Therefore, it is possible to genotype 
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only a subset of SNPs in a region, called haplotype tagging SNPs, to cover the majority 
of common genetic variation in a region and to indirectly track disease-causing variants 
[Consortium 2003; Healy 2006]. The International HapMap project 
(http://www.hapmap.org) [Consortium 2003] and, more recently, the 1000 Genomes 
Project (http://www.1000genomes.org) [Durbin et al. 2010], have tried to characterize 
the LD patterns in multiple populations, facilitating the discovery of variants that affect 
common diseases. Data from these projects can be used in indirect association testing of 
genetic markers located in candidate genes, in genomic regions identified in family-
based linkage analysis or throughout the genome [Consortium 2003].  
There are several study designs for association studies [reviewed in Cordell and 
Clayton 2005], but the population-based case-control design has become the approach 
of choice in association studies of many complex diseases [Palmer and Cardon 2005] 
and it was also used in this thesis. The problem associated with this study design is, 
however, that spurious associations may arise due to stratification and admixture within 
the population. This commonly occurs when the sample under study contains subgroups 
of different racial ethnicities and with different allele frequencies [Healy 2006]. Testing 
SNPs for Hardy-Weinberg equilibrium (HWE) is recommended, as departure from 
HWE may indicate population stratification or genotyping errors, for example [Fardo et 
al. 2009]. Careful selection of controls, genotyping of random genetic markers to assess 
population structure and correct for it, and genomic control may reduce confounding 
due to population stratification [Cordell and Clayton 2005; Palmer and Cardon 2005]. 
Additionally, family-based designs, in which parents or other unaffected family 
members are used as controls, is robust against population substructure and can be used 
to solve this problem [Cui et al. 2010]. Yet, family-based designs require that more 
individuals be genotyped and, particularly in late-onset diseases, parents and unaffected 
family members may be unavailable [Belmont and Leal 2005]. 
 
1.3.2.1 Candidate genes 
 
The majority of genetic studies on human stroke have assessed the role of 
specific candidate genes in stroke susceptibility. The candidate-gene approach requires 
an a priori identification of genes that may be related to the pathogenesis of stroke, the 
development of intermediate phenotypes (e.g. intima-media thickening) or stroke risk 
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factors (e.g. hypertension and hyperlipidemia). Usually, these candidate genes are 
chosen based on their function, but may also be selected based on their genomic 
location [Domingues-Montanari et al. 2010]. There is an extensive list of tested 
candidate genes, which are involved in lipid metabolism, inflammation, homocystein 
metabolism, renin-angiotensin-aldosterone system, coagulation system, fibrinolitic 
system, platelet receptors, etc [reviewed in Bersano et al. 2008; Dichgans 2007; 
Domingues-Montanari et al. 2008; Gulcher et al. 2005; Guo et al. 2010]. This list 
includes: 
 lipid metabolism: apolipoprotein E (APOE), paraoxonase 1 (PON1), lipoprotein 
lipase (LPL) and low-density lipoprotein receptor (LDL-R) genes,  
 inflammation: C-reactive protein (CRP), tumour necrosis factor (TNF), 
interleukin 1 beta (IL1B) and interleukin 6 (IL6) genes, 
 homocystein metabolism: methylenetetrahydrofolate reductase (MTHFR) and 
cystathionine-β-synthase (CBS) genes, 
 renin-angiotensin-aldosterone system: angiotensin-converting enzyme (ACE) 
and angiotensinogen (AGT) genes, 
 coagulation system: genes encoding the factor V Leiden (F5), prothrombin (F2), 
fibrinogen (FGA/FGB), factor VII (F7), factor XIII (F13A1), factor XII (F12), 
Von Willebrand factor (VWF),  
 fibrinolitic system: genes encoding the plasminogen activator inhibitor 1 
(SERPINE1), 
 nitric oxide metabolism: nitric oxide synthase 3 (NOS3) gene, 
 platelet receptors: integrin beta 3 (ITGB3), integrin alpha 2b (ITGA2B), integrin 
alpha 2 (ITGA2) genes. 
Despite this extensive list and a large number of studies, the identification of 
variants for stroke susceptibility has been difficult, and the clinical utility and validity of 
many candidate genes have yet to be clarified. Most of the significant associations have 
small effect sizes (relative risk <1.5) and few associations have been consistently 
replicated across studies [Bersano et al. 2008; Domingues-Montanari et al. 2008]. 
Potential reasons for this lack of reproducibility include false-positive associations in 
the original study that were correctly non-replicated in subsequent studies, limited 
sample size of replication studies, methodological differences between studies (e.g. in 
study design or phenotype definition), and/or differences in genetic or environmental 
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background  [Colhoun et al. 2003; Domingues-Montanari et al. 2008; Guo et al. 2010; 
Palmer and Cardon 2005]. The hypothesis that susceptibility loci for common stroke 
have small effects implies that thousands of individuals have to be tested to increase the 
chance of detecting an effect [Munafò and Flint 2004]. This number becomes very high 
when stroke subtypes are analyzed separately. Meta-analysis, a statistical tool that is 
used for combining results from different studies, increases the ability to detect small 
effects, determining whether a real effect is present or not [Anderson et al. 2010; Casas 
et al. 2004; Domingues-Montanari et al. 2010; Munafò and Flint 2004; Pereira et al. 
2007; Sudlow et al. 2006; Wang et al. 2009]. This has the potential to solve some 
discrepancies in genetic association studies, and it can also detect between-study 
heterogeneity and publication bias [Munafò and Flint 2004]. Nevertheless, and although 
meta-analysis can confirm the involvement of a certain genetic variant when 
heterogeneity is taken into account, it does not substitute adequately powered studies 
[Munafò and Flint 2004]. In stroke, results from these analyses need to be interpreted 
with caution, because stroke risk factors are sometimes not included as covariates and 
sample sizes remain small when differences between studies (e.g. in ethnicity) are 
correctly taken into account [Matarin et al. 2010].  
Some of the most studied candidate genes for stroke encode the factor V Leiden, 
prothrombin, MTHFR and ACE. Their possible relation with stroke is briefly described 
below. 
The factor V Leiden, encoded by the F5 gene (mapped on chromosomal region 
1q23), is a glycoprotein that is involved in the coagulation process and is regulated by 
activated protein C, a protein which limits clot formation [Kalafatis et al. 1994]. The 
c.1691G>A variant leads to an amino-acid exchange (Arg506Gln), determining 
resistance to activated protein C [Bertina et al. 1994]. The consequence of this is 
increased thrombin generation and a hypercoagulable state due to less efficient 
degradation of mutated factor V by activated protein C when compared with normal 
factor V [Dahlback 1995], which may explain why carriers of this mutation possibly 
have increased risk of stroke [Bersano et al. 2008; Casas et al. 2004]. The prothrombin, 
encoded by the F2 gene (mapped on chromosomal region 11p11-q12), is a glycoprotein 
that converts fibrinogen into fibrin. A variant in the 3’-untranslated region of the F2 
gene (c.20210G>A) is associated with increased prothrombin levels and thrombin 
formation, which may similarly lead to a procoagulant state [Franco et al. 1999]. This is 
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a plausible reason for the associations with stroke risk [Bersano et al. 2008; Casas et al. 
2004]. 
The MTHFR enzyme catalyzes a reaction that is required for conversion of 
homocysteine in methionine. The c.677C>T in the MTHFR gene (mapped on 
chromosomal region 1p36.3) leads to an amino-acid substitution (Ala222Val) and is the 
most common variant associated with moderate hyperhomocysteinemia. This mutation 
makes the enzyme thermolabile, reducing the metabolism of homocysteine [Frosst et al. 
1995]. Homocysteine serum concentration is associated with the risk of stroke in a 
dose-dependent manner [Wald et al. 2002] and association studies suggest that this 
MTHFR variant increases the risk of stroke [Bersano et al. 2008; Casas et al. 2004]. 
The ACE enzyme has an important role in blood pressure regulation and 
electrolyte balance. This enzyme converts angiotensin I to angiotensin II, which is 
involved in atherosclerotic processes and vasoconstriction, and is responsible for 
degradation of bradykinin, which in turn may stimulate vasodilator nitric oxide 
production [Kim and Iwao 2000].  An insertion/deletion (I/D) polymorphism in intron 
16 of the ACE gene (mapped on chromosomal region 17q23) partly determines plasma 
and intracellular levels of ACE in healthy individuals and in patients with stroke 
[Sharma et al. 1994; Tiret et al. 1992]. Individuals with the DD genotype have an 
increase in ACE activity compared with homozygous for the I allele [Agerholm-Larsen 
et al. 2000] and may also have an increased risk of stroke [Bersano et al. 2008; Casas et 
al. 2004].  
 
1.3.2.2 Genome-wide association studies  
 
Often, there is incomplete knowledge of the biological pathways underlying 
complex traits, which limits the selection of candidate genes for association studies. 
Researchers may also want to test genomic regions for association with a given trait 
with no a priori reason. Data from the HapMap project [Consortium 2003] and the 1000 
Genomes Project [Durbin et al. 2010] have enabled the development of array-based 
platforms that can be used in high-throughput genotyping of hundreds of thousands of 
common SNPs across the entire genome. It is thus possible to perform an association 
analysis in an unbiased way, which increases the chance of finding novel insights into 
disease pathophysiology. These genome-wide association studies (GWAS) have 
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successfully identified genetic variants involved in some complex human traits 
[Hindorff et al. 2009], but can also be problematic. The number of statistical tests 
performed in these studies is very large, which increases the potential for false positive 
results, and very stringent significance levels and replication of findings are required 
[Pearson and Manolio 2008]. GWAS have analyzed hundreds to thousands of people, 
but the detection of small overall effects, in many cases, requires larger sample sizes 
[Manolio et al. 2009]. One problem of increasing sample sizes by using a broad 
definition of the phenotype or by collecting samples from different ethnic populations is 
that the study sample may become less homogenous, which can have a negative impact 
on power. Several GWAS have been carried out in stroke [Lanktree et al. 2010]. 
The first GWAS in ischemic stroke was published in 2007 [Matarín et al. 2007]. 
Over 400,000 SNPs were assessed in 249 patients and 268 neurological controls, but 
none of them was significant after adjusting for multiple testing. This study was 
underpowered to detect loci with a moderate effect on stroke risk. The data obtained in 
this GWAS was also used to assess the role of copy number variants (CNVs) in 
ischemic stroke risk [Matarin et al. 2008]. No common genomic structural variation was 
unequivocally associated with ischemic stroke. Only one of the 45 CNVs that had not 
previously been reported in healthy individuals or that did not overlap with previously 
identified CNVs was present in more than one patient. However, this CNV was also 
detected in 5 of an additional 460 controls, which suggests that it is not a risk factor for 
ischemic stroke. The authors argued that other structural variants (smaller CNVs or 
CNVs located in genomic regions poorly covered by the genotyping arrays) may confer 
risk for stroke. 
 Kubo and colleagues [2007] identified a non-synonymous SNP in the protein 
kinase C eta (PRKCH) gene  in association with lacunar infarction in two independent 
Japanese samples. First, 52,608 SNPs were genotyped in 188 patients with cerebral 
infarction and 188 controls. In a second phase, the 1,098 SNPs with the smallest P-
values were genotyped in the remaining sample (924 individuals with cerebral 
infarction and the same number of controls). A non-synonymous SNP in PRKCH, 
possibly affecting protein kinase C η (PKCη) activity, was found significantly 
associated with lacunar infarction and this association was subsequently replicated in an 
independent sample of 1,137 cases with lacunar infarction and 1,875 controls. The 
associated SNP is likely to be specific to Asian populations as its minor allele frequency 
is significantly reduced in other populations [Kubo et al. 2007]. PKCη is expressed in 
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cells located in human atherosclerotic lesions and its expression increases with lesion 
progression [Kubo et al. 2007]. These results support a role for PRKCH in ischemic 
stroke (lacunar) pathogenesis, possibly through atherosclerosis. This group also 
identified an association with brain infarction for a SNP located in the 5’-flanking 
region of the apelin receptor gene (APLNR), which was likely to regulate the expression 
of this gene [Hata et al. 2007]. Apelin is the endogenous ligand of the apelin receptor 
protein (APJ) and has some functions in the control of blood pressure [Kagiyama et al. 
2005; Seyedabadi et al. 2002]. A different GWAS was also carried out in Japanese 
individuals (131 ischemic stroke patients and 135 controls) by an independent group. 
Approximately 520,000 SNPs were assayed, followed by genotyping of 100 SNPs in 
705 ischemic stroke patients and 3426 controls [Yamada et al. 2009]. Two non-
synonymous SNPs in the cadherin, EGF LAG seven-pass G-type receptor 1 (CELSR1) 
gene were associated with ischemic stroke. A SNP near CELSR2 (a CELSR1’s 
homologue) had previously been associated with the serum concentration of low density 
lipoprotein cholesterol and the prevalence of myocardial infarction [Kathiresan et al. 
2008; Kathiresan et al. 2009], but the CELSR1 SNPs were not related to lipid profiles 
[Yamada et al. 2009]. 
 The Icelandic group that had previously performed the first whole-genome 
linkage scan also carried out a GWAS in ischemic stroke [Gretarsdottir et al. 2008]. 
Over 300,000 SNPs were genotyped in 1,661 patients and 10,815 controls from Iceland, 
followed by replication of the most significant associations in two European samples 
(2,224 cases and 2,583 controls). Two SNPs on chromosomal region 4q25, which had 
previously been reported to associate with atrial fibrillation [Gudbjartsson et al. 2007], 
were further tested in additional European samples (2,327 patients and 16,760 controls). 
One SNP was significantly associated with ischemic stroke and the evidence for 
association increased when the analysis was restricted to the cardioembolic stroke 
subtype, which is a major complication of atrial fibrillation. The other SNP was also 
associated with cardioembolic stroke. These two genetic variants are close to the paired-
like homeodomain 2 gene (PITX2), which encodes a transcriptional activator that is 
important for development of the sinoatrial node in mice, the natural pacemaker of the 
heart [Faucourt et al. 2001; Mommersteeg et al. 2007]. In a different study from the 
same group [Gudbjartsson et al. 2007], a variant on chromosomal region 16q22 was 
associated with both atrial fibrillation and ischemic stroke. This SNP is located in the 
zinc finger homeobox 3 (ZFHX3) gene, which encodes a transcription factor, and this 
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gene has been associated with neuronal and skeletal muscle differentiation [Berry et al. 
2001]. 
Ikram and colleagues [2009] performed a GWAS in a cohort of 19,602 white 
participants. Over an average follow-up of eleven years, 1,544 persons had a stroke 
(1,164 ischemic strokes in total). Two intergenic SNPs in significant LD with each other 
and located in close proximity to the ninjurin 2 gene (NINJ2) were significantly 
associated with stroke and the evidence for association increased when the analysis was 
restricted to ischemic patients. One SNP was subsequently associated with stroke in a 
cohort of 2,430 black participants (comprising 215 stroke patients) and in a case-control 
sample of 4,265 white people (652 stroke patients). The second SNP was only 
associated in the sample of white participants possibly because of low LD between the 
two SNPs in the second sample. NINJ2 encodes the ninjurin2 protein, an adhesion 
molecule that is expressed in glia [Araki and Milbrandt 2000]. It was proposed that the 
level of expression of this protein affects how the brain tolerates ischemic insults [Ikram 
et al. 2009].  
 It is possible to draw several conclusions from the results obtained in GWAS of 
stroke. First, the results have been inconsistent, as the same locus was not identified in 
two independent studies at a genome-wide significance level (approximately P<10
-7
), 
but there is also significant heterogeneity in study designs and in ethnic backgrounds of 
individuals. Second, the effect sizes identified are modest. Third, no association has 
been found between stroke and any locus with previous evidence from candidate gene 
studies.  
 
1.3.3 Gene-gene interactions 
 
Complex diseases likely result from the effect of several genes, and possibly on 
interactions with other genes [Ritchie 2011]. The contribution of one locus to a 
phenotype may therefore depend on the genotype at a second locus, or in the extreme, 
the genetic background of an individual [Moore and Williams 2005; Tyler et al. 2009]. 
Identifying these non-additive or epistatic interactions in genetic studies is important, as 
any positive finding could shed light on the biological and biochemical pathways 
contributing to disease [Cordell 2009]. 
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 Several methods have been used to detect epistasis [reviewed in Cordell 2009; 
Ritchie 2011]. One possibility is to test for interactions that occur between two or more 
known or hypothetical genetic risk factors (e.g. to replicate a previous finding) using 
regression models. It is more common, however, to search for loci that may interact in 
genotype data from many genetic variants, obtained in candidate gene or GWAS. In this 
situation, there is probably no previous evidence linking these genetic variants with a 
specific disease, so one may wish to perform an exhaustive search of 2-loci or higher-
order interactions, which has the important disadvantage of increasing the potential for 
false positives. Furthermore, in a genome scan, while searching for 2-loci interactions is 
computationally intensive but feasible, searching for 3-loci to higher-level interactions 
is impractical [Cordell 2009; Marchini et al. 2005]. To overcome this problem, two-
stage procedures have been proposed, in which a subset of loci are selected in a first 
stage based on single-locus significance thresholds, and an exhaustive search of two-
locus interactions is performed in the filtered dataset. Alternatively, genetic markers can 
be selected in a first stage based on experimental knowledge of biological networks or 
protein-protein interactions [Emily et al. 2009; Ritchie 2011]. Data-mining methods are 
another alternative to investigate the existence of gene-gene interactions. The 
multifactor dimensionality reduction (MDR) method is one of the most commonly used 
data-mining approaches [Ritchie et al. 2001]. It is a model free and nonparametric 
method, and can detect genetic interactions in the absence of independent main effects 
[Ritchie et al. 2003; Ritchie et al. 2001]. This method reduces the dimensionality of the 
data from N dimensions to one dimension by pooling multilocus genotypes into high 
and low risk groups, and subsequently tests the new, one dimensional variable for its 
ability to classify and predict disease status. If 10 cross-validation intervals are chosen, 
the MDR divides the data into 10 parts, develops the interaction model in 9 of these 
parts, and assesses the model in the remaining 1/10 of the data. The multiple testing 
issue is addressed by combining this cross-validation strategy and permutation testing 
[Ritchie et al. 2001]. An important disadvantage of this method is that, for higher-order 
interactions, it is best suited for the analysis of relatively small number of loci [Cordell 
2009]. 
 Susceptibility to ischemic stroke may be modulated by non-linear gene-gene 
interactions [Liu et al. 2009; Shen et al. 2007]. Liu and colleagues (2009), in particular, 
investigated the existence of gene-gene interactions between five candidate genes and 
stroke and found that individuals with a combination of polymorphisms in three of these 
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genes had an increased risk of thrombotic stroke. After gene-gene interactions have 
been detected, it is desirable to elucidate how these interactions at the DNA level can 
influence phenotypes in an individual through biochemical processes that are dependent 
on biomolecular interactions [Cordell 2009; Moore 2003; Moore and Williams 2005]. It 
is challenging to make inferences about biological processes based on statistical models 
of interactions, especially in humans, which cannot be used in experimental studies 
[Moore and Williams 2005]. Nevertheless, interpretation of results can be greatly 
enhanced by testing for interactions between genes encoding proteins in the same 
pathway or with similar functions [Ritchie 2011], as was performed in this thesis. 
Although this will bias the analysis and possibly miss novel interactions between SNPs, 
it will also increase the likelihood that any identified interaction will be biologically 
plausible and interpretable [Ritchie 2011].  
Epistasis is a plausible explanation for the lack of success of many association 
studies, which have mainly used a single-locus analysis strategy [Cordell 2009]. If a 
genetic variant is individually tested for association with a phenotype but functions 
through complex mechanisms involving other genes, its effects may be missed [Cordell 
2009]. The existence of these interactions may also explain why positive results from 
linkage and association studies of complex diseases are frequently not replicated in 
subsequent studies or show inconsistencies [Greene et al. 2009; Moore 2003]. For 
example, Greene and co-workers [2009] showed that, under an epistatic model, in 
which SNPA and SNPB are interacting loci, the power to replicate a main effect at SNPA 
can be greatly affected by a small change in minor allele frequency at SNPB. 
Furthermore, an initially found protective allele at locus A may be replicated as a risk 
allele due to differences in allele frequencies at locus B [Greene et al. 2009]. 
 
1.4 Stroke outcome and functional recovery 
 
 As already referred, a significant proportion of stroke survivors are left disabled. 
These patients have an increased probability of having a second stroke episode and/or of 
dying in the following years [Hankey et al. 2002; Hardie et al. 2004]. Patients with 
large-vessel ischemic stroke lose 120 million neurons per hour, which may explain the 
motor weakness and sensory disturbances that most individuals exhibit [Lakhan et al. 
2009]. Comparing to the normal rate of neuronal loss during aging, this means that the 
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brain ages 3.6 years per hour in the absence of any treatment [Lakhan et al. 2009]. 
Despite this loss, a slow but consistent recovery occurs in the brain afterwards due to 
several physiological processes [Hurtado et al. 2006]. Edema resolution and/or 
reperfusion of the ischemic penumbra are plausible explanations for the spontaneous 
recovery that is observed in the first days after ischemic stroke [Hurtado et al. 2006]. 
Formation of new synapses from the surviving neurons and redundancy of brain 
circuits, allowing functional compensation of damaged areas, are possible mechanisms 
of brain plasticity, which also influence patient’s recovery [Hurtado et al. 2006; Lakhan 
et al. 2009]. Moreover, formation of new neurons (neurogenesis) and blood vessels 
(angiogenesis) contribute to ameliorate neurological deficits and is correlated with 
patient’s survival time, respectively [Jin et al. 2006; Krupinski et al. 1993; Nakatomi et 
al. 2002; Slevin et al. 2006]. Although the recovery mechanisms after hemorrhagic 
stroke have been less studied, it is already known that neurogenesis is induced after this 
type of stroke [Shendure and Ji 2008].  
 
Table 1. Modified Rankin Scale (mRS) 
mRS Symptoms 
0 No symptoms 
1 
No significant disability, despite symptoms 
(able to perform all usual activities and duties) 
2 
Slight disability 
(unable to perform all previous activities but able to look 
after own affairs without assistance) 
3 
Moderate disability 
(require some help, but able to walk without assistance) 
4 
Moderately severe disability 
(unable to walk without assistance and unable to attend to 
own bodily needs without assistance) 
5 
Severe disability 
(bedridden, incontinent and require constant nursing care 
and attention) 
6 Dead 
Adapted from [Kasner 2006] 
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The modified Rankin Scale (mRS) is one of the most widely used scales to 
assess stroke outcome [van Swieten et al. 1988]. It  measures the global disability of a 
patient and has been employed in clinical practice to evaluate the effect of stroke on 
patient’s activities and life-style [Kasner 2006]. mRS has been used as a primary end 
point in randomized clinical trials and can also be used to guide rehabilitation 
procedures [Kasner 2006]. This scale has seven different grades, with mRS=0 indicating 
no symptoms and mRS=6 indicating death (Table 1). In statistical analyses, the mRS 
outcomes are often dichotomized as either good or poor, but the cut-off for good/poor 
outcome is subject of controversy [Weisscher et al. 2008]. Other scales that have been 
employed to assess stroke outcome include the Barthel Index (BI), the Glasgow 
Outcome Scale (GOS) and the Stroke Impact Scale (SIS). The National Institutes of 
Health stroke scale (NIHSS) has been used as an initial assessment tool of stroke 
severity, and is predictive of long-term outcome [Kasner 2006]. This scale assesses 
level of consciousness, language (aphasia), coordination (ataxia), hemi-inattention 
(neglect), among other features. It is correlated with infarct volume, although other 
factors, including age and stroke location, contribute to this correlation [Kasner 2006]. 
 Several factors are known to affect stroke outcome. Age, gender, diabetes, blood 
pressure, initial stroke severity, previous stroke, stroke type, volume of the infarction or 
hemorrhage, among others, have been identified as significant predictors of functional 
outcome and/or patient’s mortality [Di Carlo et al. 2003; Megherbi et al. 2003; Tilling 
et al. 2001; Weimar et al. 2006; Weimar et al. 2002; Wong et al. 2005]. Moreover, it 
was shown that a family history of stroke is associated with stroke outcome, but not 
with stroke severity or mortality at 90 days, indicating that genetic factors may also 
influence stroke outcome [Jood et al. 2005; Lisabeth et al. 2005]. Studies with animal 
models, which recreate human ischemic stroke and ICH, also support this hypothesis 
[Atochin et al. 2010; Chang et al. 2011; Grossetete and Rosenberg 2008; Hyakkoku et 
al. 2010; Jeffs et al. 1997; Leker et al. 2007; Schäbitz et al. 2007; Tsuji et al. 2005]. 
Ischemic stroke can be induced in animals through occlusion of the middle cerebral 
artery (MCAO) using a clip or by injecting small blood clots [Small and Buchan 2000]. 
ICH, on the other hand, can be recreated through infusion of bacterial collagenase, 
which disrupts the basal lamina of blood vessels causing blood to flood the surrounding 
tissue [MacLellan et al. 2010]. Jeffs and colleagues [1997] performed a genome scan in 
rats to identify the genetic factors responsible for large infarct volumes after MCAO. 
They identified a quantitative trait locus that accounted for approximately 70% of total 
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variance in infarct volume [Jeffs et al. 1997]. Other studies have used KO mice to assess 
the influence of specific genes in stroke outcome. For instance, Caveolin-1 (CAV1) 
may have a deleterious role after ICH, as Cav-1 KO mice had smaller injury volumes 
and milder neurological deficits than wild-type mice after the insult [Chang et al. 2011]. 
In a different study, mice deficient in the alpha 1 subunit of soluble guanylate cyclase 
(sGCalpha1(-/-)) had larger infarct volumes and worse neurological deficits after 
ischemic stroke than wild-type mice, suggesting that sGCalpha1 is beneficial after 
stroke [Atochin et al. 2010]. 
Despite evidence of a role of genetics in stroke outcome and recovery, the 
investigation of the genetic factors involved in stroke outcome in humans is still in its 
infancy, when compared with the large number of association studies assessing the role 
of candidate genes in stroke susceptibility. The APOE gene is the most tested candidate 
gene for stroke outcome [Meschia 2004]. As observed in genetic association studies of 
stroke susceptibility, some studies have found an association between APOE and stroke 
outcome, while others failed to confirm this association [McCarron et al. 2000; 
McCarron et al. 1998; Sarzynska-Dlugosz et al. 2007; Treger et al. 2003]. A meta-
analysis found no association between presence of ε4+ genotypes and poor outcome 
after ischemic stroke or ICH, but there was significant heterogeneity between studies 
regarding the clinical scales used to assess patient’s outcome and the time of assessment 
[Martínez-González and Sudlow 2006]. APOE is located on chromosome 19 and has 
three common alleles – ε2, ε3 and ε4, which encode the three major isoforms of the 
protein ApoE. This protein is the primary mediator of cholesterol and lipid transport in 
the brain and is associated with serum lipoprotein level. Furthermore, it has an 
important role in neurological diseases, such as Alzheimer’s disease.  Other candidate 
genes tested for a role in stroke outcome include those encoding for proteins involved in 
platelet adhesion and aggregation (PLAT [plasminogen activator, tissue] and SERPINE1 
genes), in metabolic pathways regulating oxidative stress in the brain (MTHFR and 
GSTO1 [glutathione S-transferase omega 1] genes), in inflammatory pathways (PTGS2 
gene), and proteins of the thrombolytic system (GP1BA [glycoprotein Ib, alpha 
polypeptide] and ITGB3 genes) [Maguire et al. 2010; Peddareddygari et al. 2009]. Two 
PTGS2 SNPs and one ITGB3 SNP were nominally associated with stroke outcome 
[Maguire et al. 2010]. Until now, no GWAS has been carried out to investigate the role 
of genetic factors on stroke outcome. 
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1.5 Objectives and thesis outline 
 
The identification and characterization of the genetic factors underlying 
susceptibility to stroke and influencing patient’s outcome afterwards should be a 
priority matter due to the high incidence, mortality and disability associated with stroke. 
The main objective of the present thesis was therefore to identify genetic factors 
involved in stroke susceptibility and in patient’s outcome at three months. For this 
purpose, the following strategies were employed: 
 Candidate genes were selected and tested for a role in stroke susceptibility using 
a population-based case-control design and taking advantage of a Portuguese biobank of 
672 stroke patients and 530 healthy individuals.  
 Searching for genes that contribute to stroke outcome constitutes one main 
originality of this thesis. Two approaches were followed to attain this goal: candidate 
genes and GWAS. A subset of 546 stroke patients was analyzed. Extensive clinical data 
during hospitalization and information on functional outcome at three months were 
available for each patient. Candidate genes were selected and tested for association with 
patient’s outcome at three months. A pilot GWAS of approximately 250,000 SNPs was 
also carried out using a DNA pooling strategy. This made possible to perform an 
association analysis in an unbiased manner, with no prior selection of candidate genes, 
which increased the chance of finding novel insights into the mechanisms of stroke 
recovery, and in a cost-effective way.  
 
The thesis outline is as follows: 
 In chapter 2 of this work, genetic variants in two matrix metalloproteinase genes 
(MMP2 and MMP9) were tested for association with patient’s outcome at three months. 
 Four inflammatory genes (IL1B, IL6, MPO and TNF) were tested for a role in 
stroke susceptibility and outcome and these analyses are described in chapter 3.  
 In chapter 4, the association with stroke outcome was analyzed for genetic 
variants within three growth factor genes (BDNF, FGF2 and VEGFA). 
 Variants of two genes involved in the nitric oxide metabolism/oxidative stress 
(NOS1 and NOS3) were tested for association with stroke susceptibility and outcome in 
chapter 5. 
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 In chapter 6, we sought to identify novel genes contributing to patient’s outcome 
at three months, by performing a pilot GWAS in DNA pooled samples. A total of 
262,264 SNPs, located throughout the genome, were assessed, followed by individual 
genotyping to validate results from the pooling stage. 
 Chapter 7 comprises a general discussion of the results presented in chapters 2-6, 
as well as concluding remarks and future perspectives.  
 The abstracts of published manuscripts for which I contributed as co-author are 
presented in Appendix 1. 
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Abstract   
 
Background – Multiple lines of evidence suggest that genetic factors contribute to 
stroke recovery. The matrix metalloproteinases-2 (MMP-2) and -9 (MMP-9) are modulators 
of extracellular matrix components, with important regulatory functions in the Central 
Nervous System (CNS). Shortly after stroke, MMP-2 and MMP-9 have mainly damaging 
effects for brain tissue. However, MMPs also have a beneficial activity in angiogenesis and 
neurovascular remodeling during the delayed neuroinflammatory response phase, thus 
possibly contributing to stroke functional recovery.  
Methods – In the present study, the role of MMP2 and MMP9 genetic variants in 
stroke recovery was investigated in 546 stroke patients. Functional outcome was assessed 
three months after a stroke episode using the modified Rankin Scale (mRS), and patients 
were classified in two groups: good recovery (mRS≤1) or poor recovery (mRS>1). Haplotype 
tagging single nucleotide polymorphisms (SNPs) in the MMP2 (N=21) and MMP9 (N=4) 
genes were genotyped and tested for association with stroke outcome, adjusting for 
significant non-genetic clinical variables.  
Results – Six SNPs in the MMP2 gene were significantly associated with stroke 
outcome (0.002<P<0.042), two of which survived the Bonferroni correction for multiple 
testing. In the subset of ischemic stroke patients, association of five of these SNPs remained 
positive (0.004<P<0.031). No significant associations were found for the MMP9 gene.  
Conclusions – The results presented strongly indicate that MMP2 genetic variants are 
an important mediator of functional outcome after stroke. 
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Background 
 
While remaining one of the most common causes of death worldwide, stroke is also a 
leading cause of significant disability: after a first stroke event, 50-70% of stroke patients 
regain functional independence, but 15-30% are permanently disabled and 20% require 
institutional care at 3 months after onset [Asplund et al. 1998]. Clinical and demographic 
factors can influence stroke outcome. In addition, genetic factors are likely to have an impact 
in stroke recovery processes and outcome: family history of stroke is associated with stroke 
outcome [Jood et al. 2005; Lisabeth et al. 2005] and many animal models of stroke implicate 
genes that regulate angiogenesis, neuronal regeneration and proliferation, and 
neuroinflammation, in stroke recovery [McColl et al. 2007; Nygren et al. 2006; Sun et al. 
2003; Svedin et al. 2007]. 
Several lines of evidence suggest that matrix metalloproteinases (MMPs) are 
fundamental players in stroke recovery. These molecules belong to a family of zinc-
dependent endopeptidases that modulate extracellular matrix (ECM) components in many 
Central Nervous System (CNS) developmental and regenerative processes such as 
neurogenesis, axonal growth and regeneration, and myelin formation. The expression and 
activity of MMPs is tightly regulated. Most MMPs require proteolytic processing by 
proteases or other MMPs to become activated, and can be inhibited by tissue inhibitors of 
metalloproteinases (TIMPs). Dysregulated MMP activity will lead to uncontrolled 
degradation of ECM and basal lamina proteins, with serious harmful effects for the blood-
brain barrier (BBB) integrity and neuroinflammatory or neurotoxic consequences 
[Candelario-Jalil et al. 2009; Rosell and Lo 2008]. Such dysregulation of MMPs is known to 
occur after stroke, leading to a degradation of the neurovascular matrix, disrupting cell-matrix 
homeostasis and weakening the BBB, and thus contributing to cell death, neurotoxicity, 
edema and hemorrhage [Gu et al. 2005; Rosell and Lo 2008]. The variation profiles of MMPs 
in blood after a stroke event [Horstmann et al. 2003; Horstmann et al. 2006] suggest that 
these molecules can eventually be used as biomarkers for brain damage and neurological 
outcome, while their contribution to tissue destruction renders MMPs inhibitors potentially 
interesting therapeutic targets for stroke.   
Emerging studies, however, indicate that MMPs may also have a beneficial activity in 
angiogenesis and neurovascular remodeling during the delayed neuroinflammatory response 
phase after stroke, possibly contributing to stroke functional recovery [Rosell and Lo 2008]. 
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While inhibition of MMP activity has consistently been demonstrated to be effective in 
reducing edema, infarct size and hemorrhagic transformation, some studies suggest the 
existence of a time window for these beneficial effects to take place [Sood et al. 2008; Zhao 
et al. 2006].  
In the present study we tested the impact of genetic variants in MMP2 and MMP9 in 
stroke recovery, in a population sample of 546 patients evaluated for stroke outcome at three 
months after the stroke event.  
 
 
Methods 
 
Participants in the present study were recruited in the context of a wider research 
project to evaluate stroke risk factors in a Portuguese population sample, which enrolled first-
ever stroke patients under 65 years of age through Neurology and Internal Medicine 
Departments of several hospitals in Portugal. Stroke was defined as a focal neurological 
deficit of sudden or rapid onset lasting more than 24 hours, and classified into ischemic or 
intracerebral hemorrhage based on brain imaging (computed tomography and/or magnetic 
resonance imaging). The diagnosis of stroke was confirmed by a neurologist. Demographic 
characteristics (age and gender), information on previous vascular risk factors and comorbid 
conditions (diabetes mellitus, hypertension, cardiac disease, dyslipidemia, obesity), life-style 
risk factors (smoking, alcohol consumption, physical inactivity and others), and detailed 
clinical data during hospitalization, including neurological symptoms, complications and 
interventions, were collected for the majority of patients. Occurrence of aphasia, neglect, 
paresis, gaze paresis, dysphagia, permanent altered consciousness, urinary incontinence and 
medical and neurological complications were clinical parameters indicative of stroke 
severity. Stroke outcome at discharge and at three months was assessed, by direct interview, 
using the modified Rankin Scale (mRS).  
For the present study, 568 patients with relevant clinical data and a DNA sample were 
available. Eight patients had a second stroke event after enrolment, affecting patient recovery, 
and were thus excluded. Of the remaining 560, 14 did not return after discharge for the three 
months evaluation, and therefore only 546 patients were included in the analysis. Patients 
were classified in two groups, according to their mRS at three months: patients with mRS≤1 
were assigned to the “good recovery” group and patients with mRS>1 were assigned to the 
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“poor recovery” group (handicapped patients). 276 individuals were included in the good 
recovery group (63.0% males and 37.0% females) and 270 in the poor recovery group (64.4% 
males, 35.6% females). The poor recovery group included 12 patients who died before the 
three months evaluation (seven of them before hospital discharge, and five others after 
discharge). Genetic power calculations were performed using the CaTS software [Skol et al. 
2006].  
The study was approved by the Ethics Committee of Instituto Nacional de Saúde Dr. 
Ricardo Jorge and other hospitals involved, subjects gave informed consent and procedures 
followed were in accordance with institutional guidelines.  
Single nucleotide polymorphisms (SNPs) within the MMP2 and MMP9 genes and up 
to 5kb of the flanking regions were selected using the Haploview software (v4.0) [Barrett et 
al. 2005], based on their tagging potential (HapMap Release 21/phase II July 2006). 4 SNPs 
in MMP9 and 20 SNPs in MMP2 were genotyped using the Sequenom iPLEX assays with 
allele detection by mass spectroscopy, using Sequenom MassARRAY technology 
(Sequenom, San Diego, USA) and following the manufacturer’s protocol. Primer sequences 
were designed using Sequenom’s MassARRAY Assay Design 3.0 software. 1 SNP in MMP2 
was genotyped using TaqMan
®
 Pre-Designed SNP Genotyping Assays, in an ABI PRISM 
7900HT Sequence Detector System (Applied Biosystems, Foster City, USA). Extensive 
quality control was performed using eight HapMap individuals, duplicated samples within 
and across genotyping plates, Mendelian segregation in three pedigrees and no-template 
samples. Call rates <90% and deviation from Hardy-Weinberg equilibrium led to SNP 
exclusion from the analysis. 2 SNPs in MMP9 failed quality control and were substituted. In 
total, 21 MMP2 SNPs and 4 MMP9 SNPs were analyzed. 
The effect of discrete and continuous non-genetic variables on stroke outcome at three 
months was determined using the Pearson’s 2 test and Mann-Whitney test, respectively. 
These included age, gender, stroke risk factors as well as data on clinical variables collected 
during hospitalization (like occurrence of paresis, aphasia and medical complications). 
Variables with a P<0.25 in univariate analysis or of particular clinical relevance were 
included in a logistic regression model using forward selection [Hosmer and Lemeshow 
2000] and were maintained in the model if they were associated at a P≤0.05 level with stroke 
outcome. Logistic regression analyses were then used to determine the effect of each genetic 
variable on stroke outcome after adjustment for those significant non-genetic variables. Odds 
ratio (OR) and 95% confidence intervals (95% CI) were computed for the log-additive model. 
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Univariate and logistic regression analyses were performed using MASS and SNPassoc 
packages of the R software [R: A language and Environment for Statistical Computing  2004] 
(v2.6.0). The Gabriel et al. (2002) [Gabriel et al. 2002] default method of the Haploview 
software [Barrett et al. 2005] (v4.0) was used to determine haplotype blocks in the MMP2 
and MMP9 genes. Since recovery processes may be regulated differently in ischemic and 
hemorrhagic stroke patients, we performed the same analyses in the subset of ischemic stroke 
patients. The small number of hemorrhagic stroke patients (N=105) precluded the 
independent analysis of this subset.  
 Significant associations in individual SNP analysis were corrected for multiple testing 
using the Bonferroni method. The alternative SNPSpD approach, based on the spectral 
decomposition (SpD) of matrices of pairwise linkage disequilibrium (LD) between SNPs was 
also applied [Nyholt 2004]. Since some of the 21 SNPs genotyped in the MMP2 gene are in 
LD with each other in our sample, we used the SNPSpD approach to estimate the effective 
number of independent SNPs in our sample for multiple testing corrections. 
 
 
Results 
 
Clinical and demographic characteristics of the population sample are presented in 
Table 1. Univariate analysis showed that type of stroke and six clinical features indicative of 
stroke severity – occurrence of aphasia, urinary incontinence, paresis, altered consciousness, 
medical and neurological complications during hospitalization – were significant predictors 
of poor outcome. Sex ratio, age, and stroke risk factors were similar between the poor and 
good recovery groups, and approximately the same proportion of patients was being treated 
for hypertension in either group (34.0% and 34.6% in the good and poor recovery groups, 
respectively). Assuming an additive genetic model and phenotype allele frequency of 30%, 
our sample was 82% powered to detect a genotype relative risk of 1.5 with a type I error of 
5%.  
Of 21 MMP2 SNPs, six were associated with stroke outcome at three months under a 
log-additive model (0.002<P<0.042) after adjusting for the significant covariates in a 
multivariate model: history of hypertension, type of stroke, occurrence of aphasia, paresis, 
altered consciousness and medical complications during hospitalization (Table 2; see 
Supplementary table 1). History of hypertension, although not associated in the univariate 
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analysis, became significant in the multivariate model before inclusion of genetic variants, 
and was therefore included in the final regression model. SNPs rs2241145 and rs1992116 
remained significantly associated with stroke outcome after Bonferroni correction for 
multiple testing (OR[95%CI]=1.66[1.20-2.30], correctedP=0.044, and OR[95%CI]=1.67[1.20-
2.31], correctedP=0.039, respectively). Two haplotypes (one of which rare) were nominally 
associated with stroke outcome at three months (Table 3, Figure 1A; see Supplementary table 
2).   
The hypothesis that the recovery processes after ischemic and hemorrhagic stroke 
may be different and regulated by different sets of genes [Mehta et al. 2007; Xi et al. 2006] 
led us to analyze the ischemic stroke subset independently. The haemorrhagic subset was too 
small for independent analysis (N=105). In the ischemic stroke sample, five out of the 
previously associated SNPs in the MMP2 gene remained significantly associated with stroke 
outcome at three months under a log-additive model (0.004<P<0.031), after adjusting for the 
same significant covariates (excluding type of stroke) (Table 2; see Supplementary table 1). 
ORs for these SNPs in this subset were similar to the overall study sample. None of the SNPs 
remained significant after Bonferroni correction for multiple testing. However, when the 
SNPSpD method was used, taking into account regional LD patterns and therefore the 
number of SNPs which are effectively independent, the two SNPs that survived Bonferroni 
correction in the whole sample remained significant for the ischemic stroke subset 
(rs2241145 and rs1992116) (see Supplementary table 1). Four additional MMP2 SNPs were 
nominally associated with ischemic stroke outcome at three months (0.016<P<0.041, Table 
2). Only one haplotype in MMP2 was also associated (Table 3; see Supplementary table 2).  
OR analysis indicates that, for the majority of significantly associated SNPs 
(including rs2241145 and rs1992116), carriers of the minor allele (less frequent allele) are 
significant predictors of poor outcome (OR>1); only for rs243842 in the whole population 
sample, and for rs857403 and rs183112 in the ischemic subset, carriers of the minor allele 
show an improved chance of good recovery from stroke (OR<1).  
In the MMP9 gene, one rare haplotype was associated with stroke outcome in the 
overall population sample (P=0.007, Table 3, Figure 1B; see Supplementary table 2), but no 
independent association was found for any of the four tested SNPs (see Supplementary table 
1). No SNP or haplotype in the MMP9 gene was associated with stroke outcome at three 
months in the ischemic subset (see Supplementary tables 1 and 2).  
None of the tested SNPs were associated with hypertension, indicating that the MMP-
2 effect on recovery was not mediated by its role on vascular structure (data not shown).  
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Two of the MMP2 SNPs (rs1053605 and rs243849) are located in exonic regions of 
the MMP2 gene (exons 5 and 7, respectively), two SNPs (rs243866 and rs243865) are located 
upstream of the gene, and six SNPs are intronic (Figure 1A). Both nucleotide transitions in 
the exonic SNPs are silent. To investigate possible functional consequences for gene 
transcription of the two upstream SNPs (rs243866 and rs243865) and the two intronic SNPs 
that survived correction for multiple testing (rs2241145 and rs1992116), we conducted a 
bioinformatics search for putative transcription factor binding sites. The A allele of the 
upstream SNP rs243866 lies in the core of a sequence with high similarity to the matrix for 
two binding factors, the IPF1 (insulin promoter factor 1), and the POU5F1 (POU domain 
class 5 transcription factor 1). Both proteins are transcription activators. Since the AA and 
AG genotypes are more frequent in the poor recovery group, we can hypothesize that the 
presence of the A allele may lead to an increased transcription of the MMP2 gene, and thus 
explain the negative impact on stroke recovery observed in this population sample. The 
presence of the T allele in the upstream rs243865 SNP forms a sequence with high similarity 
to the matrix for the PLZF binding factor (promyelocytic leukemia zinc finger protein), while 
the sequence containing the C allele has a stronger similarity with the matrix for the 
VDR/RXR (vitamin D hormone receptor/retinoid X receptor) heterodimer. However, both 
transcription factors act as repressors, and therefore these findings are more difficult to 
interpret. The rs2241145 and rs1992116 intronic SNPs did not contain sequences for any 
known putative transcription factor binding sites.   
 
 
Discussion  
 
In the present study we show that MMP2 gene variants are strongly associated with 
patient’s functional disability at three months after stroke onset, in a large Portuguese 
population sample. Given the possible genetic heterogeneity in recovery processes after 
hemorrhagic and ischemic stroke [Mehta et al. 2007; Xi et al. 2006], we also analyzed the 
association of this gene with stroke outcome in the restricted subgroup of ischemic stroke 
patients. All but one MMP2 gene variants associated with stroke in the overall population 
sample remained associated with ischemic stroke in this smaller subset. Additional markers 
were associated only in this subset, possibly reflecting the increased genetic homogeneity of 
the ischemic group in terms of recovery processes. Associated SNPs in the ischemic subset 
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did not, however, withstand Bonferroni correction for multiple testing. This could reflect the 
reduction in power due to the smaller sample size in the restricted analysis and/or the 
overcorrection for the false positive rate that is the main frequent criticism for this method. In 
fact, the alternative SNPSpD approach [Nyholt 2004], which takes into account LD patterns 
between genotyped SNPs in the tested population, may be more appropriate since the 21 
genotyped MMP2 SNPs are not independent; with this approach, the significance of 
association of two specific SNPs with stroke, in the ischemic subset or in the overall 
population sample, was retained after multiple testing correction. The association results after 
multiple testing correction, using the stringent Bonferroni method or the SNPSpD approach, 
strongly support a role for MMP2 in stroke recovery. Validation through replication in a 
larger sample set by other groups is now advisable. 
A limitation of the present study was the lack of availability of the National Institute 
of Health Stroke Scale (NIHSS) for these patients. To control for the effect of the severity of 
stroke in patients’ outcome, we performed a logistic regression analysis using, as covariates, 
individual clinical variables associated with stroke clinical severity in our sample. Each 
selected variable was entered in the logistic regression model to identify those behaving as 
clinical predictors of stroke outcome. While this approach may not be as comprehensive as a 
widely used severity scale, it allowed us to include in the analysis parameters that reflect the 
severity of the event and, to a certain extent, patient’s status at baseline. 
While subject of controversy, the cut-off for the good and poor recovery groups was 
set between 1 and 2 because we chose to focus on a non-handicaped recovery group. 
According to Weisscher et al. (2008) [Weisscher et al. 2008], there is a clear lag on 
performance of outdoor activities between mRS 1 and 2, while between mRS 2 and 3 the 
major difference is the ability to perform complex activities of daily life, and thus a more 
clearly defined good outcome is given by setting the cut-off between mRS 1 and 2. 
Multiple studies in animal models and humans have shown that the actions of MMPs 
contribute to BBB disruption and brain cell death, early after a stroke event. These damaging 
processes can be inhibited by MMP inhibitors, leading to reductions in infarct volume and 
significant improvements in behavioural scores compared with controls [Gu et al. 2005]. 
However, fitting with their role in development and regeneration, a beneficial influence of 
MMPs in the recovery processes that occur in later stages after a stroke event, including 
angiogenesis, remyelination, neural migration and general recovery of the neurovascular unit 
has been shown [Girolamo et al. 2004; Hsu et al. 2006; Sood et al. 2008; Zhao et al. 2006]. 
At present, we cannot dissect whether gene variation in MMP2 is more important for the 
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damaging effects in the earlier stages after stroke, or to the beneficial delayed responses, or 
both. Functional studies will be required to answer this question. However, the present 
findings may have important implications. On one hand it challenges the usefulness of MMP 
inhibitors for the treatment of stroke, not only because the time window of usefulness is 
likely limited, but also because it may depend on the individual’s MMP2 genotype. On the 
other hand, and given that MMP-2 has also been suggested to influence the risk of 
hemorrhagic transformation upon recombinant tissue plasminogen activator (tPA) therapy 
[Liu et al. 2006], it is a plausible hypothesis that treatment outcome may also be associated 
with MMP2 gene variants. Further work needs to be carried out to elucidate these questions. 
 
 
Conclusions  
 
The present study further reinforces the contribution of MMPs for stroke recovery by 
showing that specific MMP2, but not MMP9, gene variants influence stroke outcome. 
Replication of these associations in larger population samples, together with approaches that 
integrate evidence from multiple levels, including gene expression and functional analysis, 
will contribute for the validation of these results. Together with previous observations, the 
study leads to the hypothesis that individual variation in the MMP2 gene may influence 
stroke treatment outcome.  
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Figures 
 
Figure 1 – Schematic diagrams of the MMP2 (A) and MMP9 (B) genes showing 
the location of the 13 exons (black boxes), the 5’ and 3’ untranslated 
regions (white boxes) and the pairwise r
2
 plots for the 21 genotyped SNPs 
in MMP2 and 4 genotyped SNPs in MMP9, in our population sample. Markers associated with three months 
outcome are indicated. Linkage disequilibrium blocks were generated using the Gabriel et al. [2002] method. 
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Tables 
 
Table 1 – Demographic and clinical characteristics of stroke patients. 
Age, mean±SD (yrs) 50.8±9 52.5±8.5 0.028
Gender (male), n/N (%) 174/276 (63.0) 174/270 (64.4) 0.734
Hypertension 159/241 (66.0) 143/240 (59.6) 0.147
Diabetes 36/259 (13.9) 47/246 (19.1) 0.115
Cardiac Disease 37/264 (14.0) 43/257 (16.7) 0.390
7.05x10
-5
Ischemic stroke 238/276 (86.2) 193/270 (71.5) – 
Hemorrhagic stroke 33/276 (12.0) 72/270 (26.7) – 
Unknow type of stroke 5/276 (1.8) 5/270 (1.9) – 
Aphasia 53/258 (20.5) 98/250 (39.2) 4.23x10
-6
Neglect 11/266 (4.1) 19/240 (7.9) 0.072
Dysphagia 15/270 (5.6) 25/251 (10.0) 0.059
Urinary Incontinence 5/272 (1.8) 15/251 (6.0) 0.014
Paresis 203/273 (74.4) 244/269 (90.7) 5.59x10
-7
Altered consciousness 21/275 (7.6) 59/265 (22.3) 1.72x10
-6
Medical complications 18/265 (6.8) 82/254 (32.3) 1.83x10
-13
Neurologic complications 14/274 (5.1) 39/267 (14.6) 2.03x10
-4
Stroke Features, n/N (%)
Age and Gender
P
*Poor Recovery 
(mRS>1)
Good Recovery 
(mRS≤1)
Characteristic
Past History, n/N (%)
Stroke type, n/N (%)
 
SD – standard deviation, yrs – years. 
*Mann-Whitney test or Pearson’s χ2 test.  
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Table 2 – Genotype frequency distribution and association with stroke outcome at three 
months for MMP2 SNPs. 
95%CI – 95% Confidence Interval. 
Results were adjusted for significant covariates; Odds Ratio (OR)>1 indicates increased probability of poor recovery for the 
carriers of the minor allele; only associated SNPs are shown. 
rs243866
G/G 142 (67.6) 117 (57.9) 1.67 [1.10-2.52] 0.014 125 (67.6) 83 (56.8) 1.78 [1.13-2.80] 0.013
A/G 66 (31.4) 76 (37.6) 59 (31.9) 55 (37.7)
A/A 2 (1.0) 9 (4.5) 1 (0.5) 8 (5.5)
rs243865
C/C 141 (67.8) 117 (57.9) 1.65 [1.09-2.50] 0.016 124 (67.8) 83 (56.8) 1.76 [1.12-2.78] 0.014
C/T 65 (31.2) 76 (37.6) 58 (31.7) 55 (37.7)
T/T 2 (1.0) 9 (4.5) 1 (0.5) 8 (5.5)
rs857403
A/A 124 (59.3) 138 (68.3) 0.71 [0.48-1.06] 0.091 105 (57.1) 103 (70.5) 0.62 [0.40-0.97] 0.035
T/A 75 (35.9) 56 (27.7) 70 (38) 37 (25.3)
T/T 10 (4.8) 8 (4.0) 9 (4.9) 6 (4.1)
rs1477017
A/A 100 (47.6) 81 (40.1) 1.42 [1.01-2.00] 0.042 86 (46.5) 55 (37.7) 1.51 [1.04-2.20] 0.031
G/A 91 (43.3) 98 (48.5) 82 (44.3) 72 (49.3)
G/G 19 (9.0) 23 (11.4) 17 (9.2) 19 (13)
rs17301608
C/C 94 (45.0) 75 (37.3) 1.40 [1.00-1.95] 0.051 80 (43.5) 50 (34.5) 1.47 [1.01-2.12] 0.041
C/T 94 (45.0) 100 (49.8) 85 (46.2) 73 (50.3)
T/T 21 (10.0) 26 (12.9) 19 (10.3) 22 (15.2)
rs1053605
C/C 188 (89.5) 170 (84.2) 2.02 [1.09-3.75] 0.023 166 (89.7) 127 (87.0) 1.82 [0.93-3.58] 0.082
C/T 22 (10.5) 28 (13.9) 19 (10.3) 16 (11.0)
T/T 0 (0.0) 4 (2.0) 0 (0.0) 3 (2.0)
rs2241145
G/G 79 (37.8) 56 (27.9) 1.66 [1.20-2.30] 0.002
‡
68 (37.0) 39 (26.9) 1.67 [1.17-2.40] 0.004
G/C 100 (47.8) 101 (50.2) 88 (47.8) 72 (49.7)
C/C 30 (14.4) 44 (21.9) 28 (15.2) 34 (23.4)
rs243849
C/C 131 (62.7) 143 (71.5) 0.70 [0.46-1.07] 0.095 112 (60.9) 108 (75) 0.59 [0.36-0.96] 0.031
T/C 70 (33.5) 52 (26.0) 65 (35.3) 33 (22.9)
T/T 8 (3.8) 5 (2.5) 7 (3.8) 3 (2.1)
rs183112
G/G 134 (64.1) 145 (72.9) 0.66 [0.43-1.03] 0.067 115 (62.5) 110 (76.9) 0.54 [0.32-0.90] 0.016
A/G 70 (33.5) 51 (25.6) 65 (35.3) 32 (22.4)
A/A 5 (2.4) 3 (1.5) 4 (2.2) 1 (0.7)
rs1992116
G/G 87 (41.6) 65 (32.3) 1.67 [1.20-2.31] 0.002
‡
76 (41.3) 48 (33.1) 1.68 [1.17-2.42] 0.004
A/G 97 (46.4) 94 (46.8) 86 (46.7) 67 (46.2)
A/A 25 (12.0) 42 (20.9) 22 (12.0) 30 (20.7)
POR [95% CI]POR [95% CI]
SNP Genotype
Whole sample
*
Ischemic subset
†
Good recovery, 
n (%)
Poor recovery, 
n (%)
Good recovery, 
n (%)
Poor recovery, 
n (%)
Genotype frequency Genotype frequency 
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*OR [95%CI] and P for the log-additive genetic model after adjustment for significant covariates (history of hypertension, 
type of stroke, and occurrence of aphasia, paresis, altered consciousness and complications during hospitalization). 
†OR [95%CI] and P for the log-additive genetic model after adjustment for significant covariates (history of hypertension, 
and occurrence of aphasia, paresis, altered consciousness and complications during hospitalization). 
‡Significant result after Bonferroni correction. 
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Table 3 – Haplotype frequency distribution of the MMP2 and MMP9 genes, and association with stroke outcome. 
Only haplotypes with significant association results are presented. 
 
MMP2 rs11643630-rs243866-rs243865 TAT 0.200 17.2 22.7 5.150 0.023 0.198 16.8 23.5 6.125 0.013
MMP9 rs8113877-rs3918253-rs2236416 TCA 0.034 4.8 1.9 7.403 0.007 0.038 4.9 2.4 3.680 0.055
Ischemic subset
Haplotype 
frequency
Good 
recovery (%)
Poor recovery 
(%)

2 P
Haplotype 
frequency
P
Whole sample
Gene Haplotypes

2
0.62.1 3.3720.011 1.8
Good 
recovery (%)
Poor recovery 
(%)
0.066MMP2
rs1477017-rs17301608-rs1132896-
rs1053605-rs2241145-rs243849-
rs243842-rs183112
ACGCGTTG 0.4 4.776 0.029 0.014
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Supplementary tables 
 
Supplementary table 1 - Association analysis results for MMP2 and MMP9 SNPs and stroke outcome. 
HWE – Hardy-Weinberg equilibrium, MA – minor allele, MAF – minor allele frequency, NS – non-significant. 
*According to Ensembl Release 56 – September 2009. 
†P for the log-additive genetic model after adjustment for significant covariates. 
‡P after Bonferroni correction. 
§P after SNPSpD approach. 
MMP2 rs1116195 55508873 upstream A 0.177 0.01 0.379 0.403 0.927 NS NS 0.610 0.01 0.370 0.401 0.844 NS NS
rs11643630 55510459 upstream T 0.207 0.02 0.377 0.423 0.050 NS NS 0.157 0.01 0.382 0.417 0.120 NS NS
rs243866 55511537 upstream A 0.082 0.00 0.174 0.229 0.014 NS NS 0.133 0.00 0.170 0.237 0.013 NS NS
rs243865 55511806 upstream T 0.082 0.00 0.173 0.230 0.016 NS NS 0.133 0.01 0.169 0.238 0.014 NS NS
rs857403 55516708 intron 1-2 T 0.614 0.00 0.242 0.193 0.091 NS NS 0.671 0.01 0.249 0.180 0.035 NS NS
rs1477017 55517162 intron 2-3 G 0.435 0.00 0.304 0.344 0.042 NS NS 0.664 0.00 0.313 0.355 0.031 NS NS
rs17301608 55518610 intron 3-4 T 0.567 0.00 0.324 0.361 0.051 NS NS 0.833 0.01 0.335 0.375 0.041 NS NS
rs1132896 55519535 exon 5 C 0.684 0.01 0.288 0.314 0.071 NS NS 1.000 0.01 0.294 0.323 0.055 NS NS
rs1053605 55519607 exon 5 T 0.216 0.00 0.063 0.087 0.023 NS NS 0.255 0.00 0.065 0.078 0.082 NS NS
rs2241145 55522200 intron 5-6 C 0.598 0.01 0.398 0.450 0.002 0.044 0.021 0.844 0.01 0.409 0.455 0.004 NS 0.044
rs243849 55523705 exon 7 T 0.892 0.01 0.218 0.177 0.095 NS NS 1.000 0.01 0.222 0.157 0.031 NS NS
rs243842 55527422 intron 9-10 C 0.855 0.00 0.387 0.365 0.058 NS NS 1.000 0.01 0.373 0.389 0.180 NS NS
rs183112 55527682 intron 9-10 A 0.313 0.01 0.200 0.165 0.067 NS NS 0.128 0.01 0.200 0.139 0.016 NS NS
rs1992116 55527891 intron 9-10 A 0.857 0.00 0.358 0.418 0.002 0.038 0.018 0.476 0.01 0.363 0.411 0.004 NS 0.042
rs11639960 55533270 intron 11-12 G 0.919 0.01 0.296 0.311 0.389 NS NS 0.645 0.01 0.300 0.304 0.355 NS NS
rs243835 55536622 intron 11-12 T 0.103 0.00 0.498 0.487 0.124 NS NS 0.847 0.00 0.492 0.479 0.179 NS NS
rs243834 55536687 intron 11-12 (splice site) G 0.122 0.01 0.500 0.485 0.095 NS NS 1.000 0.01 0.494 0.474 0.134 NS NS
rs11541998 55536763 exon 12 G 0.339 0.02 0.089 0.109 0.282 NS NS 0.241 0.02 0.084 0.105 0.147 NS NS
rs243832 55539191 intron 12-13 G 0.297 0.03 0.494 0.494 0.099 NS NS 0.696 0.03 0.500 0.489 0.142 NS NS
rs1861320 55541040 downstream T 0.928 0.00 0.387 0.398 0.414 NS NS 0.545 0.01 0.390 0.401 0.467 NS NS
rs17302903 55543073 downstream C 0.928 0.02 0.388 0.413 0.291 NS NS 0.615 0.02 0.398 0.415 0.388 NS NS
MMP9 rs8113877 44635045 upstream G 0.784 0.02 0.359 0.401 0.261 NS NS 0.599 0.02 0.356 0.371 0.376 NS NS
rs3918253 44639511 intron 3-4 C 0.860 0.00 0.411 0.420 0.792 NS NS 0.764 0.00 0.405 0.399 0.966 NS NS
rs2236416 44640575 intron 6-7 G 0.237 0.02 0.090 0.114 0.326 NS NS 0.404 0.02 0.081 0.111 0.172 NS NS
rs17577 44643111 exon 12 A 0.181 0.00 0.098 0.115 0.515 NS NS 0.284 0.00 0.088 0.111 0.318 NS NS
gene
P
†HWE P
missing genotypes 
(%)
P
§ MAF good 
recovery
HWE P
missing 
genotypes (%)
MAlocation
*
position
*marker
P
‡
P
‡
Whole sample Ischemic Subset
MAF poor 
recovery
MAF good 
recovery
MAF poor 
recovery
P
†
P
§
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Supplementary table 2 - Association analysis results for MMP2 and MMP9 haplotypes and stroke outcome. 
 
MMP2 haplotype block 1: GGC 0.599 62.2 57.6 2.396 0.122 0.599 61.5 57.9 1.148 0.284
TGC 0.200 20.6 19.5 0.204 0.652 0.200 21.5 18.2 1.381 0.240
TAT 0.200 17.2 22.7 5.150 0.023 0.198 16.8 23.5 6.125 0.013
MMP2 haplotype block 2: ACGCGCCG 0.366 37.7 35.4 0.624 0.430 0.366 36.3 37.0 0.046 0.830
GTCCCCTG 0.293 28.1 30.6 0.829 0.362 0.297 28.4 31.3 0.907 0.341
ACGCGTTA 0.187 20.1 17.3 1.363 0.243 0.177 19.9 14.9 3.679 0.055
ACGTCCTG 0.074 6.2 8.6 2.241 0.134 0.070 6.3 7.8 0.714 0.398
ATGCCCTG 0.021 2.4 1.9 0.368 0.544 0.028 2.9 2.6 0.097 0.756
GTGCCCTG 0.017 1.3 2.2 1.444 0.230 0.016 1.5 1.8 0.156 0.693
ACGCGCTG 0.013 0.8 1.9 2.613 0.106 - - - - -
ACGCGTTG 0.011 1.8 0.4 4.776 0.029 0.014 2.1 0.6 3.372 0.066
GTGCCCCG - - - - - 0.011 0.6 1.6 1.752 0.186
MMP2 haplotype block 3: GATGC 0.471 49.2 45.1 1.815 0.178 0.464 48.4 44.0 1.646 0.200
AGCAC 0.191 19.6 18.5 0.181 0.671 0.196 20.4 18.6 0.469 0.493
GACAC 0.132 14.0 12.3 0.763 0.383 0.143 14.4 14.2 0.008 0.931
AGCAG 0.098 8.9 10.6 0.939 0.332 0.092 8.4 10.1 0.767 0.381
AACAC 0.080 6.9 9.2 2.030 0.154 0.078 6.9 8.9 1.097 0.295
AGTGC 0.011 0.5 1.7 3.215 0.073 0.012 0.6 1.9 2.885 0.089
MMP2 haplotype block 4: GG 0.503 50.5 50.0 0.034 0.854 0.496 50.0 49.2 0.048 0.826
rs243832-rs1861320 CT 0.392 38.5 39.9 0.215 0.643 0.395 38.8 40.3 0.196 0.658
CG 0.104 10.7 10.1 0.118 0.731 0.108 11.0 10.5 0.060 0.806
MMP9 haplotype block 1: TTA 0.582 58.5 57.8 0.056 0.813 0.595 59.0 60.2 0.111 0.739
GCA 0.280 27.4 28.7 0.232 0.630 0.271 27.7 26.3 0.196 0.658
GCG 0.100 8.7 11.2 1.889 0.169 0.093 8.1 10.8 1.893 0.169
TCA 0.034 4.8 1.9 7.403 0.007 0.038 4.9 2.4 3.680 0.055
rs11643630-rs243866-
rs243865
Gene
Whole sample
Haplotype 
frequency
Good 
recovery (%)
Poor recovery 
(%)

2 P
rs1477017-rs17301608-
rs1132896-rs1053605-
rs2241145-rs243849-
rs243842-rs183112
rs1992116-rs11639960-
rs243835-rs243834-
rs11541998
rs8113877-rs3918253-
rs2236416
Ischemic subset
Haplotype 
frequency
Good 
recovery (%)
Poor recovery 
(%)

2 P
Haplotypes
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Abstract 
 
There is substantial evidence that inflammation within the CNS contributes to 
stroke risk and recovery. Inflammatory conditions increase stroke risk, and the 
inflammatory response is of major importance in recovery and healing processes after 
stroke. We investigated the role of inflammatory genes IL1B, IL6, MPO and TNF in 
stroke susceptibility and recovery in a population sample of 672 patients and 530 
controls, adjusting for demographic, clinical and life-style risk factors and/or stroke 
severity parameters. We also considered the likely complexity of inflammatory 
mechanisms in stroke, by assessing the combined effects of multiple genes. Two IL6 
and one MPO SNPs were significantly associated with stroke risk 
(0.022<correctedP<0.042), highlighting gene variants of low to moderate effect in stroke 
risk. An epistatic interaction between the IL6 and MPO genes was also identified in 
association with stroke susceptibility (P=0.031 after 1000 permutations). In a subset of 
546 patients, one IL6 haplotype was associated with stroke outcome at three months 
(correctedP=0.024), an intriguing finding warranting further validation. Our findings 
support the association of the IL6 gene and present novel evidence for the involvement 
of MPO in stroke susceptibility, suggesting a modulation of stroke risk by main gene 
effects, clinical and life-style factors and gene-gene interactions. 
 
Keywords: Cerebrovascular disease, Genetics, Inflammation, Regeneration and 
recovery, Risk Factors. 
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Introduction 
 
The brain was once regarded as an “immune privileged” organ, neither 
susceptible to inflammation nor affected by systemic inflammatory responses. This 
view has, however, completely changed, and the brain is nowadays known to exhibit 
key features of inflammation, such as synthesis of cytokines and glial activation, and to 
intervene in the regulation of systemic inflammation and in acute phase response after 
brain injury [reviewed in Lucas et al. 2006]. There is also substantial evidence that 
inflammation within the Central Nervous System (CNS) plays a role in many brain 
disorders including stroke, a major cause of death and significant disability in Western 
countries.  
Stroke pathophysiology is likely regulated by a combination of 
environmental/life-style and unclear genetic risk factors. Increasingly, research studies 
are suggesting that inflammation significantly contributes to stroke risk, progression and 
outcome [Rodríguez-Yáñez and Castillo 2008; Wang et al. 2007]. For instance, known 
clinical risk factors for stroke, like atherosclerosis, diabetes, obesity, hypertension, and 
peripheral infection, are associated with an elevated systemic inflammatory profile 
[Bastard et al. 2006; Hansson and Libby 2006; Moutsopoulos and Madianos 2006]. 
Atherosclerosis, in particular, is an inflammatory disease and a major contributor to 
stroke, either through thromboembolism, which results from the rupture of 
atherosclerotic plaques, or indirectly through cardioembolism [Hansson and Libby 
2006].  
Inflammation is equally of major importance in the acute phase of stroke and in 
the recovery process. It is known that the inflammatory response that follows ischemic 
or hemorrhagic stroke contributes to exacerbate the initial injury, but that 
neuroprotective and regenerative molecules are secreted at different stages after a stroke 
event [Correale and Villa 2004; Lakhan et al. 2009; Lucas et al. 2006]. Clearly, 
inflammation in CNS injury in general, and in stroke in particular, cannot be classified 
straightforwardly as harmful. Although there are many inflammatory mediators with 
detrimental effects, some can be beneficial and others may have dual roles, suggesting a 
complex orchestration in the acute and recovery phases after stroke [Lucas et al. 2006].  
 An inflammatory process is thus implicated in pathological conditions that 
increase stroke risk, in the injury mechanisms upon stroke and in the recovery pathways 
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that mediate stroke outcome. It is likely that variants of genes encoding inflammatory 
molecules will influence not only individual stroke risk, but also the extension of the 
injury and the recovery process, and a number of studies have assessed this hypothesis. 
For instance, the tumor necrosis factor (TNF) gene has been associated with 
subarachnoid hemorrhage [Yamada et al. 2006], and polymorphisms in the interleukin 1 
beta (IL1B) and interleukin 6 (IL6) genes have been associated with ischemic stroke and 
with ischemic stroke and intracerebral hemorrhage, respectively [Bis et al. 2008; 
Yamada et al. 2006]. However, conflicting results have been obtained for the IL6 gene 
[Tso et al. 2007]. Other lines of evidence show that inflammatory molecules influence 
the extension of injury and the recovery process. IL-1 beta and TNF-alpha are known to 
be released by neurons and endothelial cells in response to ischemia, initiating an 
inflammatory response and inducing IL-6 and IL-8, with deleterious consequences 
[Rodríguez-Yáñez and Castillo 2008]. The myeloperoxidase (MPO) gene is another 
intriguing candidate, as the encoded enzyme catalyses the formation of MPO-derived 
reactive species that may contribute to atherosclerosis progression and destabilization of 
atherosclerotic plaques [reviewed in Schindhelm et al. 2009]. Reinforcing the 
hypothesis of a role in stroke, MPO polymorphisms have been associated with the size 
of the brain infarct and functional outcome [Hoy et al. 2003].  
In this study we tested the genetic association of major inflammatory players 
IL1B (2q14), IL6 (7p21), TNF (6p21.3) and MPO (17q23.1) with stroke susceptibility 
and stroke outcome at three months. The apparent complexity of the inflammatory 
mechanisms in stroke, and the multiplicity of players involved suggest a concerted 
process, in which implicated molecules interact to tightly regulate each other. Still, non-
additive interactions or epistasis are generally overlooked in genetic studies. Epistasis is 
a plausible explanation for the lack of replication across different populations in 
candidate genes studies or in genome-wide association studies (GWAS), where it is 
particularly difficult to assess due to the large dimension of the data [Lanktree et al. 
2010; Moore 2003]. We therefore examined both independent gene effects and the 
occurrence of gene-gene interactions among the tested inflammatory genes in stroke 
risk and stroke recovery.  
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Materials and Methods 
 
Study population 
 
The study population included 672 first-ever stroke patients, recruited through 
Neurology and Internal Medicine Departments of several hospitals in Portugal. Stroke 
definition and the protocol for clinical assessment of patients were previously described 
[Krug et al. 2010; Manso et al. 2010]. 530 healthy controls with no clinical history of 
stroke were also enrolled. Since stroke is a late-onset disease, we included older healthy 
individuals to reduce the probability of misclassification as controls. Information on 
clinical and life-style risk factors, matching the data available for patients, was obtained 
by direct interview of control subjects. A subset of 546 patients was included in the 
outcome analysis. These patients were classified in two groups based on the modified 
Rankin Scale (mRS) at three months: patients with mRS≤1 were scored as “good 
recovery” and with mRS>1 were scored as “poor recovery” as previously described 
[Manso et al. 2010].  
The study was approved by the Ethics Committee of the Portuguese Dr. Ricardo 
Jorge National Institute of Health and other hospitals involved, and participants gave 
their informed consent.  
 
SNP genotyping 
 
To tag the genetic variation in the IL1B, IL6, MPO and TNF gene regions, single 
nucleotide polymorphisms (SNPs), located within and up to 5kb upstream and 
downstream of those genes, were selected using the H-clust method [Rinaldo et al. 
2005] (HapMap Release 21/phase II July 2006). 3 SNPs in IL1B, 6 in IL6, 2 in MPO, 
and 3 in TNF were genotyped using Sequenom iPLEX assays with allele detection by 
mass spectroscopy, using Sequenom MassARRAY technology (Sequenom, San Diego, 
California) and following the manufacturer’s protocol. Primer sequences were designed 
using Sequenom’s MassARRAY Assay Design 3.0 software. Quality control analyses 
were performed based on the genotyping of eight HapMap individuals, duplicated 
samples within and across genotyping plates, Mendelian segregation in three pedigrees 
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and no-template samples. For each SNP, call rate <90% and deviation from Hardy-
Weinberg equilibrium (HWE; P<0.05) were checked. 
 
Statistical analysis 
 
To identify potential confounders, univariate analyses were performed 
comparing demographic and clinical and life-style risk factors between patients and 
controls, using the Pearson’s 2 test and the Mann-Whitney test for discrete and 
continuous variables, respectively. Variables with a P<0.25 in univariate analysis (Table 
1) or of particular clinical relevance were included in a logistic regression model using 
forward selection [Hosmer and Lemeshow 2000] and were maintained in the model if 
they were associated with stroke susceptibility at a P≤0.05 level. The selected covariates 
were not correlated (-0.5<interaction i<0.5). Logistic regression analyses were then used 
to determine the effect of each genetic variable on stroke susceptibility after adjustment 
for the significant covariates. Odds ratio (OR) and 95% confidence intervals (95% CI) 
were computed for the log-additive model. A similar procedure was followed for the 
analysis of stroke outcome. Demographic and clinical data reflecting the severity of 
stroke was compared between patients with poor (mRS>1) and good (mRS≤1) outcome 
at three months to identify potential confounders (Table 2). Logistic regression analyses 
were then used to determine the effect of each genetic variable on patient’s outcome 
after adjustment for the significant covariates. OR and 95% CI were also computed for 
the log-additive model.  
Univariate and logistic regression analyses were performed using MASS and 
SNPassoc packages of the R software [R: A language and Environment for Statistical 
Computing  2004] (v2.6.0). Haplotype blocks in the four genes were determined using 
the default method [Gabriel et al. 2002] of the Haploview software [Barrett et al. 2005] 
(v4.0) and haplotype-based association analyses were performed. This algorithm may 
select different haplotype blocks for the entire sample and the outcome study subset, as 
occurred specifically for the IL6 gene, resulting in different haplotypes being tested for 
association with stroke susceptibility and outcome. Bonferroni correction for multiple 
testing was used to correct significant associations in individual SNP analysis, as well 
as haplotype-based association analysis. 
Testing for genetic interactions in association with stroke susceptibility and 
outcome was performed using the multifactor-dimensionality reduction (MDR) method 
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[Ritchie et al. 2001] (v2.0, beta 7.2), a nonparametric and genetic model-free approach. 
Briefly, by pooling multilocus genotypes into high and low risk groups, the MDR 
reduces the dimensionality of the data from N dimensions to one dimension. The new 
multilocus genotype attribute is then tested for its ability to classify and predict disease 
status, or good/poor outcome at three months. False-positive results due to multiple 
testing are reduced through combination of the cross-validation strategy and 
permutation testing [Moore 2003; Ritchie et al. 2001]. Since the MDR method does not 
accept missing data, we imputed missing genotypes for each SNP using the PLINK 
software (http://pngu.mgh.harvard.edu/purcell/plink/) [Purcell et al. 2007] and used 
CEU HapMap genotype data as reference. Best models for each group of genes were 
chosen from among the best 2, 3 and 4-loci models, based on the testing balanced 
accuracy (TBA) and the cross-validation consistency (CVC) of 10 cross-validation 
intervals. TBA measures how often individuals are correctly classified in relation to 
disease or outcome status and CVC measures the number of times the MDR found the 
same set of loci across the cross validation subsets. A model with a TBA>0.6 is almost 
always statistically significant, while a TBA>0.55 is considered interesting; TBA=0.5 is 
random (http://compgen.blogspot.com/2006/12/mdr-101-part-4-results.html). The 
statistical significance of the best models was calculated after 1000 permutations using 
the MDR Permutation Tool (v1.0, beta 2). OR-based MDR (OR-MDR) (v1.3-1) was 
used to determine the OR and 95% CI for each genotype combination as a quantitative 
measure of disease risk [Chung et al. 2007]. To determine the gain in information about 
disease or outcome status by combining two variables together over that provided by the 
independent analysis of these variables, the MDR uses entropy measures [Jakulin and 
Bratko 2003]. Evidence for a synergistic interaction occurs when the combination of 
two or more SNPs gives a positive information gain (IG). If the IG is negative, there is 
evidence for redundancy or correlation between SNPs; and if IG=0, the SNPs have 
independent effects. Entropy-based interaction dendrograms are used for interpreting 
epistasis models [Moore et al. 2006]. 
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Results 
 
The demographic and clinical characteristics of our population sample are 
presented in Table 1. Univariate analysis showed that four stroke risk factors – 
hypertension, diabetes, smoking and alcohol consumption – were, as expected, 
significantly more frequent in patients than in control individuals. Gender and age were 
also significantly different between these two groups. During sample collection, the 
incidence of stroke was higher in males than females, as expected in this age range; 
thus, the male/female ratio was higher in the patients’ group. Since stroke is a late-onset 
disease, we selected controls with a higher mean age than patients to reduce the 
probability of mis-classification as “stroke free”. Multivariate analyses were performed 
after univariate analyses and non-genetic confounders were identified. Adjusting for 
these covariates was carried out in the final logistic regression model, which also 
included genetic markers. 
All SNPs tested were in HWE in controls and met quality control criteria, and 
were thus further analyzed. Two contiguous SNPs in the IL6 gene were associated with 
stroke susceptibility under a log-additive model (rs2069837: P=0.005, 
OR[95%CI]=0.66[0.50-0.89]; rs2069861:  P=0.007, OR[95%CI]=1.74[1.15-2.63]) 
(Figure 1, Table 3, supplementary table 1), after adjusting for covariates significant in 
the multivariate analysis model – gender, hypertension, diabetes and smoking status. 
These associations with stroke susceptibility remained significant after Bonferroni 
correction for multiple testing (rs2069837: correctedP=0.032; rs2069861: correctedP=0.042). 
A three-marker haplotype containing the two SNPs individually associated with stroke 
susceptibility and a third SNP (rs10242595) contiguous to rs2069861 conferred an 
increased risk of stroke (A[rs2069837]–T[rs2069861]–G[rs10242595], P=0.014) 
(supplementary table 2). This association did not withstand a Bonferroni correction, 
although this method may be overconservative because these SNPs are not fully 
independent. Overall, these results highlight a region in the IL6 gene as a likely 
susceptibility locus, with contiguous tag SNPs associated with stroke susceptibility.  
One SNP in the MPO gene was significantly associated with stroke 
susceptibility (rs8178406: P=0.011, OR[95%CI]=0.78[0.65-0.95]), and this association 
survived Bonferroni correction (correctedP=0.022) (table 3). Interestingly, restricting the 
analysis to ischemic patients showed a more significant association (correctedP=0.006). 
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We did not attempt the independent analysis of hemorrhagic patients, as these were too 
few for adequate statistical power. None of the tested SNPs in IL1B and TNF were 
associated with stroke susceptibility in this sample (supplementary table 1).  
Because gene interactions may have an important impact on complex 
phenotypes, including human disease susceptibility, we investigated the existence of 
genetic interactions that could contribute to stroke risk, using the MDR method. The 
most significant model for interaction was a two-marker combination between 
rs10242595 in the IL6 gene and rs8178406 in the MPO gene (Table 4). This model 
shows a moderately increased TBA of 0.556, thus correctly classifying 55.6% of the 
individuals tested (P=0.031, based on 1000-fold permutations), but a high CVC of 9/10, 
i.e., the model was selected 9 times out of 10 cross validation subsets. The global OR 
for this model was 1.69 [95%CI=1.31-2.19]. Two genotype combinations of these SNPs 
contributed to stroke: AA(rs10242595)-CC(rs8178406) and GA(rs10242595)-
TT(rs8178406) (OR[95%CI]=2.80[1.17-7.53] and 1.53[1.22-1.99], respectively) (Table 
5). The IL6 rs10242595 SNP is part of the three-marker haplotype associated with 
stroke susceptibility (supplementary table 2), while the MPO rs8178406 SNP was 
independently associated with stroke (Table 3). Interpretation of the genetic effects 
identified by the MDR is possible using the interaction dendrogram shown in Figure 2. 
Interaction between rs10242595 and rs8178406 shows a positive information gain, 
indicating a nonlinear, synergistic relationship between the IL6 (rs10242595) and the 
MPO (rs8178406) genes (i.e. epistasis). Our finding thus suggests that an interaction 
between two genetic variants in the IL6 and MPO genes contributes to stroke 
susceptibility, warranting confirmation in independent populations. Additional models 
were not significant, although there are trends possibly suggesting that interactions 
between IL6 (rs10242595) and TNF (rs909253), as well as MPO (rs2071590) and TNF 
(rs8178406) (permuted P=0.054 and P=0.060, respectively) may contribute to stroke 
susceptibility (Table 4). 
The impact of IL1B, IL6, MPO and TNF genetic variants in patient’s outcome at 
three months was investigated in the subset of 546 patients for whom clinical 
information during hospitalization and at three months was available. The demographic 
and clinical characteristics of our population sample are presented in Table 2. 
Occurrence of aphasia, urinary incontinence, paresis, altered consciousness and medical 
and neurological complications during hospitalization, which reflect stroke severity, 
were identified in univariate analysis as significant predictors of poor outcome. One 
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SNP in the IL6 gene was associated with stroke outcome at three months (rs1800795: 
P=0.011, OR[95%CI]=1.52[1.10-2.12]) (supplementary table 3) after adjusting for 
covariates significant in the multivariate model – type of stroke, history of hypertension, 
and occurrence of aphasia, paresis, altered consciousness and complications during 
hospitalization, but did not remain significant after Bonferroni correction 
(correctedP=0.066). One two-marker haplotype containing this SNP was associated with 
an increased probability of good recovery at three months (G[rs1800795]–
A[rs2069837], P=0.008), and this haplotypic association survived Bonferroni correction 
(correctedP=0.048) (supplementary table 4). We found no evidence for an association of 
IL1B, MPO or TNF with stroke outcome at three months (supplementary tables 3 and 
4). No significant interaction model was found for stroke outcome at three months 
(supplementary table 5). 
 
 
Discussion 
 
The objective of the present study was to investigate the role of selected 
inflammatory genes in stroke susceptibility and recovery. We found evidence for a main 
effect of the IL6 and MPO genes in stroke risk, with specific polymorphisms 
significantly associated with stroke susceptibility, after adjustment for confounding 
demographic, clinical or life-style risk factors. We also report an epistatic gene 
interaction effect between IL6 and MPO in stroke susceptibility. Our genetic findings 
thus support previous evidence from other research areas for a role of inflammatory 
molecules in stroke.  
Association analysis of the IL6 gene showed that two SNPs survived Bonferroni 
correction, highlighting a region in the IL6 gene that is likely to harbour risk variants of 
moderate to low effect size. The associated SNPs are contiguous to the IL6 SNP 
(rs1800795) that has been widely tested in multiple population sets, but are not in 
linkage disequilibrium with this functional polymorphism in our sample. We did not 
replicate the association with this SNP, suggesting that the present results are signaling 
a different causative variant in the IL6 gene, but still reinforce a role of the IL6 gene in 
stroke susceptibility. Accordingly, several previous studies have failed to confirm the 
association of rs1800795 with stroke, while others showed heterogeneity regarding the 
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associated allele or genotype [Tso et al. 2007]. These conflicting results may be due to 
allelic or genetic heterogeneity and/or limitations in study designs, or reflect true 
differences in stroke etiology between populations. Our study also provided novel 
evidence for the association of the MPO gene with stroke. Of the two SNPs tested, 
covering genetic variability in this region, one was associated with stroke risk. This 
effect seemed to be largely driven by the ischemic stroke subset where the strength of 
association was improved, perhaps reflecting somewhat distinct pathological 
mechanisms for the hemorrhagic and ischemic subtypes. Validation in independent 
populations is now warranted.  
 The identification of a synergistic interaction between IL6 and MPO 
contributing to stroke susceptibility highlights the importance of testing for epistasis and 
illustrates the complexity of the inflammatory processes in stroke. It indicates that 
susceptibility may be modulated not only by a variety of genetic factors but also by non-
linear gene-gene interactions, as had been previously shown by others [Flex et al. 2004; 
Liu et al. 2009; Palmer et al. 2010]. Liu and colleagues (2009), in particular, 
investigated the existence of gene-gene interactions between five candidate genes and 
stroke and found that individuals with a combination of polymorphisms in three of these 
genes had an increased risk of thrombotic stroke. Two additional studies also report that 
the risk of stroke increases with the number of high risk genotypes in pro-inflammatory 
gene polymorphisms carried by an individual, suggesting that such polymorphisms act 
synergistically [Flex et al. 2004; Palmer et al. 2010]. Finally, our finding is in 
agreement with a previous in vitro functional study, showing that enzymatically inactive 
MPO induced IL-6 secretion in a dose and time-dependent manner by endothelial cells 
[Lefkowitz et al. 2000].  
The genetic factors influencing outcome after a stroke event are far less studied 
than genetic risk factors. The importance of inflammation after stroke onset and the 
correlation between inflammatory marker levels and infarct volume or patient’s 
outcome [Smith et al. 2004; Sotgiu et al. 2006], led us to investigate the role of several 
inflammatory genes in stroke outcome at three months.  We found an IL6 two-marker 
haplotype associated with patient’s outcome at three months. These results are 
intriguing, since IL-6 is one of the cytokines induced after stroke, playing a fundamental 
role in the inflammatory injury that follows a stroke event, but equally known to have 
neuroprotective effects in later stages after stroke [Herrmann et al. 2003]. IL-6 levels 
have been correlated with stroke severity, 12 months mortality, clinical outcome and 
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brain infarct volume [Smith et al. 2004]. However, our results require validation in 
independent, larger population samples.  
IL-6 is a pleiotropic cytokine, with both pro- and anti-inflammatory functions 
and a low level of expression in the brain under normal physiologic conditions [Luheshi 
and Rothwell 1996]. However, increased levels of IL-6 have been detected after a stroke 
event [Clark et al. 1999]. Increased expression of IL-6 has also been found in 
atherosclerotic plaques [Schieffer et al. 2000], suggesting that the identified IL6 
association with stroke susceptibility may be mediated by atherosclerosis progression. 
Likewise, abundant MPO-positive cells are present in sites of atherosclerotic plaque 
rupture, and this molecule may contribute to stroke through destabilization of the 
atherosclerotic plaques [Sugiyama et al. 2001]. It would be very interesting to correlate 
IL6 and MPO genetic variants with the carotid intimal-media wall thickness, which is a 
marker for atherosclerosis [Mattace Raso et al. 1999]. However, this data is only 
available for a small percentage of our patients, precluding this analysis for now.  
The complex interplay between genetic background, clinical and life-style 
factors and the environment may ultimately regulate the onset, acute phase and outcome 
of stroke. In the present study we present supporting evidence for a role of the IL6 and 
MPO inflammatory genes in stroke susceptibility, and show that stroke risk is 
modulated by main gene effects together with clinical and life-style factors as well as by 
gene-gene interactions. Our findings are compatible and strengthen previous genetic and 
biological observations, highlighting the need of further functional studies, particularly 
in view of the possible utility of IL-6 as a diagnostic and/or prognostic biomarker for 
stroke.  
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Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 - IL6 association results (-log10 P) with stroke susceptibility and 
pairwise r
2
 among genotyped SNPs in our population sample. The positions 
of the six SNPs relative to the IL6 gene (represented by an arrow) are 
indicated. The magnitude of linkage disequilibrium (r
2
) is represented by the 
white-black gradient shading and the values within each diamond. 
Association results above the line -log10P=1.3 are considered significant 
(P<0.050); those above -log10P=2.1 survive Bonferroni correction (P<0.008). 
Linkage disequilibrium blocks were generated using the Gabriel et al [2002] 
method. 
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Figure 2 - Interaction dendrogram for the IL6 and MPO polymorphisms in 
stroke susceptibility. The length of the dendrogram branch that connects 
two polymorphisms indicates the strength of interaction (the shorter the 
branch, the stronger is the interaction). 
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Tables 
 
Table 1 – Demographic and clinical characteristics of the population sample.  
   SD – standard deviation, yrs – years.  
   *Mann-Whitney test or Pearson's χ2 test. 
Age, mean±SD (yrs) 62.9±6.8 52.2±9.1 <10
-4
Gender (male),  n/N (%) 247/530 (46.6) 428/672 (63.7) <10
-4
Stroke Type, n/N (%)
Ischemic stroke – 551/672 (82.0) – 
Hemorrhagic stroke – 111/672 (16.5) – 
Unknow type of stroke – 10/672 (1.5) – 
Stroke Risk Factors, n/N (%)
Hypertension (>85-140 mmHg) 193/513 (37.6) 369/601 (61.4) <10
-4
Diabetes 59/501 (11.8) 102/628 (16.2) 0.033
Hypercholesterolemia (cholesterol >200 mg/dL) 328/520 (63.1) 385/623 (61.8) 0.657
Smoking 147/512 (28.7) 308/660 (46.7) <10
-4
Drinking 218/505 (43.2) 388/662 (58.6) <10
-4
Characteristic Controls Patients P
*
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Table 2 – Demographic and clinical characteristics of stroke patients analyzed for 
outcome at three months.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  SD – standard deviation, yrs – years.  
  *Mann-Whitney test or Pearson's χ2 test.  
 
Age, mean±SD (yrs) 50.8±9 52.5±8.5 0.028
Gender (male), n/N (%) 174/276 (63.0) 174/270 (64.4) 0.734
Hypertension 159/241 (66.0) 143/240 (59.6) 0.147
Diabetes 36/259 (13.9) 47/246 (19.1) 0.115
Cardiac Disease 37/264 (14.0) 43/257 (16.7) 0.390
<10
-4
Ischemic stroke 238/276 (86.2) 193/270 (71.5) – 
Hemorrhagic stroke 33/276 (12.0) 72/270 (26.7) – 
Unknow type of stroke 5/276 (1.8) 5/270 (1.9) – 
Aphasia 53/258 (20.5) 98/250 (39.2) <10
-4
Neglect 11/266 (4.1) 19/240 (7.9) 0.072
Dysphagia 15/270 (5.6) 25/251 (10.0) 0.059
Urinary Incontinence 5/272 (1.8) 15/251 (6.0) 0.014
Paresis 203/273 (74.4) 244/269 (90.7) <10
-4
Altered consciousness 21/275 (7.6) 59/265 (22.3) <10
-4
Medical complications 18/265 (6.8) 82/254 (32.3) <10
-4
Neurologic complications 14/274 (5.1) 39/267 (14.6) 2.03x10
-4
Stroke Features, n/N (%)
Age and Gender
P
*Poor Recovery 
(mRS>1)
Good Recovery 
(mRS≤1)
Characteristic
Past History, n/N (%)
Stroke type, n/N (%)
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Table 3 – Genotype and allele frequency distribution, and association with stroke 
susceptibility for the IL6 and MPO SNPs.  
 
IL6 rs2069837    
A/A 365 (76.4) 461 (81.2) 0.66 [0.50-0.89]
G/A 105 (22.0) 102 (18.0)
G/G 8 (1.7) 5 (0.9)
IL6 rs2069861    
C/C 442 (91.9) 497 (86.9) 1.74 [1.15-2.63]
T/C 39 (8.1) 70 (12.2)
T/T 0 (0.0) 5 (0.9)
MPO rs8178406   
T/T 151 (31.4) 221 (38.9) 0.78 [0.65-0.95]
T/C 254 (52.8) 262 (46.1)
C/C 76 (15.8) 85 (15.0)
Gene SNP Genotype
Genotype frequency
0.007
†
0.011
†
0.005
†
Controls, n (%) Cases, n (%)
OR [95% CI] P
 
Only associated SNPs are shown. Odds Ratio (OR) >1 indicates increased probability of having a stroke for the 
carriers of the minor allele. CI – 95% Confidence Interval.  
*OR [95% CI] and P for the log-additive genetic model after adjustment for significant covariates (gender, history of 
hypertension, diabetes, smoking status) 
†Significant result after Bonferroni correction. 
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Table 4 – Gene x gene interaction models obtained using the multifactor-dimensionality reduction (MDR) method in stroke susceptibility.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     CVC– Cross Validation Consistency, TBA – Testing Balanced Accuracy.      
     *1000 permutations P 
      
SNP1 SNP2 SNP3 SNP4
IL1B _TNF rs1143643(IL1B ) rs16944(IL1B ) rs2071590(TNF ) – 8/10 0.517 0.487
IL6 _TNF rs10242595(IL6 ) rs909253(TNF ) – – 10/10 0.549 0.054
IL6 _IL1B rs2069837(IL6 ) rs10242595(IL6 ) rs1143643(IL1B ) – 5/10 0.541 0.145
MPO _TNF rs2071590(TNF ) rs8178406(MPO ) – – 9/10 0.547 0.060
IL6 _MPO rs10242595(IL6 ) rs8178406(MPO ) – – 9/10 0.556 0.031
MPO _IL1B rs1143643(IL1B ) rs16944(IL1B ) rs8178406(MPO ) rs4401102(MPO ) 9/10 0.538 0.160
IL1B _IL6 _TNF_MPO rs10242595(IL6 ) rs1143643(IL1B ) rs8178406(MPO ) rs4401102(MPO ) 8/10 0.527 0.323
P*Genes
Best model
CVC TBA
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Table 5 – Odds Ratio (OR) of each genotype combination of IL6 rs10242595 and MPO 
rs8178406 obtained using the OR- based MDR. 
  
 
 
 
 
 
 
 
 
 
 
 
             CI – Confidence Interval. 
 
 
AA CC 17:5 2.80 [1.17-7.53]
GA CC 42:44 0.79 [0.59-1.18]
GG CC 28:32 0.72 [0.51-1.18]
AA TC 48:54 0.73 [0.56-1.06]
GA TC 136:124 0.90 [0.76-1.12]
GG TC 108:94 0.95 [0.78-1.21]
AA TT 32:33 0.80 [0.57-1.28]
GA TT 132:71 1.53 [1.22-1.99]
GG TT 77:53 1.20 [0.92-1.66]
OR [95% CI]frequency (case:control)rs8178406rs10242595
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Supplementary tables 
 
Supplementary table 1 – Association analysis results for IL1B, IL6, MPO and TNF 
markers and stroke susceptibility 
 
HWE – Hardy-Weinberg equilibrium, MA – minor allele, MAF – minor allele frequency, NS – non-significant. 
*According to Ensembl Release 56 – September 2009. 
†P for the log-additive genetic model after adjustment for significant covariates. 
‡P after Bonferroni correction. 
 
 
IL1B rs1143643 113588302 intronic/downstream T 0.924 0.3 0.348 0.327 0.195 NS
rs1143634 113590390 exonic/downstream A 0.627 0.2 0.234 0.246 0.862 NS
rs16944 113594867 upstream A 0.771 5.4 0.357 0.354 0.591 NS
IL6 rs12700386 22763009 upstream G 0.130 0.2 0.196 0.179 0.538 NS
rs2069827 22765456 upstream T 0.503 0.4 0.071 0.070 0.799 NS
rs1800795 22766645 intronic C 0.611 4.2 0.315 0.345 0.115 NS
rs2069837 22768027 intronic G 1.000 0.9 0.123 0.100 0.005 0.032
rs2069861 22771654 downstream T 0.615 0.3 0.044 0.068 0.007 0.042
rs10242595 22774231 downstream A 0.530 0.6 0.413 0.411 0.525 NS
MPO rs8178406 56344443 downstream C 0.061 0.9 0.422 0.377 0.011 0.022
rs4401102 56360837 upstream T 0.916 0.2 0.291 0.287 0.892 NS
TNF rs2071590 31539768 upstream A 0.062 0.3 0.331 0.302 0.070 NS
rs909253 31540313 upstream G 0.526 0.2 0.290 0.319 0.159 NS
rs3093662 31544189 intronic/downstream G 0.820 0.3 0.105 0.092 0.587 NS
missing 
genotypes (%)
P
‡MAF 
patients
MAF 
controls
gene marker position
*
P
†
location
* MA HWE P
Chapter 3. Inflammatory genes  
 89 
Supplementary table 2 – Association analysis results for IL1B, IL6 and TNF 
haplotypes and stroke susceptibility 
 
 
IL1B rs1143643-rs1143634 CG 0.422 41.7 42.7 0.238 0.626
TG 0.336 34.8 32.7 1.236 0.266
CA 0.241 23.5 24.6 0.442 0.506
IL6 ACG 0.531 54.3 52.1 1.139 0.286
ACA 0.303 29.0 31.3 1.457 0.227
GCA 0.110 12.3 9.9 3.572 0.059
ATG 0.057 4.4 6.7 6.011 0.014
TNF AAA 0.316 33.1 30.4 2.037 0.154
GGA 0.306 29.0 31.8 2.215 0.137
GAA 0.281 27.4 28.6 0.425 0.514
GAG 0.098 10.5 9.2 1.131 0.288
rs2071590-rs909253-
rs3093662
χ
2 PGene Haplotypes
Haplotype 
frequency
Controls (%) Cases (%)
rs2069837-rs2069861-
rs10242595
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Supplementary table 3 – Association analysis results for IL1B, IL6, MPO and TNF 
markers and stroke outcome. 
HWE – Hardy-Weinberg equilibrium, MA – minor allele, MAF – minor allele frequency, NS – non-significant. 
*According to Ensembl Release 56 – September 2009. 
†P for the log-additive genetic model after adjustment for significant covariates. 
‡P after Bonferroni correction. 
 
 
IL1B rs1143643 113588302 intronic/downstream T 0.147 0.4 0.317 0.345 0.671 NS
rs1143634 113590390 exonic/downstream A 0.908 0.0 0.248 0.243 0.887 NS
rs16944 113594867 upstream A 0.633 3.5 0.357 0.343 0.796 NS
IL6 rs12700386 22763009 upstream G 0.886 0.4 0.179 0.185 0.684 NS
rs2069827 22765456 upstream T 0.719 0.5 0.060 0.071 0.585 NS
rs1800795 22766645 intronic C 0.377 5.7 0.311 0.370 0.011 NS
rs2069837 22768027 intronic G 0.334 0.9 0.086 0.110 0.908 NS
rs2069861 22771654 downstream T 0.076 0.2 0.062 0.070 0.179 NS
rs10242595 22774231 downstream A 0.287 1.1 0.405 0.423 0.236 NS
MPO rs8178406 56344443 downstream C 0.927 0.9 0.365 0.395 0.192 NS
rs4401102 56360837 upstream T 0.834 0.2 0.269 0.304 0.305 NS
TNF rs2071590 31539768 upstream A 0.269 0.5 0.325 0.294 0.241 NS
rs909253 31540313 upstream G 0.274 0.4 0.305 0.325 0.366 NS
rs3093662 31544189 intronic/downstream G 0.605 0.5 0.080 0.099 0.520 NS
gene marker position
*
location
*
P
‡MA HWE P
MAF good 
recovery
MAF poor 
recovery
P
†missing 
genotypes (%)
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Supplementary table 4 – Association analysis results for IL1B, IL6 and TNF 
haplotypes and stroke outcome.  
 
*Significant result after Bonferroni correction. 
 
 
IL1B rs1143643-rs1143634 CG 0.424 43.5 41.2 0.561 0.454
TG 0.331 31.7 34.5 0.967 0.326
CA 0.245 24.8 24.3 0.046 0.830
IL6 haplotype block 1: GA 0.561 60.1 52.1 7.025 0.008
*
rs1800795-rs2069837 CA 0.340 31.3 36.9 3.771 0.052
GG 0.098 8.6 11.0 1.763 0.184
IL6 haplotype block 2: CG 0.520 53.3 50.6 0.776 0.379
rs2069861-rs10242595 CA 0.414 40.5 42.3 0.375 0.540
TG 0.066 6.2 7.0 0.309 0.578
TNF GGA 0.315 30.5 32.5 0.462 0.497
AAA 0.311 32.7 29.5 1.351 0.245
GAA 0.284 28.7 28.2 0.039 0.844
GAG 0.089 8.0 9.9 1.190 0.275
Gene
Haplotype 
frequency
Good 
recovery (%)
rs2071590-rs909253-
rs3093662
Poor recovery 
(%)
χ
2 PHaplotypes
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Supplementary table 5 – Gene x gene interaction models obtained using multifactor-dimensionality reduction method in stroke outcome. 
 
SNP1 SNP2 SNP3 SNP4
IL1B _TNF rs1143643(IL1B ) rs16944(IL1B ) rs909253(TNF ) – 1/10 0.5146 0.586
IL6 _TNF rs12700386(IL6 ) rs10242595(IL6 ) rs2071590(TNF ) rs1800795(IL6 ) 6/10 0.5542 0.189
IL6 _IL1B rs12700386(IL6 ) rs10242595(IL6 ) rs1800795(IL6 ) – 5/10 0.5652 0.122
MPO _TNF rs2071590(TNF ) rs909253(TNF ) rs8178406(MPO ) rs4401102(MPO ) 8/10 0.4569 0.987
IL6 _MPO rs12700386(IL6 ) rs1800795(IL6 ) rs10242595(IL6 ) – 6/10 0.5672 0.085
MPO _IL1B rs1143643(IL1B ) rs4401102(MPO ) – – 7/10 0.5638 0.112
IL1B _IL6 _TNF_MPO rs1143643(IL1B ) rs4401102(MPO ) – – 7/10 0.5647 0.157
P*TBACVCGenes
Best model
 
CVC – Cross Validation Consistency, TBA – Testing Balanced Accuracy. 
*1000 permutations P 
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Abstract 
 
Patient’s outcome after stroke likely results from complex interactions between 
multiple molecules acting in different pathways. Through effects in angiogenesis, 
neurogenesis and neuroprotection, growth factors are thought to play a role in 
improving neurological function in stroke recovery. In this study, we hypothesized that 
variants of the brain-derived neurotrophic factor (BDNF), fibroblast growth factor 2 
(FGF2) and vascular endothelial growth factor A (VEGFA) genes, as well as epistatic 
interactions among them, could influence functional outcome after stroke. A total of 
546 stroke patients were analyzed. One FGF2 SNP was nominally associated with 
stroke outcome (uncorrectedP=0.038). Analysis of epistasis yielded two significant gene-
gene interaction models, after 1000-fold permutation testing. One model combined a 
BDNF SNP and three FGF2 SNPs, with a statistically significant testing balanced 
accuracy (TBA) of 0.592 (permutedP=0.026), cross-validation consistency [CVC] of 6/10, 
and a global odds ratio (OR) (95% confidence interval [CI]) of 4.15[2.86-6.04]. The 
second model included one FGF2 SNP and two VEGFA SNPs which had a statistically 
significant TBA of 0.611 (permutedP=0.002), CVC=3/10 and global 
OR[95%CI]=2.54[1.76-3.67]. The results provide evidence for gene interactions in 
stroke outcome and highlight the complexity of the recovery mechanisms after a stroke 
event. 
 
Keywords: Cerebrovascular disease, Genetics, Interactions, Regeneration and recovery  
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Description 
 
Stroke is a major health problem in developed countries, with a very high 
incidence and mortality and an elevated morbidity. Multiple biological pathways that 
can be neuroprotective or detrimental to the brain are activated after stroke, resulting in 
a series of biochemical, hemodynamic and neurophysiologic changes which ultimately 
determine stroke outcome [Mitsios et al. 2006]. The timely orchestration of complex 
interactions between growth factors such as brain-derived neurotrophic factor (BDNF), 
heparin-binding growth factor 2 (HBGF-2) and vascular endothelial growth factor A 
(VEGF-A), which mediate neurogenesis, angiogenesis and neuroprotection mechanisms 
that contribute to functional recovery after stroke [Chen et al. 2005; Krupinski et al. 
1993; Nakatomi et al. 2002], is likely to influence neurological outcome (references in 
Supplementary Table 1).  
Hypothesizing that variation within growth factor genes BDNF, FGF2 (encoding 
the HBGF-2 protein) and VEGFA might influence patient’s outcome after stroke, we 
conducted a genetic association study in 546 first-ever stroke patients evaluated at three 
months for functional recovery. Diagnosis and classification of patients according to the 
modified Rankin Scale (mRS) at three months were described in a previous study 
[Manso et al. 2010]. The study was approved by the appropriate Ethical Committees, 
and subjects gave informed consent. Patients were classified in poor (mRS>1) and good 
(mRS≤1) recovery groups, which showed similar profiles in terms of age, male:female 
ratio and stroke risk factors (Supplementary Table 2). As expected, clinical 
characteristics reflecting the severity of stroke (occurrence of aphasia, urinary 
incontinence, paresis, altered consciousness, medical and neurological complications 
during hospitalization) were significantly more frequent in patients with poor outcome 
at three months. Haplotype tagging single nucleotide polymorphisms (SNPs) in BDNF 
(N=11), FGF2 (N=28) and VEGFA (N=8) genomic regions were genotyped using 
Sequenom MassARRAY technology (Sequenom, San Diego, USA). One SNP in the 
FGF2 gene did not meet quality control criteria [described in Manso et al. 2010] due to 
low genotyping call rate (<90%) and was excluded. Using logistic regression, we 
compared genotype frequencies between the poor and good recovery patient groups, 
after adjusting for significant confounders reflecting stroke severity in a multivariate 
analysis model: type of stroke, history of hypertension, and occurrence of aphasia, 
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paresis, altered consciousness and medical complications during hospitalization. Results 
were corrected for multiple comparisons using the Bonferroni method. Further, we 
investigated the occurrence of non-additive gene-gene interactions between BDNF, 
FGF2 and VEGFA in stroke outcome using the multifactor-dimensionality reduction 
(MDR) method [Ritchie et al. 2001]. The MDR is more powerful than traditional 
regression-based methods [Ritchie et al. 2001], with more than 80% power to detect 
interactions even in the absence of main effects [Ritchie et al. 2003]. Missing genotypes 
were imputed for each SNP using the PLINK software [Purcell et al. 2007] using 
genotypes from stroke patients and CEU HapMap individuals as reference. To correct 
for multiple testing, the MDR combines cross-validation and permutation procedures 
[Ritchie et al. 2001]. The statistical significance of the best models was calculated after 
1000 permutations using the MDR Permutation Tool (v1.0, beta 2), and the OR and 
95% CI for each genotype combination was determined using the OR-based MDR (OR-
MDR) (v1.3-1) [Chung et al. 2007]. To determine the gain in information on outcome 
status by combining two variables together over that provided by the independent 
analysis of these variables, the MDR uses entropy measures [Jakulin and Bratko 2003]; 
a positive information gain (IG) indicates a synergistic effect, while a negative IG 
constitutes evidence for redundancy and a null IG indicates an independent effect. 
Entropy-based interaction dendrograms were used to interpret epistasis models [Moore 
et al. 2006]. 
Multivariate analysis did not provide any strong evidence for an independent 
effect of any of the tested genes in stroke outcome (Supplementary Table 3). A nominal 
association of FGF2 rs12506776 with stroke outcome (P=0.038, Odds Ratio (OR) 
[95%Confidence Interval (CI)] = 0.60 [0.37-0.98]), did not withstand Bonferroni 
correction. Restricting the analysis to ischemic patients did not significantly improve 
these results (Supplementary Table 3). MDR analysis identified two gene interaction 
models, from all possible 2- to 4-marker models tested, as significant predictors of 
stroke outcome (Table 1). The interaction between BDNF SNP rs10835210 and three 
FGF2 SNPs (rs167428, rs308379 and rs3804158) had a statistically significant testing 
balanced accuracy (TBA) of 0.592, thus correctly classifying 59.2% of the individuals 
tested (P=0.026 after 1000 fold permutations), a cross-validation consistency (CVC) of 
6/10, indicating that the model was selected 6 times out of 10 cross validation subsets, 
and a global OR of 4.15 [95%CI=2.86-6.04]. The interaction dendrogram presented in 
figure 1A shows a non-linear (epistatic) synergistic interaction between BDNF 
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rs10835210 and FGF2 rs3804158, while rs167428 and rs308379 have redundant and 
independent effects in the model, respectively. A second significant model provides 
evidence for an interaction between FGF2 SNP rs167428 and two SNPs in VEGFA 
(rs3025000 and rs6900017), and was a better predictor of stroke outcome, with a higher 
TBA of 0.611 (P=0.002 after 1000 fold permutations), a CVC of 3/10 and a global OR 
of 2.54 [95%CI=1.76-3.67]. The interaction dendrogram (figure 1B) indicates that 
FGF2 rs167428 and VEGFA rs6900017 interact in a synergistic manner, whereas 
rs3025000 is redundant in this model.  
These results suggest that recovery after stroke can be modulated by epistatic 
interactions between the tested growth factor genes, a finding that now warrants 
validation in independent population samples. They further provide additional support 
for testing non-additive interactions in complex phenotypes, even in the absence of 
main gene effects, indicating that if a gene functions primarily through a complex 
network involving other genes, its effects may be missed by more traditional regression-
based methods [Cordell 2009; Moore 2003]. The identified interactions are supported 
by previous in vitro and in vivo studies, showing that HBGF-2 regulates VEGF-A-
induced angiogenesis [Mandriota and Pepper 1997], and that synergistic effects of 
HBGF-2, BDNF and neurotrophin-3 enhance neuronal survival and promoted axon 
regeneration [Logan et al. 2006]. Several studies using animal models of stroke have 
also shown that administration of specific growth factors after stroke leads to 
improvements in neurological function and induction of neuroprotective and repair 
mechanisms, including neurogenesis and angiogenesis [Chen et al. 2005; Ikeda et al. 
2005; Schäbitz et al. 2007; Sun et al. 2003]. While direct biological interpretation of the 
present findings is not yet possible, testing for gene-gene interactions can be a valuable 
strategy towards the identification of biochemical pathways involved in stroke outcome, 
highlighting the multiplicity of neurotrophic factors and complex mechanisms 
underlying this trait. 
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Figures  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 – A) Interaction dendrogram for the BDNF and FGF2 polymorphisms in 
stroke outcome, showing a synergistic effect between the BDNF rs10835210 and 
FGF2 rs3804158, an independent effect for FGF2 rs308379 and redundancy for 
FGF2 rs167428. B) Interaction dendrogram for the FGF2 and VEGFA 
polymorphisms in stroke outcome, showing a synergistic interaction between FGF2 
rs167428 and VEGFA rs6900017, and redundancy for VEGFA rs3025000. The 
length of the dendrogram branch that connects two polymorphisms indicates the 
strength of interaction (the shorter the branch, the stronger is the interaction).  
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Tables 
 
Table 1 – Gene x gene interaction models obtained using the multifactor-dimensionality reduction (MDR) method in stroke outcome. 
CVC – Cross Validation Consistency, TBA – Testing Balanced Accuracy. 
*P after 1000 permutations  
 
SNP1 SNP2 SNP3 SNP4
BDNF_FGF2 rs10835210(BDNF ) rs167428(FGF2 ) rs308379(FGF2 ) rs3804158(FGF2 ) 4.15 [2.86-6.04] 6/10 0.592 0.026
BDNF_VEGFA rs833069(VEGFA ) rs3025035(VEGFA ) rs6905288(VEGFA )  2.15 [1.50-3.07] 4/10 0.559 0.143
FGF2_VEGFA rs167428(FGF2 ) rs3025000(VEGFA ) rs6900017(VEGFA ) 2.54 [1.76-3.67] 3/10 0.611 0.002
BDNF_FGF2_VEGFA rs10835210(BDNF ) rs308441(FGF2 ) rs308379(FGF2 ) rs833069(VEGFA ) 4.07 [2.76-5.99] 2/10 0.553 0.236
P
*TBACVCGenes
Best model
global OR [95% CI]
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Supplementary tables 
 
Supplementary table 1 – Growth factors influence on stroke outcome and recovery. 
BDNF
FGF2
VEGFA
Growth factor gene ReferenceFunction
Schäbitz et al . (2007) Stroke 38:2165-2172
Raab and Plate (2007) Acta Neuropathol 113:607-626
Lee et al . (2010) J Neurosci Res. 88(15):3282-94
BDNF administration stimulated neurogenesis and enhanced stroke 
recovery after cerebral ischemia
Summary of the BDNF effects in the vascular and nervous systems
Human neural stem cells overexpressing BDNF promoted functional 
recovery and neuroprotection after intracerebral hemorrhage
Ikeda et al . (2005) Stroke 36:2725-2730
Leker et al . (2007) Stroke 38:153-161
Raab and Plate (2007) Acta Neuropathol 113:607-626
Issa et al . (2005) Angiogenesis 8:53-62
 HBGF-2 administration improved neurological outcome and reduced 
infarct volume 
Treatment with HBGF-2 led to neurogenesis and improved motor 
behaviour in ischemic stroke
Summary of the HBGF-2 effects in the vascular and nervous systems
Raised HBGF-2 expression in the penumbra of ischemic patients; 
elevated serum levels of serum HBGF-2 in patients with ischemic stroke 
or intracerebral hemorrhage
High serum levels of growth factors were associated with good outcome 
and reduced brain lesion in intracerebral hemorrhage
Sun et al . (2003) J Clin Invest 111:1843-1851
Wang et al . (2006) Brain Res 1115:186-193
Raab and Plate (2007) Acta Neuropathol 113:607-626
Tang et al . (2007) Brain Research, 1175: 134–142
Sobrino et al . (2009) J Cereb Blood Flow Metab, 29: 1968–1974
VEGF-A administration reduced infarct size and induced 
neuroprotection, neurogenesis and angiogenesis
VEGF-A administration improved functional outcome after ischemic 
stroke
Summary of the VEGF-A effects in the vascular and nervous systems
Intracerebral hemorrhage induced cerebral angiogenesis and 
upregulation of VEGF-A 
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Supplementary table 2 – Demographic and clinical characteristics of stroke patients 
analyzed for outcome at three months. Good and poor recovery was assessed using the 
modified Rankin Scale (mRS), which measures the global disability of a patient after 
stroke.  This scale has been used in clinical practice to evaluate the effect of stroke on 
patient's activities and as a primary end point in randomized clinical trials [Kasner 
2006]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 SD – standard deviation, yrs – years. 
 *Mann-Whitney test or Pearson's χ2 test.  
 
 
Age, mean±SD (yrs) 50.8±9 52.5±8.5 0.028
Gender (male), n/N (%) 174/276 (63.0) 174/270 (64.4) 0.734
Hypertension 159/241 (66.0) 143/240 (59.6) 0.147
Diabetes 36/259 (13.9) 47/246 (19.1) 0.115
Cardiac Disease 37/264 (14.0) 43/257 (16.7) 0.390
<10
-4
Ischemic stroke 238/276 (86.2) 193/270 (71.5) – 
Hemorrhagic stroke 33/276 (12.0) 72/270 (26.7) – 
Unknow type of stroke 5/276 (1.8) 5/270 (1.9) – 
Aphasia 53/258 (20.5) 98/250 (39.2) <10
-4
Neglect 11/266 (4.1) 19/240 (7.9) 0.072
Dysphagia 15/270 (5.6) 25/251 (10.0) 0.059
Urinary Incontinence 5/272 (1.8) 15/251 (6.0) 0.014
Paresis 203/273 (74.4) 244/269 (90.7) <10
-4
Altered consciousness 21/275 (7.6) 59/265 (22.3) <10
-4
Medical complications 18/265 (6.8) 82/254 (32.3) <10
-4
Neurologic complications 14/274 (5.1) 39/267 (14.6) 2.03x10
-4
Stroke Features, n/N (%)
Age and Gender
P
*Poor Recovery 
(mRS>1)
Good Recovery 
(mRS≤1)
Characteristic
Past History, n/N (%)
Stroke type, n/N (%)
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Supplementary table 3 – Association analysis results for BDNF, FGF2 and VEGFA SNPs and stroke outcome. 
 
 
FGF2 rs308393 123746619 upstream C 1.000 10.8 0.143 0.144 - - 0.536 10.4 0.140 0.149 - -
rs308395 123746942 upstream G 0.058 1.3 0.158 0.170 0.907 NS 0.291 1.6 0.154 0.182 0.568 NS
rs308420 123767943 intronic A 0.734 0.4 0.071 0.067 0.130 NS 1.000 0.5 0.068 0.070 - -
rs308418 123768263 intronic G 0.046 0.2 0.164 0.172 0.665 NS 0.226 0.2 0.158 0.181 0.975 NS
rs308417 123768337 intronic C 0.242 8.6 0.066 0.052 0.106 NS 0.380 7.7 0.065 0.048 0.259 NS
rs308435 123772018 intronic A 0.104 0.4 0.165 0.184 0.364 NS 0.169 0.5 0.158 0.180 0.233 NS
rs11938826 123772614 intronic G 0.142 0.5 0.158 0.155 0.254 NS 0.582 0.7 0.158 0.154 0.437 NS
rs167428 123773439 intronic C 0.145 0.2 0.281 0.299 0.457 NS 0.194 0.2 0.284 0.284 0.635 NS
rs308439 123773579 intronic G 0.274 0.2 0.060 0.071 0.914 NS 1.000 0.2 0.059 0.052 0.645 NS
rs308441 123774065 intronic T 0.519 1.1 0.196 0.228 0.424 NS 0.545 1.4 0.198 0.202 0.742 NS
rs17472986 123774832 intronic A 0.495 0.2 0.096 0.112 0.168 NS 0.411 0.2 0.097 0.102 0.375 NS
rs308442 123774913 intronic A 0.427 0.2 0.304 0.326 0.619 NS 0.574 0.2 0.310 0.311 0.998 NS
rs17407577 123779341 intronic C 0.690 0.4 0.064 0.050 0.781 NS 0.654 0.5 0.068 0.049 0.623 NS
rs1960669 123782568 intronic A 0.456 0.4 0.102 0.086 0.389 NS 0.275 0.5 0.105 0.089 0.417 NS
rs308379 123782896 intronic A 0.326 0.4 0.307 0.335 0.724 NS 0.187 0.5 0.316 0.333 0.709 NS
rs308382 123783194 intronic C 0.561 0.7 0.184 0.178 0.533 NS 0.520 0.7 0.190 0.178 0.438 NS
rs12644427 123783387 intronic G 0.713 6.4 0.146 0.133 0.111 NS 0.259 7.0 0.137 0.115 0.150 NS
rs308388 123787079 intronic A 0.707 1.1 0.355 0.354 0.130 NS 0.451 1.4 0.353 0.332 0.113 NS
rs7694627 123788495 intronic C 0.413 0.7 0.152 0.160 0.744 NS 0.858 0.9 0.157 0.164 0.978 NS
rs17474021 123798711 intronic C 0.411 2.0 0.154 0.157 0.681 NS 1.000 2.6 0.159 0.160 0.893 NS
rs17006255 123798993 intronic C 0.578 5.9 0.142 0.132 0.052 NS 0.490 5.6 0.135 0.110 0.047 NS
rs17408557 123800617 intronic G 0.585 0.4 0.140 0.134 1.000 NS 1.000 0.5 0.146 0.135 0.916 NS
rs12506776 123803370 intronic T 0.707 4.2 0.143 0.122 0.038 NS 0.361 3.7 0.136 0.103 0.035 NS
rs12503378 123810734 intronic G 0.719 4.9 0.144 0.137 0.083 NS 0.503 4.6 0.137 0.112 0.063 NS
rs3804158 123814900 3' UTR G 0.663 1.8 0.462 0.445 0.200 NS 0.491 1.6 0.460 0.428 0.196 NS
rs6854081 123816707 3' UTR G 0.380 0.4 0.147 0.134 0.861 NS 0.846 0.5 0.149 0.136 0.781 NS
rs7683093 123818085 3' UTR G 1.000 7.3 0.136 0.135 0.891 NS 0.676 7.2 0.140 0.140 0.963 NS
rs1476217 123818511 3' UTR C 0.283 6.6 0.349 0.344 0.200 NS 0.219 5.8 0.345 0.312 0.134 NS
Ischemic Subset
MAlocation
*
HWE P
missing 
genotypes (%)
MAF good 
recovery
MAF poor 
recovery
P
†
P
‡
gene
HWE P
Whole sample
P
‡MAF good 
recovery
MAF poor 
recovery
missing 
genotypes (%)
P
†
position
*marker
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Supplementary table 3 (cont.) – Association analysis results for BDNF, FGF2 and VEGFA SNPs and stroke outcome. 
 
HWE – Hardy-Weinberg equilibrium, MA – minor allele, MAF – minor allele frequency, NS – non-significant, UTR – untranslated region. 
*
According to Ensembl Release 56 – September 2009. 
†
P for the log-additive genetic model after adjustment for significant covariates.
 
‡
P after Bonferroni correction.
 
§
The log-additive model could not be performed for this SNP; P for the codominant model is presented. 
BDNF rs4923460 27656789 downstream T 0.897 0.9 0.211 0.209 0.832 NS 0.459 0.7 0.205 0.204 0.811 NS
rs925946 27667202 downstream T 0.833 2.7 0.282 0.298 0.653 NS 0.728 2.8 0.298 0.304 0.859 NS
rs7927728 27667472 downstream A 0.195 1.8 0.067 0.081 0.548 NS 0.282 1.6 0.071 0.081 0.509 NS
rs1519479 27667531 downstream T 0.931 1.1 0.467 0.463 0.569 NS 0.497 1.2 0.460 0.463 0.422 NS
rs2203877 27670910 downstream C 0.794 2.7 0.467 0.465 0.516 NS 0.922 2.6 0.462 0.470 0.369 NS
rs6265 27679916 exonic T 0.412 0.5 0.191 0.200 0.746 NS 0.115 0.7 0.188 0.194 0.593 NS
rs1401635 27693991 intronic C 0.755 1.1 0.293 0.292 0.902 NS 0.730 1.2 0.306 0.293 0.869 NS
rs10835210 27695910 intronic A 0.425 0.9 0.400 0.419 0.276 NS 0.269 1.2 0.390 0.424 0.131 NS
rs11030119 27728102 upstream/intronic A 0.756 0.5 0.290 0.290 0.932 NS 0.728 0.7 0.301 0.289 0.859 NS
rs962369 27734420 upstream/intronic C 1.000 1.1 0.286 0.285 0.902 NS 1.000 1.2 0.297 0.284 0.877 NS
rs11030121 27736207 upstream/intronic T 0.362 7.1 0.317 0.333 0.358 NS 0.369 6.0 0.329 0.330 0.640 NS
VEGFA rs25648 43738977 upstream/5'UTR/exonic T 0.426 0.5 0.159 0.164 0.519 NS 0.591 0.5 0.158 0.164 0.375 NS
rs833069 43742579 intronic C 0.244 4.4 0.337 0.349 0.570 NS 0.369 5.1 0.321 0.330 0.819 NS
rs3024994
§
43743507 intronic T 0.244 0.4 0.040 0.037 0.828 NS 0.178 0.5 0.034 0.044 0.336 NS
rs3025000 43746169 intronic T 0.062 0.4 0.295 0.288 0.342 NS 0.189 0.5 0.289 0.273 0.481 NS
rs3025035 43751359 intronic T 0.665 0.7 0.105 0.120 0.148 NS 0.809 0.9 0.103 0.126 0.084 NS
rs6899540 43758324 downstream C 0.856 0.7 0.123 0.147 0.888 NS 1.000 0.7 0.118 0.147 0.899 NS
rs6900017 43758485 downstream T 0.560 0.4 0.120 0.131 0.198 NS 1.000 0.5 0.119 0.127 0.163 NS
rs6905288 43758873 downstream G 1.000 0.9 0.396 0.382 0.120 NS 1.000 0.9 0.390 0.385 0.273 NS
MA
Whole sample
gene marker position
*
location
*
P
†
P
‡ HWE P
missing 
genotypes (%)
HWE P
missing 
genotypes (%)
MAF good 
recovery
MAF poor 
recovery
MAF poor 
recovery
P
†
P
‡
Ischemic Subset
MAF good 
recovery
  109 
  110 
  111 
 
 
 
 
 
 
 
Chapter 5. Nitric oxide synthase genes 
 
 
  112 
 
 
 
 
 
 
 
 
 
 
Manso H, Krug T, Sobral J, Albergaria I, Gaspar G, Ferro JM, Oliveira SA, Vicente 
AM (2011) Variants within the nitric oxide synthase 1 gene are associated with stroke 
susceptibility (Submitted) 
 
Chapter 5. Nitric oxide synthase genes 
 113 
Abstract 
 
Background – Animal studies have allowed important insights into the role of 
the nitric oxide synthase (NOS) enzymes in atherosclerosis, hypertension and stroke, as 
well as in the post-stroke process of damage control and recovery. In this study we 
tested the hypothesis that the NOS1 and NOS3 genes, respectively encoding neuronal 
NOS (nNOS) and endothelial NOS (eNOS), influence susceptibility and recovery after 
a stroke event.  
Methods and results – We conducted a case-control association study in 551 
ischemic stroke patients and 530 controls to assess the role of NOS1 and NOS3 variants 
in stroke susceptibility. Further, the same genes were tested for association with stroke 
outcome in a subset of 431 patients, and the effect of gene-gene interactions in both 
phenotypes was also investigated. Four NOS1 polymorphisms and four haplotypes were 
significantly associated with stroke susceptibility after adjusting for demographic, 
clinical and life-style risk factors, and correcting for multiple testing using the false 
discovery rate (FDR) method (0.036< SNP FDR q<0.048 and 0.018<haplotype FDR 
q<0.032). NOS1 variants were not associated with stroke outcome. We did not find any 
evidence for association between NOS3 and stroke susceptibility or outcome, or for 
significant NOS1-NOS3 synergistic interactions in either phenotype.  
Conclusions – Our results highlight NOS1 as a susceptibility factor for stroke, 
but do not corroborate previous NOS3 association findings with stroke risk. nNOS is 
known to play a major role in atherosclerosis development and in blood flow regulation, 
and its influence in stroke may therefore be mediated through these two main clinical 
risk factors. 
 
 
Keywords: Atherosclerosis, Hypertension, Nitric Oxide Synthase, Recovery, Stroke, 
Susceptibility. 
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Introduction 
 
Nitric oxide (NO) is an important inter- and intracellular messenger in several 
types of cells. It is synthesized via the oxidative L-arginine pathway by three distinct 
isoforms of nitric oxide synthase (NOS) enzymes, neuronal NOS (nNOS), inducible 
NOS (iNOS) and endothelial NOS (eNOS), which are dependent on cofactor binding 
and dimerization to become active  [Alderton et al. 2001]. Each of these enzymes shows 
a predominant tissue expression pattern, however with some overlap [Liu and Huang 
2008]. nNOS is the predominant synthase in neurons, whereas eNOS and iNOS are 
mainly expressed in endothelial cells and macrophages, respectively.  
Known risk factors for stroke, including atherosclerosis and hypertension, and 
stroke itself have been linked to abnormalities in NO signaling [Liu and Huang 2008]. 
NO produced by endothelial cells causes vasodilation and hypotension, and has several 
anti-thrombotic and antiatherosclerotic properties, such as inhibition of leukocyte 
adhesion and migration, and reduction of smooth muscle cells proliferation [Toda et al. 
2009a]. In the central nervous system (CNS) or in the peripheral nervous system (PNS), 
NO acts as a neurotransmitter and regulates multiple autonomic nervous system 
processes, including vasodilation and smooth muscle cells relaxation in the 
gastrointestinal, respiratory and genitourinary tracts [Huang 1999; Liu and Huang 2008; 
Toda et al. 2009a]. Genetically engineered animals overexpressing or with a disruption 
in NOS-encoding genes have provided particularly valuable insights into the 
pathophysiology of NOS enzymes in several disorders [reviewed in Liu and Huang 
2008]. Apolipoprotein E/nitric oxide synthase 1  (Apoe/Nos1) and Apoe/nitric oxide 
synthase 3 (Nos3) double knockouts (KO) develop greater atherosclerotic vascular 
lesions than Apoe KO mice, an animal model for human diet-induced atherosclerosis 
[Kuhlencordt et al. 2001; Kuhlencordt et al. 2006], indicating that nNOS and eNOS 
have a vasculoprotective role in atherosclerosis. Studies with Nos3 KO mice and nNOS 
inhibitors have also shown the involvement of both eNOS and nNOS enzymes in 
maintenance of blood pressure [Shesely et al. 1996; Talman and Nitschke Dragon 
2007]. Further, Nos1 KO mice have decreased infarct volumes and less neurological 
deficits after ischemic stroke than controls, while Nos3 KO mice develop larger infarct 
sizes, suggesting that nNOS contributes to tissue damage and eNOS has a protective 
role [Huang et al. 1996; Huang et al. 1994].  
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These observations implicate nNOS and eNOS in pathological conditions that 
increase stroke risk, like atherosclerosis and hypertension, and in the injury or recovery 
mechanisms that occur after stroke. Genes encoding these enzymes are therefore strong 
candidates for a role in stroke risk and recovery. Some polymorphisms within the NOS3 
gene (encoding the eNOS enzyme), such as the Glu298Asp polymorphism (rs1799983) 
known to impair the enzymatic activity of eNOS, have been previously tested for 
association with stroke [reviewed in Bersano et al. 2008]. However, contradictory 
results have been obtained in different population samples. On the other hand, no 
association study assessing the role of NOS1 gene (encoding the nNOS enzyme) in 
stroke has been published so far. We thus tested the association of these two genes with 
stroke susceptibility and with stroke outcome at three months.  
According to the STRING database [Jensen et al. 2009], which contains 
information on physical and functional protein-protein interactions, nNOS and eNOS 
are predicted functional partners. Given the likely ubiquity of gene-gene interactions in 
common human diseases [Moore 2003], we also investigated the existence of NOS1-
NOS3 interactions in stroke risk and outcome. 
 
 
Methods 
 
Population Sample 
 
The study sample included 551 first-ever ischemic stroke patients, recruited 
through Neurology and Internal Medicine Departments of several hospitals in Portugal. 
The assessment methods, inclusion criteria and history on previous stroke risk factors 
were previously described [Manso et al. 2011]. 530 healthy controls with no clinical 
history of stroke were also enrolled. Since stroke is a late-onset disease, we included 
older healthy individuals to reduce the probability of misclassification as controls. 
Demographic, clinical and life-style risk factors were compared between patients and 
controls and adjusted for, if significantly different (Table 1). A subset of 431 patients, 
for whom clinical data on functional recovery was available, was included in the 
outcome analysis. Occurrence of permanent altered consciousness, urinary 
incontinence, medical and neurological complications, neglect, aphasia, paresis, gaze 
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paresis and dysphagia during hospitalization were clinical parameters indicative of 
stroke severity. Stroke outcome was assessed, by direct interview, using the modified 
Rankin Scale (mRS) at three months after the stroke event. This scale was used to 
classify patients into two groups: patients with mRS≤1 were scored as “good recovery” 
and patients with mRS>1 were scored as “poor recovery”.  
 
SNP selection and genotyping 
 
Haplotype tagging SNPs were selected across the NOS1 and NOS3 genomic 
regions (gene ± 5kb) with the Haploview software (v4.2) [Barrett et al. 2005] (HapMap 
Release 21/phase II July 2006) to capture the complete genetic variability in these loci. 
31 NOS1 SNPs and 4 NOS3 SNPs were genotyped using Sequenom iPLEX assays with 
allele detection by mass spectroscopy, using Sequenom MassARRAY technology 
(Sequenom, San Diego, California) and following the manufacturer’s protocol. Primer 
sequences were designed using Sequenom’s MassARRAY Assay Design 3.0 software. 
Genotyping of 6 NOS1 SNPs and 1 NOS3 SNP were performed using TaqMan® Pre-
Designed SNP Genotyping Assays in an ABI PRISM 7900HT Sequence Detector 
System (Applied Biosystems, Foster City, USA). All genotyping plates contained 
quality control samples: four no-template controls, eight HapMap individuals, 
duplicated samples within and across genotyping plates, and three large pedigrees to 
check for Mendelian inconsistencies. SNPs in Hardy-Weinberg equilibrium (P>0.05) 
and with a genotyping call rate above 90% were further analyzed. Genotype 
determinations were blinded to affection and/or stroke outcome status.  
 
Statistical analysis  
 
To identify potential confounders, univariate analyses were performed. 
Specifically, demographic, clinical and life-style risk factors were compared between 
patients and controls, using the Pearson’s 2 test and the Mann-Whitney test for discrete 
and continuous variables, respectively. Variables with a P<0.25 in univariate analysis 
(Table 1) or of particular clinical relevance were included in a logistic regression model 
using forward selection  and were maintained in the model if they were associated with 
stroke susceptibility at a P≤0.05 level [Hosmer and Lemeshow 2000]. Covariates in the 
final logistic regression model were not correlated (-0.5<interaction i<0.5). The effect 
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of each genetic variable on stroke susceptibility was determined by logistic regression, 
after adjustment for the significant covariates. Odds ratio (OR) and 95% confidence 
intervals (95% CI) were computed for the log-additive model. The analysis of stroke 
outcome followed a similar procedure. Demographic and clinical data reflecting the 
severity of stroke was compared between patients with poor (mRS>1) and good 
(mRS≤1) outcome at three months to identify potential confounders (supplementary 
table 3). The effect of each genetic variable on patient’s outcome was determined by 
logistic regression, after adjustment for the significant covariates. OR and 95% CI were 
also computed for the log-additive model. Univariate and logistic regression analyses 
were performed using MASS and SNPassoc packages of the R software [R: A language 
and Environment for Statistical Computing  2004] (v2.10.1), respectively. Haplotype 
blocks in the two genes were determined using the Gabriel et al. [2002] or the solid spin 
of linkage disequilibrium (LD) methods of the Haploview software (v4.2) [Barrett et al. 
2005] and haplotype-based association analyses were performed using the same 
software. To reduce type I error, we applied the false discovery rate (FDR) multiple 
testing correction in individual SNP and haplotype-based association analyses. SNPs (or 
haplotypes) with q values ≤5% were considered significant, which resulted in a 
FDR≤5% among the significant SNPs (or haplotypes). q values were calculated using 
the qvalue package of the R software [R: A language and Environment for Statistical 
Computing  2004].  
 
Gene-gene interaction analysis 
 
The multifactor-dimensionality reduction (MDR) method (v2.0, beta 7.2) 
[Ritchie et al. 2001], a nonparametric and genetic model-free approach, was used to test 
for genetic interactions in association with stroke susceptibility and outcome. Briefly, 
by pooling multilocus genotypes into high and low risk groups, the MDR reduces the 
dimensionality of the data from N dimensions to one dimension. The new multilocus 
genotype attribute is then tested for its ability to classify and predict disease status, or 
good/poor outcome at three months. False-positive results due to multiple testing are 
reduced through combination of a cross-validation strategy and permutation testing 
[Moore 2003; Ritchie et al. 2001]. Missing genotypes were imputed for each SNP using 
the PLINK software (http://pngu.mgh.harvard.edu/purcell/plink/) [Purcell et al. 2007] 
and individual genotypes obtained in the present study and from CEU HapMap subjects 
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were used as reference. The best interaction models were chosen from among the best 2, 
3 and 4-marker models, based on the testing balanced accuracy (TBA), which measures 
how often individuals are correctly classified in relation to disease or outcome status, 
and the cross-validation consistency (CVC) of 10 cross-validation intervals, which 
measures the number of times the MDR found the same set of loci across the cross 
validation subsets. The statistical significance of the best models was calculated after 
1000 permutations using the MDR Permutation Tool (v1.0, beta 2). To interpret 
interaction models and identify non-linear interactions, MDR uses measures of entropy 
[Jakulin and Bratko 2003], which is the extent of uncertainty associated with a variable, 
to assess information gain (IG). When the combination of two or more SNPs gives a 
positive information gain (IG), there is evidence for a synergistic interaction; when IG 
is negative, SNPs are correlated; and if IG=0, the SNPs have independent effects. 
 
 
Results 
 
The demographic and clinical characteristics of investigated patients and 
controls are reported in Table 1. Hypertension, diabetes, smoking and alcohol 
consumption – four well-known stroke risk factors – were significantly more frequent in 
patients than in controls, as shown by univariate analyses. The frequency of stroke 
during sample collection was higher in males than females, as expected. Multivariate 
analyses were performed subsequent to univariate analyses to identify potential non-
genetic confounders. The final logistic regression model included the covariates 
significant in the multivariate analysis model – gender, hypertension, diabetes and 
smoking – as well as genetic markers. 
All SNPs genotyped in the NOS1 and NOS3 genes met quality control criteria 
and were further evaluated. Figure 1 shows the association results and the LD pattern 
among all genotyped markers in our sample. Seven NOS1 SNPs were associated with 
ischemic stroke under a log-additive model, after adjusting for significant covariates 
(0.004<P<0.042) (Table 2, Supplementary table 1). Four of these SNPs (rs2293050, 
rs2139733, rs7308402 and rs1483757) remained significantly associated with ischemic 
stroke after correcting for multiple testing (0.036<FDR q<0.048). We observed that 
rs2293050 and rs2139733, two of the four significant SNPs, are in almost complete LD 
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(r
2
 ≈0.97) and may therefore signal the same variant. Eight haplotypes in the NOS1 gene 
were associated with stroke (0.001<P<0.046) (Table 3, Supplementary table 2), four of 
which remained significant after multiple testing correction (0.018<FDR q<0.032). 
Evidence for association of three of these four haplotypes was increased when 
compared to that of individually associated markers, with one specific haplotype 
increasing stroke susceptibility (haplotype A-T-T-G-T for markers rs7977109-
rs11068438-rs11611788-rs11068445-rs7298903) and two others protecting from stroke 
(haplotype C-T-G-A-C for markers rs1607817-rs2293050-rs7314935-rs2139733-
rs7309163 and haplotype G-A for markers rs547954-rs7308402) (Tables 2 and 3).   
We carried out a bioinformatics analysis to investigate possible functional 
consequences for gene transcription and/or protein activity of the significant SNPs and 
haplotypes in NOS1. Since they are located in introns and are not splice-site variants, 
these SNPs are not likely to be functional, but may be in LD with variants affecting the 
activity and/or subcellular distribution of nNOS. The nNOS protein has five functional 
domains: PDZ, NO synthase, flavodoxin, FAD binding and NAD binding. The PDZ 
domain, encoded by part of exon 2, is required to anchor nNOS to the cellular 
membrane. rs7308402 and rs1483757, as well as haplotype G[rs547954]-A[rs7308402], 
located in neighbor intron 2, were significantly associated with stroke, and may be in 
LD with functional variants in this domain, affecting the subcellular distribution and/or 
activity of the protein. The genomic region from rs1607817 to rs7309163, 
encompassing the protective haplotype C-T-G-A-C and the associated SNPs rs2293050 
and rs2139733, includes exons 5-9 which encode part of the NO synthase domain. 
Exonic variants in this region may therefore alter nNOS activity. 
Two out of five NOS3 SNPs were associated with stroke after adjusting for the 
previously mentioned significant covariates (rs1800783: P=0.014, OR[95%CI]=0.79 
[0.65-0.95]; rs2373929: P=0.027, OR[95%CI]=1.24 [1.02-1.50]) (Table 2, 
Supplementary table 1), but none of these associations withstood multiple testing 
correction. No haplotype was significantly associated with stroke susceptibility 
(Supplementary table 2). 
Gene-gene interactions are likely to have an important impact on complex 
phenotypes, including susceptibility to common stroke. Thus, we investigated the 
existence of gene-gene interactions between NOS1 and NOS3 using the MDR method. 
All possible 2- to 4-marker models were tested. The most significant interaction model 
in stroke susceptibility corresponded to an interaction between three SNPs in NOS1 
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(rs1093330, rs2139733 and rs7977109) and one SNP in NOS3 (rs2373929). This model 
had a statistically significant TBA of 0.577 (P=0.010, based on 1000-fold 
permutations), thus being able to correctly classify approximately 58% of the 
individuals tested, a CVC of 9/10, indicating that the model was selected 9 times out of 
10 cross validation subsets, and a global OR of 3.13 [95%CI=2.41-4.06]. Table 4 shows 
that six genotype combinations of these four SNPs protected from stroke, while two 
others increased susceptibility to this disease. The genetic effects identified by MDR 
were interpreted using the entropy-based interaction dendrogram presented in Figure 
2A, which highlights the gain of information on case/control status by knowing the 
genotypes at the four SNPs. The interaction dendrogram shows a non-linear synergistic 
interaction between two NOS1 SNPs, rs1093330 and rs7977109, whereas NOS1 
rs2139733 and NOS3 rs2373929 have redundant and independent effects in the model, 
respectively. These results suggest that the effects of the NOS1 and NOS3 genes on 
stroke susceptibility are independent. 
The impact of NOS1 and NOS3 genetic variants in patient’s outcome at three 
months was also analyzed. This was investigated in a subset of 431 stroke patients for 
whom clinical information during hospitalization and at three months was available 
(Supplementary table 3). It was observed that clinical characteristics reflecting the 
severity of stroke (occurrence of aphasia, urinary incontinence, paresis, altered 
consciousness, medical and neurological complications during hospitalization) were 
significantly more frequent in patients with poor outcome at three months, as expected. 
SNP association analyses did not provide any strong evidence for an independent effect 
of NOS1 or NOS3 in stroke outcome (Supplementary tables 4 and 5). Since the MDR 
method may identify gene-gene interactions even in the absence of independent effects, 
we investigated the existence of NOS1-NOS3 interactions that might influence patient’s 
recovery after stroke. The best interaction model that was identified corresponded to a 
4-marker combination between three SNPs in NOS1 (rs11068428, rs2139733 and 
rs7977109) and one SNP in NOS3 (rs743507). This model correctly classified 
approximately 57.3% of the individuals (TBA of 0.573, P=0.051 based on 1000-fold 
permutations), and was selected 6 times out of 10 cross-validation subsets (CVC of 
6/10); its global OR was 5.08 [3.29-7.83]. The entropy-based interaction dendrogram 
presented in Figure 2B shows an epistatic interaction between one NOS1 SNP 
(rs2139733) and one NOS3 SNP (rs743507). Nevertheless, since the TBA of the 
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interaction model was only nominal (permutedP=0.051), it is unlikely that a NOS1-NOS3 
interaction strongly contributes to patient’s outcome after stroke. 
 
 
Discussion 
 
The NOS3 gene is predominantly expressed in the endothelium, a key player in 
vasodilation, and Nos3 KO mice are hypertensive and have vascular abnormalities 
[Shesely et al. 1996]. NOS3 was thus identified early as a candidate gene for stroke and 
has been repeatedly tested for association with this disease. NOS1 gene expression was 
initially found in neurons and the aggressive behaviour and enlarged stomachs that 
characterize Nos1 KO mice [Huang et al. 1993] were not suggestive of a role of this 
enzyme in stroke. However, it is nowadays clear that nNOS has an important 
vasculoprotective role in atherosclerosis and is involved in blood pressure control 
[Kuhlencordt et al. 2006; Talman and Nitschke Dragon 2007; Toda et al. 2009b]. It has 
been suggested that NO released from autonomic nitrergic nerves innervating the 
systemic vasculature, together with endothelial NO, plays a role in vasodilation 
[reviewed in Toda et al. 2009b]. It is therefore plausible that nNOS influences stroke 
susceptibility through very different but complementary mechanisms from eNOS. In 
this study, we provide novel genetic evidence supporting this hypothesis, identifying a 
significant association of the NOS1 gene with stroke susceptibility. In the tested 
population sample, four SNPs and four haplotypes were significantly associated with 
stroke, after adjusting for demographic, clinical and life-style risk factors. These SNPs 
were located in or near gene regions that are critical for protein function, namely the 
PDZ domain, required to anchor nNOS to the cellular membrane, and the NO synthase 
domain.  
In contrast, we found no evidence supporting a role of the NOS3 gene in stroke 
risk in our population set. Previously, several NOS3 variants have been tested for 
association with stroke, with approximately half of the studies showing positive results 
and the others failing to confirm these associations [reviewed in Bersano et al. 2008]. 
Some negative studies might have been underpowered to replicate the initial findings, as 
their sample sizes were relatively small, but a meta-analysis with 1086 cases and 1089 
controls was also negative [Bersano et al. 2008; Casas et al. 2004]. Another study with 
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the largest sample size thus far, involving the analysis of 1901 patients and 1747 
controls, obtained positive results [Berger et al. 2007]. It is possible that contradictory 
results reflect true differences between populations with distinct ethnic backgrounds, 
but heterogeneity between studies cannot be excluded, e.g. in the analyzed phenotype 
(ischemic stroke vs. small vessel stroke), or the age of patients (children vs. adults). In 
the present work, we covered, for the first time, the whole genetic variability in this 
region to prevent potential negative association findings due to allelic or LD pattern 
heterogeneity across populations, which are plausible reasons for inconsistencies 
between studies. Further, our results were adjusted for significant confounders, not 
consistently done in all studies, thus decreasing the chance of finding positive 
associations due to non-genetic risk factors. An effort to carry out association studies in 
other populations, analyzing the whole genetic variability of this region and not only 
previously associated SNPs, and taking into account non-genetic risk factors, will be 
necessary for an adequate meta-analysis,  providing the necessary data to properly 
dissect the contribution of NOS3 to stroke risk. 
Because the NOS isoforms have partially overlapping mechanisms of regulation, 
physiological functions and tissue distributions, and nNOS and eNOS are predicted 
functional partners according to the STRING database, we investigated the existence of 
NOS1-NOS3 interactions. Identifying interactions between loci may contribute to better 
understanding of the pathophysiological pathways involved in stroke risk and recovery, 
but this is not often investigated in association studies. Our results, however, did not 
support any epistatic interactions between the NOS1 and NOS3 genes in stroke 
susceptibility, suggesting on the contrary that the effects of the two genes are 
independent. We also identified a non-additive interaction between two SNPs in NOS1. 
These markers are far apart from each other (approximately 34kb) and were not 
individually associated with stroke. It is possible that they are in LD with two functional 
variants whose interaction may influence folding kinetics and stability of the protein, 
but further studies are needed to test this hypothesis.  
We found no evidence supporting a contribution of NOS1 and NOS3 gene 
variants to patient’s recovery. This was unexpected, since previous animal studies have 
shown that absence of either gene has an impact in neurological outcome and/or infarct 
volumes after stroke [Huang et al. 1996; Huang et al. 1994]. It is possible that a NOS1 
and NOS3 gene variant with a modest effect in patient’s outcome was undetected in this 
smaller subset. No significant gene interaction model was identified for this phenotype. 
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nNOS-derived NO is an important molecule for synaptic plasticity and neuronal 
signaling, and it also controls blood flow and muscle contractility in the smooth, cardiac 
and skeletal muscles [Zhou and Zhu 2009]. eNOS and nNOS show atheroprotective 
effects in a mouse model of atherosclerosis and are known to regulate vasodilation 
through different mechanisms. NO liberated from the endothelium (produced through 
eNOS), brain neurons and perivascular nitrergic nerves (produced through nNOS) act 
on vascular smooth muscle cells to produce relaxation, lowering blood pressure [Toda 
et al. 2009b]. Endothelial dysfunction and impairment of nitrergic nerve function lead to 
systemic hypertension [Toda et al. 2009b]. The biological functions of nNOS seem 
therefore critical for atherosclerosis progression and development of hypertension, with 
subsequent influence on stroke risk, and may be underlying the positive NOS1 
association results. Interestingly, Nakata et al [2007] showed that statins, which have 
been used to treat hypercholesterolemia, up-regulate nNOS in human endothelial cells, 
rat vascular smooth muscle cells and mouse aortas, suggesting yet a different functional 
mechanism whereby nNOS may be regulating stroke risk through its expression in cells 
other than neurons. This observation also demonstrates a novel vascular effect of statins 
mediated through nNOS, suggesting that this enzyme could also be involved in the 
reduction of stroke incidence that was observed for statins, in addition to the lowering 
of cholesterol levels [Baigent et al. 2005]. Further understanding of specific nNOS-
mediated signaling pathways may highlight these as critical targets for stroke prevention 
[Zhou and Zhu 2009].  
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Figures 
 
 
Figure 1 – NOS1 association results (-log10 P) with stroke risk and pairwise r
2
 among genotyped SNPs in 
our population sample. The relative positions of the 37 NOS1 SNPs are indicated. The white-black 
gradient shading represents the magnitude of linkage disequilibrium (r
2
). Association results above the 
line -log10P=1.3 are considered significant (P<0.050); SNPs withstanding the multiple testing correction 
(FDR q<0.05) are indicated. 
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Figure 2 – Interaction dendrograms for the NOS1 and NOS3 polymorphisms in stroke 
susceptibility (A) and outcome (B). The length of the dendrogram branch that connects two 
polymorphisms indicates the strength of interaction (the shorter the branch, the stronger is the 
interaction). 
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Tables 
 
Table 1 – Demographic and clinical characteristics of the population sample.  
 
Age, mean±SD (yrs) 62.9±6.8 52.2±9.2 <10
-4
Gender (male),  n/N (%) 247/530 (46.6) 352/551 (63.9) <10
-4
Stroke Risk Factors, n/N (%)
Hypertension (>85-140 mmHg) 193/513 (37.6) 278/490 (56.7) <10
-4
Diabetes 59/501 (11.8) 89/522 (17.0) 0.017
Hypercholesterolemia (cholesterol >200 mg/dL) 328/520 (63.1) 320/511 (62.6) 0.880
Smoking 147/512 (28.7) 262/542 (48.3) <10
-4
Drinking 218/505 (43.2) 321/544 (59.0) <10
-4
Characteristic P
*Patients Controls 
 
SD – standard deviation, yrs – years.  
*Mann-Whitney test or Pearson's χ2 test. 
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Table 2 – Genotype frequency distribution and association with stroke susceptibility for 
the NOS1 and NOS3 SNPs.  
NOS1 rs2293050
C/C 145 (30.1) 188 (39.8) 0.76 [0.63-0.92] 0.004 0.036
T/C 244 (50.7) 206 (43.6)
T/T 92 (19.1) 78 (16.5)
rs2139733
T/T 138 (30.3) 182 (40.7) 0.76 [0.62-0.92] 0.004 0.036
A/T 231 (50.8) 190 (42.5)
A/A 86 (18.9) 75 (16.8)
rs7309163
C/C 220 (47.3) 194 (42.6) 1.23 [1.01-1.51] 0.042 0.165
C/T 203 (43.7) 196 (43.1)
T/T 42 (9.0) 65 (14.3)
rs11068445
G/G 319 (71.7) 349 (76.9) 0.72 [0.55-0.96] 0.023 0.110
A/G 111 (24.9) 100 (22.0)
A/A 15 (3.4) 5 (1.1)
rs547954
G/G 293 (61.3) 264 (56.1) 1.29 [1.03-1.61] 0.024 0.110
G/A 162 (33.9) 174 (36.9)
A/A 23 (4.8) 33 (7.0)
rs7308402
G/G 232 (48.2) 262 (55.5) 0.74 [0.60-0.91] 0.004 0.037
G/A 199 (41.4) 177 (37.5)
A/A 50 (10.4) 33 (7.0)
rs1483757
A/A 143 (29.7) 179 (37.8) 0.77 [0.64-0.93] 0.007 0.048
G/A 242 (50.2) 214 (45.2)
G/G 97 (20.1) 80 (16.9)
NOS3 rs1800783
T/T 124 (25.9) 144 (31.1) 0.79 [0.65-0.95] 0.014 0.068
A/T 248 (51.9) 231 (49.9)
A/A 106 (22.2) 88 (19.0)
rs2373929
G/G 193 (39.9) 160 (33.7) 1.24 [1.02-1.50] 0.027 0.068
A/G 216 (44.6) 231 (48.6)
A/A 75 (15.5) 84 (17.7)
FDR q
†Gene P
*
Controls, n (%)
GenotypeSNP
Cases, n (%)
Genotype frequency 
OR [95% CI]
 
Only associated SNPs are shown. Odds Ratio (OR) >1 indicates increased probability of having a stroke for the 
carriers of the minor allele. CI – Confidence Interval, FDR – false discovery rate. 
*OR [95% CI] and P for the log-additive genetic model after adjustment for significant covariates (gender, history of 
hypertension, diabetes and smoking status) 
† FDR q values 
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Table 3 – Haplotype frequency distribution of the NOS1 gene and association with stroke susceptibility.  
 
NOS1 rs816361-rs9658536 CA 0.092 10.4 8.0 3.967 0.046 0.119
ACGTT 0.330 30.5 35.4 5.819 0.016 0.068
CTGAC 0.305 33.5 27.6 8.635 0.003 0.018
ATTGT 0.303 27.3 33.1 8.437 0.004 0.032
AATAC 0.132 14.8 11.6 4.565 0.033 0.119
GA 0.283 31.6 25.1 11.408 0.001 0.018
AG 0.235 21.1 25.8 6.558 0.010 0.032
rs576881-rs9658267-rs9658266-rs1552227 AGGT 0.264 28.8 24.1 6.116 0.013 0.067
FDR q*Gene
rs7977109-rs11068438-rs11611788-rs11068445-
rs7298903
Haplotype 
frequency
Controls 
(%)
Haplotypes
rs547954-rs7308402
rs1607817-rs2293050-rs7314935-rs2139733-
rs7309163
P
Cases 
(%)
χ
2
 
Only associated haplotypes are shown. FDR – false discovery rate. 
* FDR q values 
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Table 4 – Frequency and odds ratio (OR) of the significant genotype combinations of 
rs1093330, rs2139733, rs7977109 and rs2373929 in stroke susceptibility. The OR-
based MDR was used in the analysis. 
 
TT AA GG AG 1:9 0.11 [0.06-0.85]
CT AA AG AG 2:10 0.20 [0.11-0.89]
CC TT GG AG 5:14 0.35 [0.21-0.96]
CC AT AG GG 6:16 0.37 [0.22-0.93]
CT AT GG GG 6:16 0.37 [0.22-0.93]
CT AT AG GG 13:30 0.42 [0.30-0.80]
CT TT AG GG 21:10 2.05 [1.10-4.31]
CT AT AG AG 43:20 2.10 [1.35-3.51]
rs1093330 OR [95% CI]frequency (case:control)rs2373929rs7977109rs2139733
 
CI – Confidence Interval. 
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Supplementary tables 
 
Supplementary table 1 – Association analysis results for NOS1 and NOS3 markers and stroke susceptibility.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NOS1 rs816361 117655131 intronic G 0.632 2.9 0.353 0.339 0.676
rs9658536 117657521 intronic A 0.820 0.4 0.106 0.080 0.062
rs904658 117665544 intronic C 0.513 3.6 0.384 0.358 0.275
rs3741475 117669914 3'UTR/exonic A 0.355 2.7 0.253 0.248 0.827
rs816357 117682766 intronic G 0.111 0.2 0.125 0.122 0.698
rs816354 117684716 intronic G 1.000 1.4 0.106 0.106 0.766
rs816353 117684780 intronic T 0.434 0.2 0.492 0.473 0.331
rs816346 117690874 intronic A 0.378 0.4 0.112 0.109 0.924
rs11068428 117693817 intronic/exonic A 0.563 0.1 0.344 0.321 0.360
rs12829185 117694020 intronic T 0.634 0.2 0.240 0.242 0.918
rs1093330 117696534 intronic C 0.250 4.3 0.497 0.479 0.388
rs1607817 117712186 intronic A 1.000 0.6 0.310 0.358 0.078
rs2293050 117718822 intronic T 0.661 0.6 0.448 0.372 0.004 0.036
rs7314935 117718837 intronic A 1.000 0.9 0.102 0.088 0.338
rs2139733 117726742 intronic A 0.587 5.6 0.446 0.366 0.004 0.036
rs7309163 117729274 intronic T 0.533 4.1 0.309 0.366 0.042 0.165
rs7977109 117730340 intronic G 0.258 0.6 0.494 0.481 0.357
rs11068438 117737545 intronic A 0.324 0.1 0.157 0.123 0.075
rs11611788 117738376 intronic C 0.068 0.0 0.066 0.065 0.907
rs11068445 117744929 intronic A 0.405 6.2 0.161 0.117 0.023 0.110
rs7298903 117747210 intronic C 0.307 0.3 0.151 0.118 0.095
rs547954 117754506 intronic A 0.793 1.2 0.210 0.258 0.024 0.110
rs7308402 117759447 intronic A 0.614 0.6 0.316 0.251 0.004 0.037
rs1483757 117761540 intronic G 0.726 0.4 0.457 0.385 0.007 0.048
rs816293 117762699 intronic G 0.705 0.4 0.358 0.400 0.125
HWE PMAgene
MAF 
controls
location
*
position
*marker
missing genotypes 
(%)
FDR q
‡MAF 
patients
P
†
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Supplementary table 1 (cont.) – Association analysis results for NOS1 and NOS3 markers and stroke susceptibility.  
 
NOS1 rs1520810 117765189 intronic A 0.517 0.5 0.213 0.234 0.405
rs9658281 117767578 intronic T 0.582 0.3 0.272 0.238 0.102
rs3782218 117771511 intronic/upstream T 0.756 0.4 0.168 0.152 0.299
rs576881 117772835 intronic/upstream G 0.439 0.5 0.340 0.377 0.121
rs9658267 117777520 intronic A 0.209 5.4 0.122 0.103 0.151
rs9658266 117777535 intronic C 0.314 0.9 0.125 0.108 0.240
rs1552227 117779035 intronic T 1.000 0.2 0.288 0.241 0.064
rs527590 117781918 intronic T 1.000 0.6 0.251 0.257 0.563
rs1123425 117786105 intronic G 0.862 0.0 0.464 0.449 0.559
rs17509231 117794323 intronic T 0.669 0.2 0.116 0.114 0.890
rs3782221 117795881 intronic A 0.914 0.5 0.279 0.280 0.791
rs1879417 117803515 upstream C 0.330 0.0 0.432 0.455 0.372
NOS3 rs12703107 150683629 upstream T 0.547 0.4 0.236 0.252 0.086
rs1800783 150689397 intronic A 0.432 1.9 0.478 0.443 0.014 0.068
rs3918186 150702432 intronic T 0.788 0.6 0.090 0.092 0.922
rs743507 150707488 intronic C 0.617 0.2 0.320 0.297 0.066
rs2373929 150714812 downstream A 0.515 0.0 0.372 0.421 0.027 0.068
MAF 
patients
P
†
FDR q
‡MA HWE P
missing genotypes 
(%)
MAF 
controls
gene marker position
*
location
*
 
FDR – false discovery rate, HWE – Hardy-Weinberg equilibrium, MA – minor allele, MAF – minor allele frequency, NS – non-significant, UTR – untranslated region. 
*According to Ensembl Release 56 – September 2009. 
†P for the log-additive genetic model after adjustment for significant covariates. 
‡ FDR q values. 
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Supplementary table 2 – Association analysis results for NOS1 and NOS3 haplotypes and stroke susceptibility. 
 
NOS1 haplotype block 1: CG 0.561 54.2 58.0 3.110 0.078
GG 0.346 35.2 34.0 0.331 0.565
CA 0.092 10.4 8.0 3.967 0.046 0.119
haplotype block 2: AG 0.627 61.5 63.9 1.358 0.244
CA 0.249 25.1 24.7 0.036 0.850
CG 0.123 13.3 11.2 2.146 0.143
haplotype block 3: GGGCT 0.512 50.5 52.0 0.499 0.480
TGATC 0.240 23.9 24.0 0.003 0.954
TAGCC 0.110 11.1 10.8 0.038 0.845
TGACC 0.090 10.2 7.9 3.179 0.075
TGGCC 0.042 4.0 4.5 0.303 0.582
haplotype block 4: ACGTT 0.330 30.5 35.4 5.819 0.016 0.068
CTGAC 0.305 33.5 27.6 8.635 0.003 0.018
CCGTC 0.246 23.4 25.8 1.647 0.199
CTAAC 0.094 10.2 8.6 1.669 0.196
haplotype block 5: GTTGT 0.490 49.8 48.2 0.541 0.462
ATTGT 0.303 27.3 33.1 8.437 0.004 0.032
AATAC 0.132 14.8 11.6 4.565 0.033 0.119
ATCGT 0.066 6.6 6.6 0.004 0.947
rs7977109-rs11068438-rs11611788-
rs11068445-rs7298903
Cases (%) χ
2
FDR q
*
rs1607817-rs2293050-rs7314935-
rs2139733-rs7309163
P
Haplotype 
frequency
Haplotypes
rs816353-rs816346-rs11068428-
rs12829185-rs1093330
rs904658-rs3741475
rs816361-rs9658536
Gene Controls (%)
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Supplementary table 2 (cont.) – Association analysis results for NOS1 and NOS3 haplotypes and stroke susceptibility. 
 
NOS1 haplotype block 6: GG 0.482 47.3 49.1 0.761 0.383
GA 0.283 31.6 25.1 11.408 0.001 0.018
AG 0.235 21.1 25.8 6.558 0.010 0.032
haplotype block 7: TC 0.521 51.4 52.8 0.423 0.516
TT 0.255 27.3 23.8 3.435 0.064
AC 0.224 21.4 23.5 1.339 0.247
haplotype block 8: GGGC 0.358 33.9 37.7 3.441 0.064
AGGT 0.264 28.8 24.1 6.116 0.013 0.067
AGGC 0.262 24.9 27.3 1.589 0.208
AACC 0.113 12.3 10.4 1.894 0.169
haplotype block 9: CAC 0.424 41.8 43.0 0.295 0.587
TGC 0.249 24.7 25.1 0.044 0.835
CGC 0.207 21.6 19.8 1.038 0.308
CAT 0.115 11.5 11.4 0.001 0.974
NOS3 haplotype block 1: GA 0.454 47.3 43.6 2.947 0.086
GT 0.302 29.1 31.2 1.082 0.298
TT 0.238 23.1 24.4 0.480 0.488
haplotype block 2: AT 0.604 59.3 61.5 1.088 0.297
AC 0.305 31.7 29.3 1.466 0.226
TT 0.088 8.7 8.8 0.013 0.910
Cases (%) χ
2 P FDR q
*Gene Haplotypes
Haplotype 
frequency
Controls (%)
rs12703107-rs1800783
rs3918186-rs743507
rs527590-rs1123425-rs17509231
rs547954-rs7308402
rs1520810-rs9658281
rs576881-rs9658267-rs9658266-
rs1552227
 
* FDR q values. FDR – false discovery rate.  
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Supplementary table 3 - Demographic and clinical characteristics of ischemic stroke 
patients analyzed for outcome at three months 
 
Age, mean±SD (yrs) 50.8±9.0 52.1±8.7 0.137
Gender (male), n/N (%) 154/238 (64.7) 122/193 (63.2) 0.748
Hypertension 130/205 (63.4) 83/171 (48.5) 0.004
Diabetes 34/225 (15.1) 36/180 (20.0) 0.196
Cardiac Disease 35/226 (15.5) 35/184 (19.0) 0.344
Aphasia 44/224 (19.6) 63/180 (35.0) 5x10
-4
Neglect 9/231 (3.9) 14/171 (8.2) 0.067
Dysphagia 13/235 (5.5) 19/181 (10.5) 0.060
Urinary Incontinence 2/235 (0.9) 12/182 (6.6) 0.001
Paresis 175/235 (74.5) 173/192 (90.1) <10
-4
Altered consciousness 9/238 (3.8) 33/190 (17.4) <10
-4
Medical complications 10/231 (4.3) 48/180 (26.7) <10
-4
Neurologic complications 12/236 (5.1) 22/192 (11.5) 0.015
Past History, n/N (%)
Stroke Features, n/N (%)
Age and Gender
P
*Poor Recovery 
(mRS>1)
Good Recovery 
(mRS≤1)
Characteristic
 
SD – standard deviation, yrs – years. 
*Mann-Whitney test or Pearson's χ2 test.  
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Supplementary table 4 – Association analysis results for NOS1 and NOS3 markers and stroke outcome.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NOS1 rs816361 117655131 intronic G 1.000 2.6 0.320 0.372 0.297
rs9658536 117657521 intronic A 0.756 0.5 0.093 0.070 0.165
rs904658 117665544 intronic C 0.754 3.0 0.393 0.344 0.104
rs3741475 117669914 3'UTR/exonic A 0.898 1.6 0.247 0.257 0.975
rs816357 117682766 intronic G 0.829 0.2 0.127 0.127 0.928
rs816354 117684716 intronic G 0.800 1.2 0.102 0.111 0.748
rs816353 117684780 intronic T 1.000 0.2 0.487 0.477 0.285
rs816346 117690874 intronic A 1.000 0.5 0.108 0.117 0.999
rs11068428 117693817 intronic/exonic A 1.000 0.0 0.334 0.321 0.494
rs12829185 117694020 intronic T 0.602 0.2 0.233 0.260 0.398
rs1093330 117696534 intronic C 0.768 4.4 0.496 0.481 0.264
rs1607817 117712186 intronic A 0.917 0.2 0.368 0.344 0.113
rs2293050 117718822 intronic T 0.049 0.7 0.371 0.361 0.975
rs7314935 117718837 intronic A 1.000 1.4 0.100 0.068 0.143
rs2139733 117726742 intronic A 0.032 4.9 0.367 0.356 0.976
rs7309163 117729274 intronic T 0.916 2.8 0.376 0.349 0.090
rs7977109 117730340 intronic G 0.923 0.5 0.475 0.479 0.217
rs11068438 117737545 intronic A 0.203 0.2 0.127 0.135 0.823
rs11611788 117738376 intronic C 1.000 0.0 0.059 0.070 0.262
rs11068445 117744929 intronic A 0.371 3.5 0.123 0.130 0.699
rs7298903 117747210 intronic C 0.277 0.0 0.124 0.132 0.823
rs547954 117754506 intronic A 0.804 1.4 0.251 0.285 0.159
rs7308402 117759447 intronic A 1.000 0.7 0.243 0.233 0.955
rs1483757 117761540 intronic G 0.357 0.5 0.376 0.388 0.968
rs816293 117762699 intronic G 0.418 0.5 0.405 0.370 0.225
MAF poor 
recovery
P
†MA HWE P
missing genotypes 
(%)
MAF good 
recovery
gene marker position
*
location
*
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Supplementary table 4 (cont.) – Association analysis results for NOS1 and NOS3 markers and stroke outcome.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HWE – Hardy-Weinberg equilibrium, MA – minor allele, MAF – minor allele frequency, NS – non-significant., UTR – untranslated region. 
*According to Ensembl Release 56 – September 2009. 
†P for the log-additive genetic model after adjustment for significant covariates.  
 
rs1520810 117765189 intronic A 0.700 0.2 0.253 0.249 0.693
rs9658281 117767578 intronic T 0.679 0.0 0.216 0.233 0.666
rs3782218 117771511 intronic/upstream T 0.319 0.5 0.122 0.164 0.250
rs576881 117772835 intronic/upstream G 0.146 0.7 0.382 0.356 0.949
rs9658267 117777520 intronic A 0.600 5.3 0.117 0.088 0.240
rs9658266 117777535 intronic C 0.804 1.2 0.125 0.084 0.133
rs1552227 117779035 intronic T 1.000 0.2 0.209 0.275 0.123
rs527590 117781918 intronic T 0.902 0.9 0.265 0.277 0.908
rs1123425 117786105 intronic G 0.628 0.0 0.468 0.451 0.195
rs17509231 117794323 intronic T 0.333 0.0 0.101 0.122 0.249
rs3782221 117795881 intronic A 0.818 0.7 0.297 0.301 0.581
rs1879417 117803515 upstream C 0.561 0.0 0.462 0.440 0.863
NOS3 rs12703107 150683629 upstream T 0.801 0.7 0.276 0.236 0.246
rs1800783 150689397 intronic A 0.624 2.3 0.436 0.471 0.109
rs3918186 150702432 intronic T 1.000 0.7 0.085 0.099 0.618
rs743507 150707488 intronic C 0.361 0.0 0.305 0.301 0.518
rs2373929 150714812 downstream A 0.921 0.0 0.424 0.422 0.985
MAF poor 
recovery
P
†gene marker position
*
location
* MA HWE P
missing genotypes 
(%)
MAF good 
recovery
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Supplementary table 5 – Association analysis results for NOS1 and NOS3 haplotypes and stroke outcome.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NOS1 haplotype block 1: AG 0.628 60.8 65.2 1.767 0.184
CA 0.251 24.5 25.8 0.184 0.668
CG 0.120 14.5 9.0 6.028 0.014 0.107
haplotype block 2: GGGCT 0.514 50.8 52.1 0.129 0.719
TGATC 0.246 23.3 26.1 0.890 0.346
TAGCC 0.111 10.7 11.7 0.192 0.661
TGACC 0.083 10.1 6.0 4.634 0.031 0.122
TGGCC 0.044 4.6 4.1 0.115 0.735
haplotype block 3: ACGTT 0.355 36.3 34.4 0.312 0.576
CTGAC 0.273 26.2 28.7 0.660 0.417
CCGTC 0.267 25.3 28.4 0.999 0.318
CTAAC 0.083 9.6 6.6 2.586 0.108
haplotype block 4: TTGTG 0.543 56.6 51.4 2.314 0.128
TTGTA 0.262 24.9 27.9 0.959 0.327
ATACG 0.126 12.2 13.2 0.201 0.654
TCGTG 0.064 5.9 7.0 0.442 0.506
haplotype block 5: GA 0.619 62.4 61.2 0.140 0.708
AG 0.238 24.3 23.2 0.138 0.711
GG 0.143 13.3 15.6 0.941 0.332
rs816353-rs816346-
rs11068428-rs12829185-
rs1093330
rs1607817-rs2293050-
rs7314935-rs2139733-
rs7309163
rs11068438-rs11611788-
rs11068445-rs7298903-
rs547954
rs7308402-rs1483757
FDR q
*Gene Haplotypes
Good 
recovery (%)
Poor recovery 
(%)
χ
2 P
Haplotype 
frequency
rs904658-rs3741475
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Supplementary table 5 (cont.) – Association analysis results for NOS1 and NOS3 haplotypes and stroke outcome.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FDR – false discovery rate. * FDR qvalues 
 
NOS1 haplotype block 6: TC 0.525 53.0 51.8 0.123 0.725
AC 0.251 25.3 24.9 0.026 0.873
TT 0.224 21.6 23.3 0.345 0.557
haplotype block 7: GGGC 0.371 38.2 35.7 0.556 0.456
AGGC 0.284 28.7 27.9 0.076 0.782
AGGT 0.237 20.6 27.5 5.618 0.018 0.107
AACC 0.103 11.7 8.5 2.371 0.124
haplotype block 8: CAC 0.425 42.6 42.4 0.003 0.956
TGC 0.267 26.1 27.4 0.176 0.675
CGC 0.194 20.7 17.7 1.265 0.261
CAT 0.110 10.1 12.2 0.951 0.329
NOS3 haplotype block 1: GA 0.441 42.3 46.4 1.494 0.222
GT 0.300 30.0 30.0 0.000 0.997
TT 0.248 26.3 23.0 1.291 0.256
TA 0.010 1.4 0.6 1.269 0.260
haplotype block 2: AT 0.611 61.7 60.4 0.158 0.691
AC 0.298 29.8 29.7 0.000 0.982
TT 0.086 7.8 9.6 0.817 0.366
P FDR q
*Haplotype 
frequency
Good 
recovery (%)
Poor recovery 
(%)
χ
2Gene Haplotypes
rs3918186-rs743507
rs12703107-rs1800783
rs527590-rs1123425-
rs17509231
rs1520810-rs9658281
rs576881-rs9658267-
rs9658266-rs1552227
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Abstract 
 
Stroke is a major cause of morbidity and mortality in developed countries, with 
large numbers of stroke survivors left with variable degrees of disability. Given the 
increased life expectancy of populations, finding adequate treatments that promote 
recovery of patients is a priority task, requiring the elucidation of the molecular 
pathways influencing brain recovery. Few studies, however, have assessed the role of 
genes in stroke outcome. The present report describes a pilot genome-wide association 
study (GWAS) of 262,264 single nucleotide polymorphisms (SNPs) to identify the 
genetic factors contributing to patient’s outcome at three months. We compared SNP 
allele frequencies in a pool of non-disabled stroke patients (as assessed by the modified 
Rankin scale [mRS]=0), with a pool of severely disabled or deceased patients (mRS≥3), 
and selected the 100 most interesting SNPs for validation by individual genotyping. 36 
SNPs were validated, showing significant differences between patients with extremely 
good and extremely poor outcome at three months at a significance level of 5%  
(1.7x10
-4
<P<0.049). These SNPs were further analyzed in a larger sample including 
patients with the whole range of mRS scores, using a more clinically sensible threshold 
set at mRS≤1 for good recovery and mRS>1 for poor recovery. 15 SNPs were 
associated with stroke outcome (4.3x10
-4
<uncorrectedP<0.047), six of which remained 
associated after adjusting for stroke severity parameters (0.002<uncorrectedP<0.039). Two 
of these SNPs, rs10273634 and rs10974334, are located within the Bardet-Biedl 
syndrome 9 (BBS9) and GLIS family zinc finger 3 (GLIS3) genes. In addition, we found 
a GLIS3 haplotype significantly associated with stroke outcome (uncorrectedP=0.004, false 
discovery rate [FDR] q=0.024). Our results suggest that the BBS9 and GLIS3 genes may 
play a role in stroke outcome. This work represents an initial effort towards the 
elucidation of stroke outcome and recovery pathways using a genome-wide approach, 
and further supports the feasibility and accuracy of DNA pooling strategies for GWAS 
of complex traits. 
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Introduction 
 
Besides being one of the leading causes of mortality in developed countries, 
secondary only to cancer and ischemic heart disease, stroke is also a main cause of 
disability, with a significant proportion of stroke survivors requiring institutional care 
and/or remaining permanently disabled [Asplund et al. 1998; Hankey et al. 2002]. 
Patients surviving a first-ever stroke also have an increased risk of death and/or of 
suffering a second event in the following years [Hankey et al. 2002; Hardie et al. 2004]. 
With increasing life expectancy, this public health problem tends to worsen, with 
significant social and economic consequences. Thus, it is essential not only to improve 
stroke preventive strategies, but also to find therapies that reduce stroke-induced 
disability and improve recovery.   
A large body of data from animal studies show that genetic factors influence the 
severity of brain damage and the recovery process after stroke [Atochin et al. 2010; 
Chang et al. 2011; Hyakkoku et al. 2010; Jeffs et al. 1997]. Furthermore, family history 
of stroke was shown to be associated with stroke outcome, while this association was 
not observed for stroke severity or mortality at 90 days [Jood et al. 2005; Lisabeth et al. 
2005]. Still, this field of stroke genetics remains almost unexplored. Until now, 
relatively few candidate genes have been tested for association with stroke outcome. 
The apolipoprotein E (APOE) gene is the most widely tested candidate, with some 
studies finding an association between this gene and stroke outcome, while others fail to 
confirm this association [Martínez-González and Sudlow 2006; McCarron et al. 2000; 
McCarron et al. 1998; Sarzynska-Dlugosz et al. 2007; Treger et al. 2003]. The 
heterogeneity between studies regarding the clinical instruments used to assess patient’s 
outcome and the time of assessment may in part explain the discrepancies [Martínez-
González and Sudlow 2006]. Other candidate genes analyzed are involved in platelet 
adhesion and aggregation (PLAT and SERPINE1 genes), in thrombosis (GP1BA and 
ITGB3 genes), in neurovascular injury and/or neurovascular remodeling (MMP2 and 
MMP9 genes), in metabolic pathways regulating oxidative stress in the brain (MTHFR 
and GSTO1 genes) and in inflammatory pathways (IL6, MPO, IL1B, TNF and PTGS2 
genes) [Maguire et al. 2010; Manso et al. 2010; Manso et al. 2011; Peddareddygari et al. 
2009].  
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Thus far, no genome-wide association study (GWAS) for stroke outcome has 
been reported. While GWAS strategies allow searching for variants that affect a 
common trait, without making any prior assumptions, the single nucleotide 
polymorphism (SNP) microarrays that are used are extremely expensive, rendering 
these studies beyond the reach of many laboratories. A suitable alternative to overcome 
this difficulty is to pool DNA from different individuals and to estimate the SNP allele 
frequencies from the DNA pools using microarrays, a strategy known as allelotyping. 
SNPs associated with the phenotype in an initial phase can then be confirmed by 
individual genotyping. Several studies have shown the feasibility, reliability and 
accuracy of a pooling experiment on high-density genotyping arrays to estimate allele 
frequencies, as compared to individual genotyping [Anantharaman and Chew 2009; 
Bossé et al. 2009; Docherty et al. 2007; Meaburn et al. 2006], and DNA pooling has 
successfully been used to identify genes associated with several traits [Brown et al. 
2008; Butcher et al. 2008; Diergaarde et al. 2010; Meaburn et al. 2008; Shifman et al. 
2008a; Shifman et al. 2008b]. For instance, Shifman et al [2008b] identified an intronic 
SNP in the reelin gene (RELN) that confers a sex-specific risk of schizophrenia and this 
association was replicated in four additional independent population samples. Brown 
and colleagues [2008] identified a new melanoma risk locus on chromosome 20 that 
was replicated in two other samples. The gama-glutamyltransferase 1 (GGT1) gene was 
also identified as a risk locus for pancreatic cancer using a pooled sample strategy 
[Diergaarde et al. 2010]. Results from these and other studies show that it is possible to 
perform a GWAS in a cost-effective way by combining the advantages of microarrays 
to genotype thousands of SNPs and DNA pooling.  
In this study, we present a pilot GWAS with stroke outcome in pooled samples. 
This work was conducted in three stages: 1) pooling-based association analysis of two 
pools of patients classified in the extremes of a clinical outcome assessment instrument, 
the modified Rankin Scale (mRS); 2) validation of the pooling strategy by individual 
genotyping of the 100 most interesting SNPs; 3) association analysis with stroke 
outcome of validated SNPs in a larger sample of stroke patients using a more clinically 
sensible mRS cut-off for good and poor recovery. 
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Materials and Methods 
 
Participants and outcome classification 
 
414 first-ever stroke patients below 65 years of age were recruited through 
Neurology and Internal Medicine Departments of several hospitals in Portugal. Stroke 
was defined as a focal neurological deficit of sudden or rapid onset lasting more than 24 
hours, and classified as ischemic based on brain imaging (computed tomography and/or 
magnetic resonance imaging). Stroke diagnosis was confirmed by a neurologist. Age, 
gender, information on previous stroke risk factors and detailed clinical data during 
hospitalization were collected for the majority of patients. Occurrence of aphasia, 
neglect, paresis, gaze paresis, dysphagia, permanent altered consciousness, urinary 
incontinence and medical and neurological complications during hospitalization were 
clinical parameters indicative of stroke severity. The demographic and clinical 
characteristics of this sample set are shown in Table 1.  
Stroke outcome was assessed, by direct interview, using the mRS at three 
months after the stroke event. The mRS measures the global disability of a patient and 
is employed in clinical practice to evaluate the effect of stroke on the patient’s daily 
activities and life style. Patients are classified in seven grades, with mRS=0 indicating 
no disability and mRS=6 indicating death. In the first step of the present study, to 
increase the distinction between outcomes and the homogeneity within the pooled 
samples and thus improve our chances for gene discovery, we constructed two pools of 
patients with more extreme mRS scores, mRS=0 (no disability symptoms) (N=87) and 
mRS≥3 (moderate to severe disability and death) (N=100). For the final joint 
association analysis, in a larger population set individually genotyped, we used a more 
clinically sensible cut-off set at mRS≤1 (no symptoms or some symptoms but able to 
perform all usual activities) for good recovery and mRS>1 (unable to perform all usual 
activities to bedridden and death) for poor recovery. With this classification, a total of 
230 individuals were included in the good recovery group (64.3% males and 35.7% 
females), and 184 in the poor recovery group (63.0% males and 37.0% females). 
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Study design 
 
The study design is delineated in Figure 1 and was carried out as follows:  
 
a) DNA pool construction 
 
All DNA samples had been previously genotyped with excellent results (>90% 
call rates) and were thus known to be of adequate quality for the present study. A DNA 
sample from each individual was quantified in duplicate using the NanoDrop ND-1000 
spectrophotometer (NanoDrop Technologies, Wilmington, DE) and a third DNA 
quantification was performed if the coefficient of variation (CV) (the standard deviation 
divided by the mean) of the two independent measurements was >5%.  
Each DNA sample was diluted to a concentration of 50ng/μL and equimolar 
amounts of DNA from each individual were pooled by manual pipetting. To assess 
variance in allele frequency estimates due to pipetting and technical errors, the two 
pools were created in triplicate (replicates of pool formation) and each replicate was 
assayed on three replicate chips (technical replicates), yielding a total of nine 
measurements per pool.  
 
b) Allelotyping of pooled DNA  
 
Pools were allelotyped using the 250K Affymetrix GeneChip
®
 Mapping Assay – 
Nsp I according to the standard protocol for individual DNA samples (see the 
GeneChip
®
 Mapping 500K Assay Manual for full protocol). Approximately 262,000 
SNPs can be typed using this chip, with each SNP allele interrogated by 6 or 10 probes. 
Each microarray was washed and stained using the GeneChip
® 
Fluidics Station 450, and 
was scanned using the GeneChip
® 
Scanner 3000. For quality control checks, the 
manufacturer’s individual reference DNA was also assayed on a separate microarray 
(accuracy of genotyping call = 99.7%). This sample was used as a positive control to 
test for assay performance. 
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c) Estimation of SNP-MaP allele frequency 
 
The raw probe intensities were extracted from the CEL files using the SNPMaP 
package [Davis et al. 2009] of the R software [R: A language and Environment for 
Statistical Computing  2004] and quantile-normalized across arrays. An estimate of the 
allele frequency in pooled DNA was calculated for each SNP based on the relative 
intensities of the two alleles (relative allele signal [RAS]). The allele frequency 
estimates in each pool were the average frequencies across the nine measurements (3 
replicates of pool formation x 3 technical replicates). The CV for each SNP was also 
calculated across the nine replicates. The CV is a relative measure of the variability of 
the data, with a CV<10% indicating low variability [Allaby 1999]. SNPs showing high 
variability across replicates (CV>10%), which greatly increase the likelihood of false 
positives [Macgregor 2007], were excluded.  
 
d) Selection of SNPs for individual genotyping 
 
Since there is no consensus on the best strategy for SNP selection, we chose the 
100 most interesting markers based on four plausible strategies, and assessed the 
performance of each upon validation by individual genotyping. We initially selected the 
SNPs that had the largest allele frequency differences between the two pools of 
extremely good and poor outcome [Abraham et al. 2008] and the lowest Student’s t-test 
p-values for the differences between allele frequency estimates [Baum et al. 2008; 
Diergaarde et al. 2010; Meaburn et al. 2008]. For these two approaches, we established 
somewhat arbitrary cut-offs by visually inspecting the slopes of the curves of allele 
frequency differences and Student’s t-test p-values, and defining a point where this 
slope tended to stabilize. Additionally, we selected the SNPs that were clustered in 3 or 
more consecutive markers within 100kb from each other, or clustered in 3 or more 
consecutive markers within the same gene (according to RefSeq database), amongst the 
top 1,000 SNPs with larger allele frequency differences between pools and the top 1,000 
SNPs with lower t-test p-values. If two or more SNPs were in linkage disequilibrium 
(LD) (r
2
>0.5) with each other, only one of them was selected. A script was written in R 
to perform this analysis using some functions from the matrixStats and 
ClassComparison (OOMPA project) packages.  
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e) Individual genotyping and statistical analyses 
 
Genotyping of 96 SNPs was performed using the Sequenom iPLEX assays with 
allele detection by mass spectroscopy, using Sequenom MassARRAY technology 
(Sequenom, San Diego, California) and following the manufacturer’s protocol. Primer 
sequences were designed using Sequenom’s MassARRAY Assay Design 3.0 software. 
The remaining 4 SNPs were genotyped using TaqMan® Pre-Designed or Custom SNP 
Genotyping Assays, in an ABI PRISM 7900HT Sequence Detector System (Applied 
Biosystems, Foster City, USA). Genotyping was performed blinded to patient’s 
functional outcome at three months. Extensive quality control (QC) was carried out, 
using no-template controls, 8 HapMap individuals, duplicated samples within and 
across genotyping plates, and one large pedigree to check for Mendelian 
inconsistencies. SNPs showing genotypic inconsistencies in the HapMap and/or 
duplicated samples (n=3), with a genotyping call rate below 90% (n=8) and/or showing 
deviation from Hardy-Weinberg equilibrium (P<0.01) (n=1) were excluded. In total, 88 
SNPs met QC criteria and were further analyzed.  
Association analysis using logistic regression was performed for each SNP to 
validate the pooling results, in the initial sample set. Validated SNPs (P<0.05) were 
further genotyped in an additional sample (patients with mRS=1 or 2) and association 
analyses were carried out in the combined sample, comparing the good recovery patient 
group (mRS≤1) with the poor recovery patient group (mRS>1). The effect of each 
genetic variable on patient’s outcome was determined by logistic regression, before and 
after adjustment for the significant covariates (history of hypertension, occurrence of 
aphasia, paresis, altered consciousness and medical complications during 
hospitalization). SNP-based association analyses were performed using the SNPassoc 
package of the R software [R: A language and Environment for Statistical Computing  
2004]. Haplotype blocks in the GLIS family zinc finger 3 (GLIS3) gene were 
determined using the default method [Gabriel et al. 2002] of the Haploview software 
(v4.2) [Barrett et al. 2005] and haplotype-based association analyses were performed 
using the same software. To reduce the type I error, we applied the false discovery rate 
(FDR) multiple testing correction in individual SNP and haplotype-based association 
analyses. SNPs (or haplotypes) with q values≤5% were considered significant, which 
resulted in a FDR≤5% among the significant SNPs (or haplotypes). q values were 
Chapter 6. Genome-wide association study in stroke outcome  
 152 
calculated using the qvalue package of the R software [R: A language and Environment 
for Statistical Computing  2004]. 
 
 
Results 
 
Allelotyping and pooling validation by individual genotyping  
 
After allelotyping on genotyping arrays, the average allele frequency estimates 
were calculated for each SNP and compared between the two pools of patients with very 
good (mRS=0) and very poor (mRS≥3) outcome at three months. Since DNA pooling 
introduces experimental errors in allele frequency estimations that are related to pool 
construction and array variation, affecting the efficiency of pooling, only SNPs with 
low variability (CV<10%) among replicates were included in this exploratory analysis. 
46 SNPs with the largest allele frequency differences between the two pools of good 
and poor outcome, 34 SNPs with the lowest Student’s t-test p-values, as well as 14 
SNPs clustering within 100kb and 15 SNPs clustering within the same gene, were 
selected for validation. Of these, nine markers were selected by more than one strategy, 
and a total of 100 were individually genotyped.  
The efficiency of the pooling-based association analysis was determined by the 
number of SNPs, among these selected 100, that were associated with stroke outcome 
after individual genotyping. Individual genotyping was carried out in the same subset of 
187 stroke patients with extremely good or extremely poor outcome at three months 
(mRS=0 and mRS≥3, respectively) to validate the pooling results. 12 SNPs were 
excluded due to failure of quality control measures and 88 SNPs were further analyzed. 
Table 2 shows the association analysis results after individual genotyping of these 
markers. 36 SNPs (approximately 41%) showed significant differences between patients 
with extremely good and extremely poor outcome at three months, at a significance 
level of 5% (1.7x10
-4
<P<0.049) (Table 2). Of these, 13 SNPs had p-values below 0.005.  
We investigated whether allelotyping provides a reliable estimate of the absolute 
allele frequency differences between the two groups of patients with extremely good 
and extremely poor outcome. After comparing the allele frequency differences 
estimated by allelotyping and genotyping for the 36 validated SNPs, we found that the 
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effect size determined by allelotyping was underestimated when compared with the 
individual genotyping results (Wilcoxon rank sum test, W=100, P=6.9x10
-10
) (Figure 
2). This means that the observed allele frequency differences between groups are 
significantly larger than those estimated by allelotyping, and individual genotyping is 
therefore needed to obtain a reliable estimate of those differences.  
We next evaluated the SNP selection strategies by comparing the percentage of 
true-positive markers obtained for each. SNPs were considered as true-positive or 
validated if there was a significant difference between the two groups of patients at a 
significance level of 5%. Selecting SNPs according to allele frequency difference 
between groups and selecting consecutive SNPs showed better performances, as 56.8% 
and 57.1%, respectively, of the SNPs selected in this way were validated by individual 
genotyping. Choosing SNPs according to the t-test p-values showed a poor 
performance, with a SNP validation of 20.7%. Selecting SNPs within the same gene 
showed an intermediate performance, as 28.6% of SNPs were validated. 
 
Association analysis in the combined sample 
 
The 36 SNPs with association p-values below 0.05 were genotyped in an 
additional sample of 227 patients with mRS=1 or 2, and a joint association analysis was 
carried out in the combined sample. This test was performed to verify if the association 
with stroke outcome of the 36 validated SNPs still held when the cut-off for good/poor 
outcome was set between 1 and 2 (mRS≤1 vs. mRS>1), which is more clinically 
sensible. 15 out of 36 SNPs were associated with stroke outcome at three months in the 
combined sample (4.3x10
-4
<P<0.047) and three other markers showed a trend towards 
association (Table 3). Six SNPs remained associated after adjusting for significant 
covariates (history of hypertension, and occurrence of aphasia, paresis, altered 
consciousness and medical complications during hospitalization) (0.002<P<0.039). 
Two of these SNPs, rs10273634 and rs10974334, were intragenic and located in the 
Bardet-Biedl syndrome 9 (BBS9 on 7p14) and GLIS family zinc finger 3 (GLIS3 on 
9p24.2) genes, respectively. Another associated SNP, rs290916, was located 
downstream from a novel processed transcript (RP11-428L9.1-001), for which there is 
little information. The other three SNPs were located in intergenic regions and far from 
other known loci: rs1243659 is 27kb from the olfactory receptor 6S1 (OR6S1) gene;  
rs7664979 is 61kb and 48kb from the hematopoietic prostaglandin D synthase 
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(HPGDS) and PDZ and LIM domain 5 (PDLIM5) genes, respectively; and rs9293983 is 
232kb from the collagen type XII alpha 1 (COL12A1) gene. While the functional 
consequences of these intergenic polymorphisms are currently unknown, we can 
hypothesize that they (or other variants in LD with these markers) are located in 
regulatory regions (e.g. enhancers) and may influence the expression levels of distantly 
transcribed genes. None of these 6 associations withstood correction for multiple 
testing, although rs10273634 on BBS9 had a nominal FDR q value (q=0.057).  
Since rs10974334 and two other genotyped SNPs, rs7024250 and rs1000128, 
were located within the same gene (GLIS3), we performed a haplotype-based 
association analysis in the combined sample. One haplotype in this gene (T[rs7024250]-
A[rs1000128]-G[rs10974334]) was significantly associated with stroke outcome after 
correcting for multiple testing (P=0.004, FDR q=0.024). 
 
 
Discussion 
  
In contrast with stroke susceptibility, few studies have assessed the role of 
candidate genes in stroke outcome and no GWAS has previously been reported. We 
carried out an association study of 262,264 SNPs with stroke outcome using, in the first 
stage, a DNA pooling strategy, as a cost effective way of conducting a GWAS. The 
efficiency of the DNA pooling strategy was determined by the number of SNPs 
validated by individual genotyping. In this case, the percentage of SNP validation was 
approximately 41%, which is considerably higher than the percentage obtained in some 
previous pooling studies:  16% [Butcher et al. 2008], 12% [Meaburn et al. 2008], 17% 
[Shifman et al. 2008a] and 31% [Shifman et al. 2008b], studies that, however, identified 
relevant genes subsequently replicated in independent samples. Such variation may be 
explained by different study designs. In this study we improved our methods to obtain a 
better performance. Our pools were created in triplicate and were assayed on replicate 
arrays, for a better control of variability in pooling construction and array technique, 
which strongly influence the efficiency of pooling [Macgregor 2007]. Two studies with 
lower percentages of SNP validation did not perform any of these replicates [Butcher et 
al. 2008; Meaburn et al. 2008] and the two other did not have replicates of pool 
construction [Shifman et al. 2008a; Shifman et al. 2008b], possibly explaining their 
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lower efficiency. Interestingly, Meaburn et al [2008] selected SNPs based on t-test p-
values, which also had a poor performance in our study (12% vs. 20.7%, respectively). 
For this pilot study, SNP exclusion was based on a CV>10% among replicates to 
reduce the chance of pursuing false positives in the following stage. This proved to be a 
very stringent criterion, excluding a large number of markers from further analysis. For 
instance, two excluded SNPs, rs10486524 and rs7857436, were located within the BBS9 
and GLIS3 genes, respectively. Although they had a slightly higher CV (11% and 12%, 
respectively) than the two SNPs associated with stroke outcome, their predicted allele 
frequency differences between groups were similar, and should thus be individually 
genotyped for validation. A less stringent cut-off (e.g. CV>15%) for SNP exclusion 
may be advantageous, as any false positive result will be identified in the stage of 
individual genotyping, and the risk of missing associated markers will be decreased.  
We also found that two SNP selection strategies were clearly better performers: 
selecting SNPs based on the allele frequency differences between groups and the 
clustering strategies improved the number of validated markers. The other two 
approaches, however, were still valuable and can complement the allele frequency 
differences and clustering strategies. For instance, the GLIS3 SNP that showed the 
second highest evidence for association with stroke outcome in the combined sample 
belonged to a cluster of three consecutive markers within the same gene, but because 
they are far apart from each other (>100kb), they would have been missed if we did not 
inspect clusters within the same gene.  
Six polymorphisms were associated with patient’s outcome independently of 
stroke severity parameters. These associations did not withstand multiple testing 
correction, and replication of positive findings in independent datasets is required. The 
putative functions of the three intergenic SNPs should be investigated, as these markers 
may be influencing the expression levels of distantly located genes and consequently of 
patient’s outcome after stroke. Further studies are also needed to investigate the role of 
the new processed transcript RP11-428L9.1-001 and its potential relation to stroke 
outcome.  
The BBS9 gene encodes different isoforms of the PTHB1 protein, which are 
expressed in a variety of tissues, including the brain [Adams et al. 1999]. Mutations in 
this gene were identified in patients with Bardet-Biedl syndrome (BBS) (MIM ID: 
209900) [Nishimura et al. 2005], a pleiotropic genetic disease that is associated with 
increased susceptibility to hypertension, diabetes and congenital heart disease [Elbedour 
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et al. 1994; Green et al. 1989; Harnett et al. 1988]. Obesity is one of the major clinical 
manifestations of BBS. Interestingly, it was observed that mice maintained in dietary 
energy restriction had smaller infarct volumes and less neurological impairment after 
stroke, which suggests that excessive energy intake or obesity can negatively influence 
stroke outcome [Arumugam et al. 2010].  
 Different isoforms of the zinc finger protein GLIS3 are encoded by alternative 
splicing of the GLIS3 gene. GLIS3 is a transcription factor that contains five C2H2-type 
Krüppel like zinc finger motifs, and can act as a transcriptional activator and repressor 
[Kim et al. 2003]. This protein is expressed in a variety of tissues, including the brain 
[Kim et al. 2003]. Mutations within GLIS3 cause a neonatal diabetes syndrome 
associated with several other conditions, like congenital hypothyroidism and hepatic 
fibrosis [Senée et al. 2006]. In addition, polymorphisms within GLIS3 have been 
associated with type 1 diabetes [Barrett et al. 2009], and with glycemic traits and type 2 
diabetes [Dupuis et al. 2010]; and it was observed that diabetes is associated with severe 
disability after stroke [Kaarisalo et al. 2005].  
This work was an initial effort towards the elucidation of the biochemical 
pathways involved in stroke outcome and recovery, with the advantage of a genome-
wide approach without setting an a priori hypothesis. Our results highlight two 
unexpected genes, as frequently happens in GWAS, and further studies are required to 
validate this hypothesis and to understand their connection to stroke-induced disability 
and/or stroke recovery processes. Namely, an association analysis needs to be 
conducted with haplotype tagging SNPs fully covering the genetic variability within 
these genes, and the results need to be replicated in independent population samples, 
which are currently being recruited by several research groups. As with most complex 
diseases and traits, large samples will be required for adequate power to detect low to 
moderate size effects or rare variants and, as such, pooling of resources and population 
samples is advised. The study results also further supported the feasibility of DNA 
pooling as a cost-effective strategy for GWAS, as previously shown by other studies of 
complex traits and, as a pilot study, it highlighted potential design improvements, which 
will be pursued in the future. 
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Figure 1 – Study design of the present study. The mRS at three months was used to create a “very good 
recovery” and “very poor recovery” group of patients. Specifically, the “very good” and “very poor 
recovery” groups included patients with no symptoms (mRS=0) (N=87) and patients with moderate to 
severe disability or deceased (mRS≥3) (N=100), respectively. DNA samples from these individuals were 
pooled together in the corresponding groups followed by allelotyping on genotyping arrays. SNPs were 
prioritized for individual genotyping to validate our pooling results. Validated SNPs, i.e. showing 
differences between the two groups (P<0.05), were genotyped in an additional sample of patients with 
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mRS=1 and 2 (N=227), followed by joint association analysis with stroke outcome in the combined 
sample. For the joint association analysis, the cut-off for good/poor recovery was set between 1 and 2, 
because it is more clinically sensible: patients with mRS≤1 were assigned to the “good recovery” group 
and patients with mRS>1 were assigned to the “poor recovery” group. 
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Figure 2 – Boxplots showing the distribution of the allele frequency 
differences between patients with very good (mRS=0) and very poor 
(mRS≥3) outcome at three months that were estimated by allelotyping and 
by individual genotyping. This figure is derived from the results of the 36 
validated SNPs. 
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Tables 
 
Table 1 – Demographic and clinical characteristics of ischemic stroke patients analyzed 
for outcome at three months 
 
Age, mean±SD (yrs) 50.7±9.0 52.1±8.9 0.125
Gender (male), n/N (%) 148/230 (64.3) 116/184 (63.0) 0.784
Hypertension 127/198 (64.1) 77/163 (47.2) 0.001
Diabetes 34/217 (15.7) 35/173 (20.2) 0.241
Cardiac Disease 33/218 (15.1) 33/175 (18.9) 0.327
Aphasia 43/217 (19.8) 56/173 (32.4) 0.005
Neglect 9/223 (4.0) 14/165 (8.5) 0.067
Dysphagia 13/227 (5.7) 19/175 (10.9) 0.060
Urinary Incontinence 2/227 (0.9) 12/175 (6.9) 0.001
Paresis 168/227 (74.0) 165/184 (89.7) <10
-4
Altered consciousness 8/230 (3.5) 31/181 (17.1) <10
-4
Medical complications 10/223 (4.5) 43/171 (25.1) <10
-4
Neurologic complications 12/228 (5.3) 19/183 (10.4) 0.051
Past History, n/N (%)
Stroke Features, n/N (%)
Age and Gender
P
*Poor Recovery 
(mRS>1)
Good Recovery 
(mRS≤1)
Characteristic
 
SD – standard deviation, yrs – years. 
*Mann-Whitney test or Pearson's χ2 test.  
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Table 2 – Results of individual genotyping for the SNPs selected in the pooling stage.  
 
SNP ID Chr position gene 
Rank based on allelotyping  
selection 
strategies
*
 
SNP type allele 
 
validation sample 
 
difference t-test 
 freq Good Recov 
(mRS=0) 
freq Poor Recov 
(mRS≥3) 
P
†
 
  
rs12751992 1 63246918 LOC199897 12 36 1 A/G G  41.3 54.7 0.011 
rs705547 1 64503365  22 624 1 A/G G  45.9 62.8 0.002 
rs17300340 1 178588341 ACBD6 21 78 1 C/T C  80.2 89.4 0.026 
rs1453766 2 5309265  >1000 35 2 G/T G  56.4 65.8 0.069 
rs6761743 2 84331467  >1000 18 2 C/T C  72.4 75.5 0.493 
rs4673324 2 205926709 PARD3B  27 148 1 A/G A  75.3 68.1 0.148 
rs2600753 2 237214589  >1000 30 2 C/T C  69.2 74.5 0.270 
rs7425755 2 240352740 LOC150935 >1000 4 2 C/T C  66.9 71.1 0.399 
rs6793158 3 55210273  >1000 25 2 A/G G  56.4 59.0 0.626 
rs811322 3 139812552 FAIM  13 99 1 A/G A  63.1 46.8 0.003 
rs7639507 3 156171973  >1000 10 2 A/G G  69.2 75.8 0.156 
rs4469109 4 61049121  >1000 9 2 A/G G  92.4 89.4 0.284
‡
 
rs7664979 4 95544420  >1000 22 2 C/T C  58.4 71.3 0.012 
rs12508742 4 134733668  124 >1000 3 G/T T  66.9 55.9 0.041 
rs2587163 4 186457029 SNX25 23 327 1 C/G G  65.1 48.9 0.001 
rs10060876 5 2611690  34 >1000 1 A/G A  91.9 85.3 0.051 
rs1150462 5 5964422  9 >1000 1 C/T T  68.8 61.2 0.137 
rs1328254 5 49596616  >1000 31 2 C/T T  59.3 57.4 0.694 
rs17627020 5 54203597  42 >1000 1 C/G G  99.4 93.7 0.010 
rs4958803 5 154774673  >1000 19 2 C/G G  51.7 54.8 0.558 
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rs10050717 5 164099184  32 371 1 A/T A  62.9 51.1 0.035 
rs10071045 5 164779960  4 183 1 A/T T  45.9 55.9 0.074 
rs415223 6 4513282  >1000 26 2 C/T T  79.1 73.7 0.240 
rs423137 6 42768633  >1000 11 2 C/T C  76.7 72.1 0.351 
rs10484654 6 53990696 C6orf142 >1000 13 2 A/C C  64.0 57.6 0.238 
rs9293983 6 75618311  8 736 1 A/G G  54.1 68.6 0.004 
rs7769736 6 143879125  >1000 1 2 C/G C  57.5 56.8 0.892 
rs7811384 7 3568874 SDK1 26 937 1 A/G A  66.3 53.7 0.014 
rs17792244 7 9200867  16 >1000 1 A/G G  45.3 54.3 0.108 
rs10273634 7 33318154 BBS9 46 947 1 C/T C  85.5 76.8 0.027 
rs2598044 7 37856841 TXNDC3 5 >1000 1 A/G G  59.9 77.7 3.7x10
-4
 
rs4588727 7 63859252  >1000 6 2 G/T T  80.8 69.5 0.013 
rs2928672 8 23466270 SLC25A37 >1000 14 2 A/G G  66.3 58.4 0.100 
rs7831651 8 51859645 SNTG1 >1000 27 2 G/T G  67.4 70.2 0.563 
rs11786647 8 57927246  >1000 28 2 C/G G  73.6 67.4 0.201 
rs2941422 8 76682389  31 227 1 C/T T  66.5 53.7 0.015 
rs1463186 8 93669646  152 949 3 C/T C  50.0 57.4 0.123 
rs1449243 8 93676222  448 >1000 3 G/T T  72.7 69.5 0.462 
rs11562770 8 119086110 EXT1 40 >1000 1 A/G A  70.9 51.6 1.7x10
-4
 
rs17646599 8 137757137  37 >1000 1 A/G A  86.6 80.5 0.131 
rs7024250 9 3823480 GLIS3 29 >1000 1,4 G/T T  95.3 89.5 0.026
‡
 
rs1000128 9 4017185 GLIS3 141 >1000 4 A/G A  73.8 64.7 0.049 
rs10974334 9 4092339 GLIS3 288 276 4 G/T T  65.7 81.1 5.1x10
-4
 
rs1576657 9 12429164  479 33 2 C/G C  57.7 51.6 0.208 
rs947403 10 1006601  39 580 1 C/T T  52.4 41.5 0.037 
rs7476580 10 1366089 ADARB2 30 >1000 1 C/T C  61.2 70.0 0.088 
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rs290916 10 9000349  19 >1000 1 C/T C  65.9 81.6 4.0x10
-4
 
rs1904006 10 53479033 PRKG1 18 453 1 C/T T  83.1 74.2 0.039 
rs7097525 10 123052530  253 16 2 C/T C  55.8 60.6 0.358 
rs12364058 11 18191988  >1000 24 2 C/T T  56.5 50.5 0.266 
rs17824184 11 76617563 GDPD4 6 603 1 A/G A  80.2 68.4 0.013 
rs10895266 11 101533105 YAP1 20 761 1 A/G A  62.9 54.2 0.114 
rs2513605 11 105823864  >1000 5 2 C/T C  46.5 53.2 0.194 
rs10502193 11 114169861  14 >1000 1 A/G A  90.7 83.7 0.099 
rs6590261 11 126806806  292 >1000 3 A/G G  43.0 58.4 0.003 
rs7947171 11 126838598  563 7 2,3 A/T T  57.0 70.7 0.003 
rs17187 11 126897371  474 >1000 3 C/G G  88.4 75.8 0.001 
rs11223888 11 133908599  35 >1000 1 C/T C  44.2 51.6 0.156 
rs12830815 12 52483533  1 885 1 A/G G  52.9 68.1 0.005 
rs10506321 12 52510591  171 >1000 3 A/G G  52.3 66.3 0.009 
rs12822967 12 64948897  11 232 1 A/G A  63.4 55.3 0.115 
rs10506806 12 77979113  25 >1000 1 C/T C  75.6 68.0 0.109 
rs7131780 12 101722143  7 83 1 C/G G  79.1 65.4 0.004 
rs10778623 12 107244706 CMKLR1 301 >1000 3 C/T C  57.0 63.7 0.180 
rs9532718 13 40542722 WBP4 >1000 2 2 A/C A  57.6 47.3 0.044 
rs7985623 13 59220111 DIAPH3 44 549 1 C/G G  66.9 54.2 0.019 
rs1243659 14 20151347  >1000 34 2 C/T T  77.9 86.7 0.026 
rs1295826 14 69186662 KIAA0247 >1000 8 2 G/T G  83.1 92.0 0.012 
rs7145567 14 77428041 ADCK1 38 240 1 A/G A  65.7 53.8 0.031 
rs2035801 15 96162993  >1000 23 2 A/G A  62.9 61.1 0.719 
rs1470984 15 99515982  >1000 20 2 C/T C  57.6 50.5 0.154 
rs4619425 16 7091509 A2BP1 99 >1000 4 C/G G  82.6 75.8 0.112 
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rs11077149 16 7204783 A2BP1 241 >1000 4 C/T C  52.9 56.5 0.535 
rs8050137 16 7391457 A2BP1 387 >1000 4 C/T T  85.5 81.6 0.329 
rs3027232 17 7962790 ALOXE3 >1000 32 2 A/G G  71.5 81.1 0.037 
rs2970016 17 47531938 CA10 CA10 3 29 1,2 C/G G  45.3 53.7 0.101 
rs12962942 18 10275603  28 59 1 C/T C  59.8 67.4 0.158 
rs16942806 18 22667875  2 >1000 1 A/G A  89.0 84.2 0.182 
rs7258452 19 62139806  45 >1000 1 C/T T  73.3 65.3 0.115 
rs6108882 20 11187261  >1000 3 2 A/G G  52.3 60.5 0.135 
rs3761896 20 12937901 SPTLC3 >1000 217 3, 4 A/G A  86.0 80.0 0.108 
rs2073302 20 13000671 SPTLC3 416 665 3,4 C/T C  56.4 69.5 0.009 
rs1041327 20 14798101 MACROD2 223 397 4 A/G G  84.3 86.8 0.512 
rs6131684 20 15572156 MACROD2 43 177 1, 4 A/G G  44.8 53.2 0.095 
rs175793 20 15808386 MACROD2 695 >1000 4 C/T C  87.2 84.2 0.418 
rs467155 21 30227845 GRIK1 17 >1000 1 C/T T  91.4 86.8 0.069 
rs220161 21 42422362 UMODL1 725 >1000 3, 4 C/G C  87.8 80.5 0.064 
rs220162 21 42422585 UMODL1 144 740 3, 4 G/T G  62.8 70.7 0.119 
                          
Chr – Chromosome, freq Good Recov – allele frequency (%) in patients with good outcome, freq Poor Recov – allele frequency (%) in patients with poor outcome 
*Selection strategies: 1 – allele frequency difference, 2 – Student’s t-test p-values, 3 – clustering within 100kb, 4 – clustering within a gene. 
†P for the log-additive model. 
‡P for the codominant model. 
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Table 3 – Association results in the combined sample for the 36 validated SNPs.  
 
SNP ID Chr position gene 
 
freq Good 
Recov 
(mRS≤1) 
freq Poor 
Recov 
(mRS>1) 
unadjustedP
*
 adjustedP
†
 OR [95% CI]
†
 FDR q
‡
 
 
 
  
           
rs11562770 8 119086110 EXT1  60.0 54.6 0.112    
rs2598044 7 37856841 TXNDC3  69.1 74.9 0.077    
rs290916 10 9000349   68.5 79.2 4.3x10
-4
 0.016 0.59 [0.39-0.92] 0.150 
rs10974334 9 4092339 GLIS3  69.6 79.7 7.4x10
-4
 0.038 0.64 [0.42-0.98] 0.155 
rs2587163 4 186457029 SNX25  58.1 48.9 0.008 0.337   
rs17187 11 126897371   81.2 76.0 0.066    
rs705547 1 64503365   51.3 55.5 0.241    
rs7947171 11 126838598   65.1 68.2 0.349    
rs811322 3 139812552 FAIM   56.9 49.7 0.047 0.545   
rs6590261 11 126806806   51.1 58.2 0.040 0.703   
rs9293983 6 75618311   58.4 65.2 0.047 0.039 0.68 [0.46-0.98] 0.155 
rs7131780 12 101722143   76.1 69.1 0.028 0.070   
rs12830815 12 52483533   57.9 63.0 0.149    
rs10506321 12 52510591   56.8 61.0 0.232    
rs2073302 20 13000671 SPTLC3  58.3 62.8 0.193    
rs17627020 5 54203597   98.7 95.1 0.005 0.090   
rs12751992 1 63246918 LOC199897  50.7 52.2 0.661    
rs7664979 4 95544420   59.8 67.4 0.027 0.025 0.65 [0.45-0.95] 0.155 
rs1295826 14 69186662 KIAA0247  86.2 91.3 0.026 0.078   
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SNP ID Chr position gene 
 
freq Good 
Recov 
(mRS≤1) 
freq Poor 
Recov 
(mRS>1) 
unadjustedP
*
 adjustedP
†
 OR [95% CI]
†
 FDR q
‡
 
 
 
  
           
rs4588727 7 63859252   74.7 70.9 0.235    
rs17824184 11 76617563 GDPD4  78.3 72.1 0.050    
rs7811384 7 3568874 SDK1  58.3 56.3 0.558    
rs2941422 8 76682389   60.7 57.1 0.292    
rs7985623 13 59220111 DIAPH3  64.3 59.8 0.197    
rs1243659 14 20151347   80.0 87.1 0.005 0.008 0.50 [0.29-0.84] 0.109 
rs17300340 1 178588341 ACBD6  81.3 86.7 0.037 0.169   
rs7024250 9 3823480 GLIS3  91.0 89.6 0.020 0.485   
rs10273634 7 33318154 BBS9  86.5 78.0 7.7x10
-4
 0.002 2.21 [1.32-3.7] 0.057 
rs7145567 14 77428041 ADCK1  58.0 55.9 0.563    
rs10050717 5 164099184   58.9 54.1 0.180    
rs947403 10 1006601   51.3 46.7 0.177    
rs3027232 17 7962790 ALOXE3  73.1 80.9 0.009 0.095   
rs1904006 10 53479033 PRKG1  78.6 76.9 0.555    
rs12508742 4 134733668   59.4 59.7 0.952    
rs9532718 13 40542722 WBP4  52.0 50.0 0.575    
rs1000128 9 4017185 GLIS3  67.3 63.3 0.221    
                      
Odds Ratio (OR) >1 indicates increased probability of poor outcome at three months for the carriers of the minor allele.  
Chr – Chromosome, CI – confidence interval, FDR – false discovery rate, freq Good Recov – allele frequency (%) in patients with good outcome, freq Poor Recov – allele frequency (%) in 
patients with poor outcome 
*P for the log-additive model 
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†OR [95% CI] and P for the log-additive genetic model after adjustment for significant covariates (history of hypertension, and occurrence of aphasia, paresis, altered consciousness and medical 
complications during hospitalization) 
‡FDR q values 
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Table 4 – Association analysis results for the GLIS3 haplotypes and stroke outcome.  
 
 
TAT 0.434 0.418 0.455 1.187 0.276
TGT 0.221 0.199 0.248 2.775 0.096
TAG 0.168 0.201 0.126 8.430 0.004 0.024
TGG 0.081 0.092 0.068 1.578 0.209
GAT 0.053 0.054 0.052 0.013 0.908
GGT 0.033 0.027 0.040 1.188 0.276
freq Good Recov 
(mRS≤1)
FDR q
*
rs7024250-rs1000128-
rs10974334
χ
2 P
freq Poor Recov 
(mRS>1)
GLIS3
Gene Haplotypes
Haplotype 
frequency
 
FDR – false discovery rate, freq Good Recov – allele frequency (%) in patients with good outcome, freq Poor Recov – allele frequency (%) in patients with poor outcome 
*FDR q values 
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7.1 General discussion 
 
 
Unraveling the genetic basis of stroke is a challenging task for several reasons. 
In most cases, stroke is a complex trait with polygenic etiology, i.e. reflecting the 
influence of many loci that modulate different pathophysiological processes. 
Furthermore, stroke is characterized by i) phenotypic heterogeneity – with different 
subtypes possibly reflecting different etiologies, ii) allelic or genetic heterogeneity – in 
which an identical phenotype might be caused by distinct mutations in the same or 
different genes, respectively, iii) phenocopy – some individuals without an inherited 
risk allele will have the disease due to random or environmental causes, iv) variable 
penetrance – some individuals carrying an inherited risk allele may not have a stroke 
(owing to epistatic interactions for example), and v) confounders – coexistence of other 
risk factors, like hypertension, in affected individuals can make it harder to assess the 
effects of a gene [Hassan and Markus 2000]. These features may partially explain the 
lack of replication or contradictory results of many published linkage and association 
studies on stroke. For instance, the association with stroke may be missed due to allelic 
or linkage disequilibrium (LD) pattern heterogeneity between populations if only the 
associated markers in the original study are tested in the replication study. When two 
populations have different ethnicities, distinct causal variants may exist in the same 
gene in these populations (allelic heterogeneity), which can be in LD with different 
genetic markers. It is also possible that a specific causal variant is associated with 
different genetic markers in the two populations owing to differences in LD patterns. 
Therefore, replication studies that are carried out in populations with different 
ethnicities and genetic backgrounds should analyze the complete genetic variation in a 
region/gene to reduce the likelihood of no association due to allelic or LD pattern 
heterogeneity. Other possible explanations for replication failure include differences in 
study designs or the existence of false positive results in the original study that were 
correctly non-replicated in the following studies. 
 
To identify the genetic risk factors for stroke, a candidate gene approach was 
used in this thesis. Several studies have shown the important role of inflammation and 
oxidative stress in stroke susceptibility: known risk factors for stroke, such as 
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hypertension and atherosclerosis, are associated with an elevated systemic inflammatory 
profile, and the nitric oxide metabolism plays a role in atherosclerosis and blood 
pressure regulation [Bastard et al. 2006; Carvalho et al. 2006; Hansson and Libby 2006; 
Kuhlencordt et al. 2001; Kuhlencordt et al. 2006; Moutsopoulos and Madianos 2006; 
Shesely et al. 1996]. Four inflammatory genes (IL1B, IL6, MPO and TNF) and two 
genes involved in the oxidative stress processes (NOS1 and NOS3) were thus selected 
and tested for association with stroke. These analyses were carried out in a sample of 
672 stroke patients and 530 healthy controls for whom detailed clinical and life-style 
information on stroke risk factors were available. This made possible to identify and 
adjust our results for potential confounders, and to detect associations that are 
independent of these non-genetic risk factors. 
 NOS3 is a widely tested candidate gene, as Nos3 knockout (KO) animals are 
hypertensive and develop greater atherosclerotic lesions. Earlier studies with Nos1 KO 
animals, on the other hand, did not anticipate a role of the nNOS protein in stroke, 
possibly explaining the lack of interest on the NOS1 gene. Further studies with nNOS 
inhibitors and Apoe/Nos1 double knockout (KO) mice, however, have suggested that 
NOS1 is also a strong candidate for a role in stroke risk [Kuhlencordt et al. 2006; 
reviewed in Toda et al. 2009a; reviewed in Toda et al. 2009b]. The work described 
herein support this latter hypothesis, while not confirming the effect of NOS3 variants in 
this phenotype. We also showed that variants in the inflammatory genes IL6 and MPO 
are positively associated with stroke and identified an epistatic interaction effect 
between them. The IL6 findings support previous association results that have been 
obtained in different population samples, reinforcing IL6 as a susceptibility gene for 
stroke. A methodological improvement in comparison to earlier studies is that, instead 
of analyzing a single SNP, we analyzed haplotype tagging SNPs covering the full 
genetic variation in that genomic region. This was done to increase the probability of 
replication of the IL6 association, preventing potential negative results due to allelic or 
LD pattern heterogeneity between populations, and to clarify the association of this 
gene with stroke. Indeed, different IL6 markers were associated with stroke in our 
sample when compared with previous studies, proving the effectiveness of our strategy. 
Overall, these results indicate that susceptibility to stroke may be modulated by main 
gene and gene-gene interaction effects, in addition to the well-known contribution of 
clinical and life-style risk factors. Furthermore, they are compatible and strengthen 
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previous evidence from other research areas for a role of inflammation and oxidative 
stress in stroke susceptibility.  
Genome-wide association studies (GWAS) use high-throughput genotyping 
technologies to perform an unbiased search for genetic variants that underlie complex 
traits. In GWAS for stroke, several new candidate loci have been identified 
(http://genome.gov/gwastudies), but none was observed in two independent studies at a 
genome-wide significance level [Lanktree et al. 2010]. Although GWAS have identified 
previously unsuspected loci in stroke and other diseases, they also have limitations. 
Large sample sizes are required to detect variants that have small overall effects and 
testing for gene-gene interactions is computationally difficult due to the large dimension 
of the data. Furthermore, it is possible that the effect size of any given SNP is not large 
enough to reach the required stringent significance level of these studies (typically   
<10
-7
). Finally, GWAS often involve the analysis of individuals from different 
populations, which can reduce power when genetic or allelic heterogeneity, as well as 
differences in LD patterns, occur between populations. Therefore, although the 
candidate gene approach has been gradually replaced by the genome-wide approach, it 
still remains a useful strategy to identify genetic risk factors for stroke, as was shown in 
this thesis.  
Three out of six candidate genes tested (IL6, MPO, NOS1) showed positive 
association results. It would be interesting to perform the same association analyses in 
subgroups of patients with specific subtypes of ischemic stroke to investigate if the 
evidence for association increases, but this information was not available for the 
majority of stroke patients. Very stringent significance levels were used to minimize the 
problem of false positives due to multiple comparisons and to increase confidence about 
positive association findings. However, genetic markers are often not independent, 
which is one of the assumptions underlying Bonferroni correction, but associated due to 
LD. Therefore, it is possible that some association signals not withstanding Bonferroni 
correction were also true positive findings, since this correction is overly conservative. 
An alternative is to control for the expected proportion of false positive findings using 
false discovery rate (FDR) methods [Rice et al. 2008]. These are less computationally 
intensive and less conservative than permutations and Bonferroni methods, respectively. 
In the NOS1/NOS3 study, although no association withstood Bonferroni correction, 
when the four SNPs with the smallest P-values are considered significant, less than 5% 
of these are expected to be false positives (FDR<5%) [Storey and Tibshirani 2003]. 
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Replication of positive results in independent datasets may be the most adequate 
strategy to assess true positive findings, if strict criteria for study design and population 
ethnicity can be met, which is often not possible. As already mentioned, replication 
studies frequently show contradictory results or a lack of replication due to population 
differences or heterogeneity in study designs [Colhoun et al. 2003; Liu et al. 2008; 
Palmer and Cardon 2005].  
No marker within the TNF and IL1B genes was associated with stroke 
susceptibility. Assuming an additive genetic model and disease allele frequency of 10-
40%, our sample was well powered (90-99%) to detect a genotype relative risk of 1.5 
with a type I error of 5%. Since this sample had enough power to detect common 
variants of low to moderate effect sizes and the genetic variability in the TNF and IL1B 
genomic regions was covered, it is unlikely that these genes have common variants that 
influence stroke risk, at least in the Portuguese population. 
Although additive variance may account for more than 50% of total genetic 
variance [Hill et al. 2008], epistasis or non-additive interactions are documented in 
model organisms [Kroymann and Mitchell-Olds 2005; Shao et al. 2008] and several 
lines of evidence suggest that they are ubiquitous in common human diseases [Moore 
2003]. Indeed, gene-gene interactions have been identified in association studies of 
autism [Coutinho et al. 2007], type 2 diabetes [Neuman et al. 2010] and stroke [Liu et 
al. 2009; Shen et al. 2007], among many others. Epistasis is, however, not often 
investigated, which may explain why it has not been widely observed in the etiology of 
many complex human traits [Greene et al. 2009]. The investigation of gene-gene 
interactions constitutes a novelty aspect of this work, since the effects of a gene may be 
missed if it is considered in isolation while functioning through complex networks 
involving other genes [Cordell 2009]. It is expected that detecting interactions between 
loci will lead to better understanding of the biological and biochemical pathways that 
underlie a disease [Cordell 2009]. In addition, epistasis may explain the lack of 
replication or inconsistency of results (in which an initially found protective allele is 
replicated as a risk allele) of some replication studies [Greene et al. 2009; Moore 2003]. 
The MDR method was used to investigate the existence of gene-gene interactions since 
it is more powerful than traditional regression-based methods [Ritchie et al. 2001] and it 
has increased power to detect interactions even in the absence of main effects [Ritchie et 
al. 2003]. Moreover, this method addresses the problem of multiple testing through 
combination of the cross-validation strategy and permutation testing [Moore 2003; 
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Ritchie et al. 2001]. The MDR identified an IL6–MPO interaction influencing stroke 
susceptibility. Interestingly, the identified interaction is in agreement with a previous in 
vitro study, showing that enzymatically inactive MPO induced IL-6 secretion in a dose 
and time-dependent manner by endothelial cells [Lefkowitz et al. 2000]. Further studies 
are now needed to understand the contribution of this interaction specifically in stroke 
[Moore 2003]. 
The “common disease, common variant” hypothesis argues that most of the 
genetic susceptibility to common diseases is due to genetic variants that are relatively 
frequent in the general population [Schork et al. 2009]. At the beginning of this work, 
this hypothesis was largely accepted in human genetics research. Thus, haplotype 
tagging SNPs with minor allele frequency ≥0.05 in the HapMap CEU population were 
selected in each candidate gene and tested for association with stroke susceptibility. As 
observed in previous association studies of complex traits [Bodmer and Bonilla 2008], 
the effect sizes that were detected in the IL6, MPO and NOS1 genes are relatively small 
(OR<2). Furthermore, since the majority of the disease-associated polymorphisms are 
located in introns and are not splice-site or exonic variants, it is unlikely that they have 
themselves a functional role. Most probably, they are in LD with the functional variants. 
Thus, although the indirect association approach offered the opportunity to map disease 
genes as a consequence of association between tested markers and the true functional 
variants, understanding the contribution of these genes to disease etiology is only 
possible if the causal variants are identified [Bodmer and Bonilla 2008; Orr and 
Chanock 2008].  
In the future, the association results of this work should be replicated in samples 
from the same ethnic population as the original study [McCarthy et al. 2008; Zondervan 
and Cardon 2007]. Since initial association studies frequently overestimate the true 
effect size, which is designated as the “winner’s curse” [Ioannidis 2008], replication 
studies must have adequate power to detect effect sizes that are usually smaller than 
those of the initial study [Colhoun et al. 2003]. If an association is not replicated, the 
potential sources of errors and bias responsible for the original association signals could 
be evaluated [McCarthy et al. 2008]. In addition, it would be desirable to replicate 
genetic associations in a different ethnic population to assess their generalization 
[McCarthy et al. 2008].  
Given that the identified disease-associated variants in the IL6, MPO and NOS1 
genes are unlikely to have a functional role, the following step will be to sequence the 
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genomic regions defined by strong association signals to identify putatively causal 
variants. Relevant regions for protein function or expression, including promoters, 
exons, intron-exon boundaries and other splicing regions, and the 5’ and 3’ untranslated 
regions (UTRs), could be prioritized in a first stage. After putatively causal variants 
have been identified, computational approaches, and in vitro and in vivo studies are 
required to confirm if these variants are truly causal, to quantify their contribution to 
stroke and to elucidate their functional roles.  
 
The studies on the genetic factors involved in stroke outcome are scarce, with 
the majority of them assessing the role of the APOE gene in this phenotype. The fact 
that patients are often left disabled after stroke, which has a huge social and economic 
impact, lead to the urgency of finding genes that may influence patient’s outcome and 
recovery. Filling this gap was one of the main objectives of this work and the novel 
results obtained represent an important step towards this objective.  
Several lines of research have shown the major contribution of inflammation, 
oxidative stress, neurogenesis, angiogenesis, neurovascular injury and neurovascular 
remodeling for stroke-associated brain damage and/or stroke recovery. Therefore, 
candidate genes involved in inflammatory processes (IL1B, IL6, MPO and TNF) and 
oxidative stress (NOS1 and NOS3), as well as growth factor genes (BDNF, FGF2 and 
VEGFA) and matrix metalloproteinase genes (MMP2 and MMP9), were selected and 
tested for association with stroke outcome. Variants in the MMP2 gene and epistatic 
interactions between the growth factor genes BDNF, FGF2 and VEGFA were associated 
with patient’s outcome at three months, constituting novel evidence for a role of these 
genetic factors in this complex phenotype. Recombinant tissue plasminogen activator 
(tPA), currently the only approved treatment for ischemic stroke, can activate MMPs, 
which in turn have been implicated in blood-brain barrier breakdown and neurovascular 
injury right after stroke [Adibhatla and Hatcher 2008; Zhao et al. 2006]. It is thus 
possible that MMP2 gene variants influence patient’s outcome after tPA treatment. On 
the other hand, and given that MMPs contribute to neurovascular remodeling during the 
later repair phase after stroke [Adibhatla and Hatcher 2008], the usefulness of MMP 
inhibitors as potentially therapies for stroke may be limited in time and dependent on 
MMP2 genotype. Epistatic interaction effects between the BDNF, FGF2 and VEGFA 
genes were identified in stroke outcome even in the absence of main gene effects, which 
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provides additional support for gene-gene interaction analysis in complex phenotypes. 
The existence of these interactions in stroke outcome had not been demonstrated before.  
A pilot genome-wide association study was also carried out, allowing an 
unbiased search for genetic factors influencing stroke outcome, which led to novel 
findings: BBS9 and GLIS3 variants were associated with patient’s outcome after stroke. 
Mutations in BBS9 have been identified in patients with Bardet-Biedl syndrome, which 
is characterized by obesity, among other features [Nishimura et al. 2005]; excessive 
energy intake or obesity can negatively influence stroke outcome [Arumugam et al. 
2010]. GLIS3 variants have been associated with type 1 and type 2 diabetes [Barrett et 
al. 2009; Dupuis et al. 2010], a disease that is associated with severe disability after 
stroke [Kaarisalo et al. 2005]. 
The majority of the associated polymorphisms in MMP2, as well as in BBS9 and 
GLIS3, are intronic, with no anticipated influence on splicing. These markers are 
probably in LD with the functional variants. The detected effect sizes are modest, like 
those obtained in other association studies of complex traits and in our analysis of 
stroke susceptibility. The advantage of the SNPSpD approach, which estimates the 
effective number of independent SNPs in the tested population by taking into account 
LD patterns between genotyped SNPs [Nyholt 2004], was demonstrated in the 
MMP2/MMP9 association study. Clearly, the Bonferroni correction is extremely 
conservative in this case, where only 10 out of 21 MMP2 SNPs were independent. 
Adjusting the significance level by the number of independent SNPs is a more 
reasonable solution to deal with the multiple testing issue. The sample size is not very 
large, but was adequately powered (82%) to detect a genotype relative risk of 1.5 with a 
type I error of 5% assuming an additive genetic model and allele frequency of 30%.  
The GWAS that was performed using DNA from pooled samples represents one 
of the main novelties of this work, as until now no GWAS had been carried out in 
stroke outcome. The DNA pooling strategy has some limitations (e.g. it does not allow 
the analysis of haplotypes), but this pilot work confirms its feasibility and further 
supports the notion that this strategy can be used to perform GWAS in a cost-effective 
way. Since DNA pooling introduces extra experimental errors that can affect power, and 
to minimize the probability of prioritizing artifactual results, SNPs with high variability 
among replicates were eliminated and four different strategies were used to select SNPs 
for individual genotyping. Removing SNPs with high variability among replicates 
increased confidence for individual genotyping, but also restricted the number of SNPs 
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that could be assessed. This may be a caveat of this study, because some of the excluded 
SNPs may have an impact in patient’s outcome at three months and, in a second stage, it 
may be advisable to return to the allelotyping data and be less stringent on this criterion. 
However, as an exploratory approach, we decided to focus on the most consistently 
highlighted SNPs. Two novel loci were identified, which may provide new insights into 
the pathophysiological mechanisms that underlie stroke recovery.  
The extensive clinical data during hospitalization that was available for our 
patients permitted the identification of clinical variables that are significant predictors of 
patient’s disability after three months. These variables reflect the severity of the event 
and, to a certain extent, patient’s status at baseline, and were included in the logistic 
regression analysis to control for the effect of the severity of stroke in patient’s 
outcome. It would be interesting to use the National Institute of Health Stroke Scale 
(NIHSS), a widely accepted severity scale, or the size and location of the cellular 
territory affected by stroke, but these were not available for the studied patients. 
Additionally, statistical approaches that use the original ordered data, like ordinal 
logistic regression, constitute an alternative to mRS dichotomization [Bath et al. 2007]. 
Because two classes of the response variable have few individuals, namely the mRS=5 
(N=13) and mRS=6 (N=12), we did not employ ordinal logistic regression using the 
original ordered data, but decided to divide the response variable into two groups 
(mRS≤1 and mRS>1) and to use binary logistic regression in the analysis. The results 
here presented represent a significant progress in the field of stroke genetics, both in 
terms of the number of genes studied and the novelty of results obtained, and may 
provide important clues on the complex mechanisms that occur during patient’s 
recovery.  
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7.2 Concluding remarks and future perspectives 
 
  
Until now, no robust or consistent associations have been obtained in GWAS of 
stroke [Lanktree et al. 2010]. In the future, multiple well powered studies should try to 
replicate the GWAS findings in independent samples to assess the role of these genetic 
factors in stroke risk. A multistage GWAS that is being carried out, involving the 
collaboration of many groups (including ours) and the analysis of thousands of patients 
and controls, may help to clarify stroke etiology. Meta-analyses can also be performed, 
not only to increase the probability of detecting small effect sizes, which may solve 
some of the discrepancies in genetic association studies, but also to provide more 
precise estimates of effect sizes [Domingues-Montanari et al. 2010; Munafò and Flint 
2004]. Meta-analyses do not, however, substitute adequately powered studies [Munafò 
and Flint 2004]. We and our collaborators carried out a meta-analysis of five SNPs and 
two haplotypes in the ALOX5AP gene to investigate the contribution of these genetic 
variants for stroke, since previous association results had been contradictory 
[Domingues-Montanari et al. 2010]. We found an association of one SNP, rs10507391, 
with ischemic stroke, suggesting that ALOX5AP is indeed a risk locus for stroke. SNPs 
that are not directly genotyped can be accurately estimated through imputation, and this 
can be incorporated into meta-analyses of GWAS that used different genotyping 
platforms and into individual studies, increasing the power of these studies [Li et al. 
2009; Servin and Stephens 2007].  
Restricting the analysis to younger patients is desirable, as the relative influence 
of genetics on stroke susceptibility decreases with age [Jerrard-Dunne et al. 2003]. In 
addition, since stroke is a heterogeneous disease in terms of clinical presentation, the 
complexity of the phenotype must be taken into account. One of the strategies that have 
been used is the analysis of intermediate phenotypes, like carotid intima-media 
thickness or leukoaraiosis, which are highly heritable [Carmelli et al. 1998; Turner et al. 
2004]. The other alternative is to perform association analyses in less clinically 
heterogeneous subgroups of patients, because it was found that heritability of stroke 
depends on stroke subtypes [Jerrard-Dunne et al. 2003; Polychronopoulos et al. 2002] 
and some associations are only observed in specific subtypes [Gschwendtner et al. 
2009; Gudbjartsson et al. 2009]. The analysis of samples from populations with 
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different ethnic backgrounds [Durbin et al. 2010] and from population isolates [Service 
et al. 2006] offers some advantages, including the identification of a wide variety of risk 
loci for stroke and etiological pathways [McCarthy et al. 2008]. Future studies should 
also assess the role of structural and rare variants in stroke, and investigate the existence 
of gene-gene and gene-environment interactions [Cirulli and Goldstein 2010; Cordell 
2009; Thomas 2010].  
 
Genetic studies on stroke outcome are still in their infancy, but this situation has 
to change in the near future, as these studies may identify novel therapeutic targets and 
lead to new pharmacological treatments to reduce stroke damage and/or to enhance 
recovery processes. The work here presented represents a significant change of this 
situation doubling the number of candidate genes tested for a role in stroke outcome. In 
addition, the first GWAS was carried out in this complex phenotype resulting in the 
identification of two previous unsuspected loci (BBS9 and GLIS3). The non-hypothesis 
driven nature of GWAS is the main advantage of these studies and can lead to 
unexpected results, as demonstrated in this work. Similarly to what was already 
discussed for stroke susceptibility, future genetic studies should be better powered to 
detect small effects and should use imputation techniques to estimate SNPs that are not 
directly genotyped, thus increasing the power of these studies. Furthermore, the role of 
structural and rare variants, and the existence of gene-gene and gene-environment 
interactions in stroke outcome need to be properly assessed, and the study of population 
isolates or with different ethnic backgrounds will contribute to identify a wide variety of 
loci with significant impact in stroke outcome. It would be interesting to analyze 
patients with similarities in terms of stroke subtype, location and severity of the insult 
but with very different outcomes, since the influence of specific genes may become 
more evident. Future studies should also assess the impact of genetic factors on stroke 
outcome at the short and long term, because some molecules have opposite effects at 
different stages. For instance, it was observed that MMPs have a deleterious role right 
after stroke but have beneficial effects in later stages, possibly contributing to functional 
recovery [Rosell and Lo 2008].  
 
Candidate gene and genome-wide association analyses, like those performed in 
this work, are only first steps in understanding the pathways contributing to stroke and 
underlying patient’s recovery afterwards. Integrating information from these and 
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functional genomic studies, including gene expression and proteomics studies, may 
provide important insights into the key pathways that are involved in these complex 
traits. Still, the ultimate goal resides in translating genetic findings into clinical 
advances, improving stroke prevention, diagnosis and treatment.  
 
During the past five years, hundreds of loci have been associated with several 
common traits in GWAS [Hindorff et al. 2009], but most of them have reduced effects 
and explain only a small proportion of the heritability of those traits [Maher 2008; 
Manolio et al. 2009]. This “missing heritability” suggests that additional genetic 
variants, either unknown common variants with very small effects or structural and rare 
variants that are poorly or not detected by current methods, contribute to inherited risk 
[Maher 2008; Manolio et al. 2009; Pearson and Manolio 2008]. Epigenetics, reduced 
power to assess the impact of gene-gene and gene-environment interactions, or 
inaccurate estimates of heritability are other plausible explanations for the observed 
“missing heritability” [Maher 2008; Manolio et al. 2009; Pearson and Manolio 2008].  
One of the major limitations of current GWAS is that only a portion of the total 
genetic variations is assessed [Ku et al. 2010]. Copy number variations (CNVs), 
generally defined as deletions and duplications that are larger than 1kb, are highly 
common in the human genome and interesting results have been obtained for several 
diseases [Ku et al. 2010]. For instance, it was observed that rare CNVs, disrupting genes 
involved in developmental pathways, are more frequent in patients with schizophrenia 
when compared to subjects without the disease [Walsh et al. 2008]. In addition to gene 
disruption, CNVs can contribute to disease by gene dosage alteration or by uncovering 
deleterious alleles, among other possible mechanisms [Estivill and Armengol 2007]. 
These structural variants can be detected using array-based methods, such as the SNP 
arrays and oligonucleotides comparative genomic hybridization arrays. Nevertheless, 
despite recent improvements in newer genotyping arrays, these methods have poor 
sensitivity to detect variants that are smaller than 5-10kb. Comparatively, sequencing-
based methods have higher sensitivity to detect smaller CNVs and can also detect other 
structural variants, like short indels (with sizes ranging from 100bp to 1kb) and copy 
neutral variations (inversions and translocations), which cannot be investigated using 
SNP genotyping arrays [Ku et al. 2010]. In the future, studies need to assess a larger 
component of total genetic variations, including non-SNP genetic variants. 
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The “common disease, rare variant” hypothesis is an alternative to the “common 
disease, common variant” hypothesis, arguing that genetic susceptibility to common 
diseases is mainly influenced by multiple rare variants, possibly with relatively large 
penetrance [Schork et al. 2009]. Both common and rare variants may contribute to 
common diseases, but the relative impact of each type of variants is still unknown 
[Cirulli and Goldstein 2010]. Sequencing specific genes has demonstrated that a 
combination of rare variants can be associated with common diseases and disease-
related phenotypes, including type I diabetes, blood pressure, obesity and low low-
density lipoprotein (LDL) cholesterol [Ahituv et al. 2007; Cohen et al. 2005; Ji et al. 
2008; Nejentsev et al. 2009]. To characterize the contribution of rare variants to the 
phenotype, researchers can use next generation sequencing technologies. The 
advantages of these technologies include the production of large quantities of sequence 
data cheaply and the ability to detect minor alleles accurately [Metzker 2010; Tucker et 
al. 2009]. Studies involving rare variants may focus on specific genes, on genomic 
regions identified in GWAS or linkage studies, on exons or the entire genomes [Bansal 
et al. 2010; Cirulli and Goldstein 2010]. While the costs associated with whole-exome 
and whole-genome sequencing remain high, two strategies to discover rare variants are 
to sequence individuals that are at the extreme ends of a quantitative trait (e.g. age at 
onset) or belonging to families with multiple affected individuals [Cirulli and Goldstein 
2010; Manolio et al. 2009]. An alternative to DNA-sequencing is to use custom 
genotyping arrays to genotype variants identified in previous sequencing studies, such 
as the 1000 Genomes Project (http://www.1000genomes.org) [Durbin et al. 2010]. Pilot 
data from this project, whose aim is to characterize over 95% of human DNA variations 
with MAF≥1% in multiple populations but may also identify lower frequency variants, 
has been used to design the next generation genotyping arrays [Durbin et al. 2010]. For 
example, the Illumina’s 2.5M genotyping array, which was launched last year, already 
contains common and rare variants from the 1000 Genomes Project. Data from this 
project will not only drive the development of more efficient genotyping arrays, but also 
accelerate fine mapping of genomic regions identified in GWAS and improve the power 
of imputation methods, which will allow better localization of disease-associated 
variants [Durbin et al. 2010; Ku et al. 2010].   
In spite of several limitations, GWAS have provided new insights into the 
etiology of several diseases. Results from those studies suggest that autophagy is an 
important disease mechanism in Crohn’s disease, as several polymorphisms associated 
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with disease susceptibility are located within or near genes related to this process, which 
was not anticipated, and loci identified in type 2 diabetes encode proteins involved in 
insulin secretion, rather than insulin signaling, which had been the focus of research 
[Hingorani et al. 2010]. Furthermore, GWAS have shown that some genetic regions 
influence the risk of different diseases. For example, different SNPs in the same region 
on chromosome 12 influence the risk of celiac disease, type 1 diabetes and myocardial 
infarction and the same SNP on chromosome 8 affects type 2 diabetes and prostate 
cancer risks [Hingorani et al. 2010]. Kalirin (KALRN), previously implicated in 
susceptibility to cardiovascular disorders, has also been associated with stroke, 
indicating that it may represent a common risk factor for vascular diseases [Krug et al. 
2010]. These unexpected findings indicate that some common diseases, initially 
considered as very different, may have a partially overlapping etiology.   
The primary objective of GWAS is the identification of biological pathways 
involved in a given trait, but their ultimate objective lies in the translation of findings 
into clinical advances [McCarthy et al. 2008; Pearson and Manolio 2008]. This ultimate 
goal will be one of the biggest challenges in the near future. New therapeutic targets 
may be identified within causal pathways, which could lead to new pharmaceutical and 
preventative approaches [McCarthy et al. 2008]. In addition, the knowledge of 
individual patterns of disease predisposition will lead to personalized medicine 
[McCarthy et al. 2008]. However, the majority of disease-associated variants identified 
have modest effect sizes. This implies that, for most individuals, using GWAS findings 
in screening for disease risk will provide limited information beyond that available from 
conventional risk factors [Hingorani et al. 2010; McCarthy et al. 2008]. Therefore, 
while the predictive genetic tests that have arisen commercially are hoped to 
revolutionize diagnostic approaches and population risk calculations, they may have 
little clinical value and can have serious adverse consequences for patients and their 
families [Janssens and Khoury 2006; McCarthy et al. 2008; Pearson and Manolio 2008]. 
Low frequency variants with intermediate penetrance effects, which are not detected by 
current GWAS approaches but could be identified by high-throughput sequencing 
technologies, are likely to be more clinically valuable [McCarthy et al. 2008]. 
Moreover, population-based cohort studies are required to analyze the effects of newly 
identified risk loci, providing information on their absolute risk and insights into the 
interactive effects with environmental factors [Hingorani et al. 2010]. Given the 
extraordinary progresses in recent years, new and exciting findings are expected in the 
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near future, as additional examples of the enormous complexity of human diseases and 
traits. 
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Abstract  
 
 
Background – The genetic contribution to stroke is well established but it has 
proven difficult to identify the genes and the disease-associated alleles mediating this 
effect, possibly because only nuclear genes have been intensely investigated so far. 
Mitochondrial DNA (mtDNA) has been implicated in several disorders having stroke as 
one of its clinical manifestations. The aim of this case-control study was to assess the 
contribution of mtDNA polymorphisms and haplogroups to ischemic stroke risk. 
Methods – We genotyped 19 mtDNA single nucleotide polymorphisms (SNPs) 
defining the major European haplogroups in 534 ischemic stroke patients and 499 
controls collected in Portugal, and tested their allelic and haplogroup association with 
ischemic stroke risk. 
Results – Haplogroup H1 was found to be significantly less frequent in stroke 
patients than in controls (OR=0.61, 95% CI=[0.45-0.83], P=0.001), when comparing 
each clade against all other haplogroups pooled together. Conversely, the pre-HV/HV 
and U mtDNA lineages emerge as potential genetic factors conferring risk for stroke 
(OR=3.14, 95%CI=[1.41-7.01], P=0.003, and OR=2.87, 95%CI=[1.13-7.28], P=0.021, 
respectively). SNPs m.3010G>A, m.7028C>T and m.11719G>A strongly influence 
ischemic stroke risk, their allelic state in haplogroup H1 corroborating its protective 
effect. 
Conclusion – Our data suggests that mitochondrial haplogroup H1 has an impact 
on ischemic stroke risk in a Portuguese sample. 
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Abstract  
 
 
Background – Variants in the 5-lipoxygenase-activating protein (ALOX5AP) and 
phosphodiesterase 4D (PDE4D) genes have first been associated with ischemic stroke 
(IS) through whole-genome linkage screens. However, association studies obtained 
conflicting results. We aimed to investigate the contribution of selected single 
nucleotide polymorphisms (SNPs) in these genes for the first time in a large Iberian 
population. 
Methods – A case-control design was used to analyze one SNP in ALOX5AP and 
five SNPs in PDE4D in a total of 1,092 IS patients and 781 healthy controls of two 
different subsets from Spain and Portugal. The analysis was adjusted for confounding 
variables and the results were integrated in a meta-analysis of all case-control studies. In 
addition, ALOX5AP gene expression levels were determined in controls and IS cases.  
Results – A first meta-analysis of both subsets showed that the T allele of the 
SG13S114 SNP in ALOX5AP was a risk factor for IS after Bonferroni correction [OR = 
1.22 (1.06–1.40); P=0.006]. A second meta-analysis of white populations confirmed 
these results [OR = 1.18 (1.07–1.31); P=0.001]. ALOX5AP gene expression analysis in 
a subset of controls and cases revealed that the SG13S114 genotypes modulate mRNA 
levels of ALOX5AP (P=0.001) and mRNA levels were higher in IS cases (2.8±2.4%) 
than in controls (1.4±1.3%; P =0.003). No association of the variants in PDE4D with IS 
was observed in our study. 
Conclusions – The ALOX5AP SG13S114 variant is an independent risk factor 
for IS in the Iberian population and is associated with ALOX5AP expression levels. The 
role of this gene in stroke merits further investigation.  
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Abstract 
 
 
Cerebrovascular and cardiovascular diseases are the leading causes of death and 
disability worldwide. They are complex disorders resulting from the interplay of genetic 
and environmental factors, and may share several susceptibility genes. Several recent 
studies have implicated variants of the Kalirin (KALRN) gene with susceptibility to 
cardiovascular and metabolic phenotypes, but no studies have yet been performed in 
stroke patients. KALRN is involved, among others, in the inhibition of inducible nitric 
oxide synthase, in the regulation of ischemic signal transduction, and in neuronal 
morphogenesis, plasticity, and stability. The goal of the present study was to determine 
whether SNPs in the KALRN region on 3q13, which includes the Ropporin gene 
(ROPN1), predispose to ischemic stroke (IS) in a cohort of Portuguese patients and 
controls. We genotyped 34 tagging SNPs in the KALRN and ROPN1 chromosomal 
region on 565 IS patients and 517 unrelated controls, and performed genotype 
imputation for 405 markers on chromosome 3. We tested the single marker association 
of these SNPs with IS. One SNP (rs4499545) in the ROPN1–KALRN intergenic region 
and two SNPs in KALRN (rs17286604 and rs11712619) showed significant (P< 0.05) 
allelic and genotypic (unadjusted and adjusted for hypertension, diabetes, and ever 
smoking) association with IS risk. Thirty-two imputed SNPs also showed an association 
at P<0.05, and actual genotyping of three of these polymorphisms (rs7620580, 
rs6438833, and rs11712039) validated their association. Furthermore, rs11712039 was 
associated with IS (0.001<P<0.01) in a recent well-powered genome-wide association 
study [Ikram et al. 2009]. These studies suggest that variants in the KALRN gene region 
constitute risk factors for stroke and that KALRN may represent a common risk factor 
for vascular diseases. 
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Abstract 
 
Stroke is a complex disorder resulting from the interplay of several genetic and 
environmental factors. Numerous attempts to elucidate its genetic underpinnings have 
led to conflicting results. We hereby propose a novel approach to the identification of 
ischemic stroke (IS) susceptibility genes by converging data from several unbiased 
genetic and genomic tools. Namely, we tested the association with IS of genes that: i. 
were differentially expressed between IS cases and controls; ii. mapped to previously 
reported linkage peaks; and iii. were nominally associated with stroke in published 
genomewide association studies (GWAS). 
We performed gene expression profiling in peripheral blood mononuclear cells 
of twenty IS cases and twenty age- and sex-matched controls. Sixteen of the 
differentially expressed genes map to previously reported whole-genome linkage peaks, 
and one of these, the TTC7B gene, has been associated (P=5.23x10
-5
) with major 
cardiovascular disease in Framingham Heart Study 100K GWAS [Larson et al. 2007]. 
Forty six tagging single nucleotide polymorphisms (SNPs) in TTC7B or its 10 kb 
flanking regions were genotyped and tested for association in 565 Portuguese IS cases 
and 520 controls. SNPs nominaly associated in at least one of the tests performed and 
SNPs defining associated haplotypes were then tested in 570 IS Spanish cases and 390 
controls. Several SNPs and haplotypes in the intron 5 – intron 6 region of TTC7B were 
also found associated with IS risk in the Spanish and combined datasets. 
Multiple independent lines of evidence therefore support the role of TTC7B in 
stroke susceptibility, but further work is warranted to pinpoint the exact risk variant and 
to elucidate its pathogenic potential. 
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